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ABSTRACT
Sexual behavior in male rats is a complex rewarding behavior and many
neurotransmitters and neuropeptides play an important role in mediation of sexual
performance, motivation and reward. The hypothalamic neuropeptide orexin has been
shown play a key role in reward associated with food and drugs of abuse, but the role of
this neuropeptide in control of sexual performance, motivation and reward is currently
unclear. First, it was shown that orexin neurons in the hypothalamus are activated during
sexual performance and reward. Next, using cell specific lesions of orexin neurons it was
demonstrated that orexin is involved in arousal and anxiety, but is not critical for sexual
performance or motivation. Moreover, orexin was shown to play a critical role in control
of sexual reward. Thus, these studies provided novel information regarding a role for
orexin in this natural reward behavior. Recent studies have shown that sexual behavior in
male rats causes neuroplasticity in the mesolimbic system and enhanced psychostimulantinduced locomotor activity and drug craving. The latter of which is dependent on a period
of abstinence from sexual behavior, suggesting an increased vulnerability for addiction
following loss of sexual reward. Thus, the next goal of this thesis determined if
abstinence from sexual behavior also leads increased vulnerability for other disorders
related to reward processing, specifically depression-like behavior. It was demonstrated
that a prolonged (28 day) but not short (1 or 7 day) period of abstinence causes
depression-like behavior in sexually experienced male rats seen as increased passive
stress coping behaviors and anhedonia. Development of depression-like behavior was
associated with increased levels of corticotropin releasing factor mRNA in the
paraventricular nucleus of the hypothalamus and increased hypothalamic-pituitary-
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adrenal axis activity in response to an acute stressor. Thus, these studies provide novel
information on behavioral and neuroplastic alterations observed following a prolonged
period of abstinence from mating and suggest that loss of sexual reward in male rats may
be a paradigm to study depression following loss of social reward in humans.

Keywords: orexin, hypocretin, sexual behavior, neural activation, motivation, reward,
hypothalamus, conditioned placed preference, anxiety, depression, abstinence, passive
stress coping, anhedonia, corticotropin releasing factor, hypothalamic-pituitary adrenal
axis, corticosterone, adrenocorticotropic hormone
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CHAPTER 1: GENERAL INTRODUCTION

Sections 1.2-1.5 were published in Progress in Brain Research 198: 64-77 (2012)

1.1 Introduction – Part 1
1.1.1 Natural Reward Behaviors
An individual’s behavior is altered by experience (Schultz, 2006). If a behavior is
followed by reward, this will increase frequency of the behavior (i.e. reinforcement),
however if a behavior is followed by punishment, frequency of the behavior will be
decreased (Schultz, 2006). The brain system that is critical for mediation of reward
behaviors is the mesolimbic system, which consists of interconnected brain regions
including the ventral tegmental area (VTA), nucleus accumbens (NAc) and medial
prefrontal cortex (mPFC) (Morgane et al., 2005). The mesolimbic system is important for
mediation of natural rewards including feeding (Hernandez and Hoebel, 1988, Martel and
Fantino, 1996, Avena et al., 2008, Vucetic and Reyes, 2010), drinking (Yoshida et al.,
1992), maternal behavior (Numan, 2007), social bonding (Young et al., 2001, Young et
al., 2011) and sexual behavior (Pfaus et al., 1990a, Balfour et al., 2004, Frohmader et al.,
2010, Pitchers et al., 2010).
There is great interest in understanding the neurobiology of natural reward
behaviors and how these behaviors change the brain to alter subsequent behavior. As
such, studies in this thesis will examine the neurobiology of sexual behavior and
neuroplasticity related to sexual behavior, an extremely motivated and rewarding
behavior in mammals (Paredes, 2009).

1.1.2. Male Rat Sexual Behavior
The model animal for studies in this thesis is the male rat. In male rats, sexual
behavior is a complex interaction which involves pursuit and investigation of the female,
2

mounts, intromissions, culminating in ejaculation (Hull et al., 2002 ). Following
investigation the male will mount the female and perform rapid pelvic thrusts, without
penetration (Agmo, 1997). An intromission begins with a mount and continues until the
male performs a deeper pelvic thrust that results in vaginal penetration (Agmo, 1997).
Culmination of this sexual activity is ejaculation, which in turn is followed by a 4-7
minute period of sexual inactivity, the post-ejaculatory interval, after which the male
reinitiates sexual behavior. Male rats will perform numerous copulatory series prior to
reaching sexual satiety (Agmo, 1997).

1.1.3 Sexual Motivation and Performance
In male rats, approach and investigation of the receptive female is indicative of
sexual motivation. Latencies to first mount and intromission are also considered to be
measures of sexual motivation. Sexual behavior is highly motivating in male rats, as
males spend increased time investigating a receptive female presented behind a barrier
vs. a nonreceptive female, show increased speeds to reach a sexually receptive female in
a straight runway test (Lopez et al., 1999) and change levels more frequently in the
bilevel chamber test in search of a sexually receptive female (Mendelson and Pfaus,
1989). Males also show decreased latencies to mount and intromission with repeated
sexual experience, indicating increased sexual motivation (Pfaus et al., 1990b, Agmo,
1997). Sexual performance in male rats is indicated by the frequency of mounts and
intromissions an animal performs in a copulatory series, and also by latencies to
ejaculation (Agmo, 1997). Sexual performance is enhanced by sexual experience, as
copulation efficiency is increased (increased numbers of intromissions relative to number

3

of mounts) (Agmo, 1997), and latencies to ejaculation are shortened (Pitchers et al.,
2012). The neural systems mediating sexual motivation and performance begin with
chemosensory input from the olfactory bulb that project to the medial amygdala (MeA),
which sends these signals to the medial preoptic area (mPOA), both directly and
indirectly, via the bed nucleus of the stria terminalis (BnST). Genitosensory inputs are
relayed through the spinal cord to the subparafascicular thalamic nucleus (SPFp) which
projects to the MeA and mPOA. Furthermore the mPOA, MeA, BnST and SPFp all show
cFos activation following display of sexual behavior (Coolen et al., 1996, 1997b),
indicating neural activation by mating. The mPOA is a major integrative site for control
of sexual behavior and lesions of this brain region cause impairments in both sexual
motivation (Paredes et al., 1993, Edwards et al., 1996) and performance (Larsson and
Heimer, 1964, Arendash and Gorski, 1983).

1.1.4 Sexual Reward
In humans, ejaculation is associated with the pleasurable feeling of orgasm.
Similarly in rats, ejaculation is associated with reward and is the most rewarding
component of sexual behavior (Tenk et al., 2009). Sexual behavior in male rats has been
shown to be a rewarding and reinforcing behavior as males will perform operant tasks,
(Everitt et al., 1987, Everitt and Stacey, 1987) climb barriers (Sheffield et al., 1951) or
cross electrified grids (Moss, 1924) to gain access to a sexually receptive female.
Moreover, male rats facilitate their sexual performance with repeated sexual experience
(Pitchers et al., 2012) and form a conditioned place preference for sexual behavior
(Agmo and Berenfeld, 1990, Tenk et al., 2009). The mesolimbic system, which is critical
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for mediation of reward, is activated during sexual behavior. It has been shown that both
sexual behavior and exposure to cues associated with sexual reward lead to cFos
activation in the NAc and increased cFos activation of dopamine neurons in the VTA
(Balfour et al., 2004), suggesting an important role of these brain regions in mediation of
sexual reward.

1.1.5. Neuropeptides in Sexual Motivation, Performance and Reward
As mentioned above, sexual behavior is a complex behavior that involves
integration of many different brain regions. As such, there are also many
neurotransmitters and neuropeptides involved in mediation of this behavior that will be
discussed below.

Glutamate
Glutamate is the main excitatory neurotransmitter in the central nervous system
and is released in the mPOA during sexual behavior (Dominguez et al., 2006). NMDA
receptors also become activated in the mPOA following copulation (Dominguez et al.,
2007). Both systemic (Powell et al., 2003) and intra-mPOA (Dominguez et al., 2007)
administration of glutamate antagonists also have been shown to lead to impairments in
sexual performance. Thus, glutamate appears to play a facilitatory role in sexual
performance. Moreover, blockade of N-methyl-D-aspartate (NMDA) receptors decreased
mating induced cFos as well as mating induced phosphorylation of the NR1 subunit of
the NMDA receptor in the mPOA (Dominguez et al., 2007), suggesting that facilitatory
effects of glutamate on sexual performance may be via NMDA receptors in the mPOA.

5

Dopamine
Dopamine has also been shown to play a role in sexual behavior. Systemically
administered dopamine agonists facilitate male sexual performance (Ahlenius and
Larsson, 1990, Pfaus and Phillips, 1991, Melis and Argiolas, 1995, Olivier et al., 2007),
while systemic administration of dopamine antagonists impair sexual performance
(Ahlenius and Larsson, 1990). Dopamine is released into the mPOA with presentation of
a receptive female and remains elevated throughout display of sexual behavior (Hull et
al., 1995), indicating a role for mPOA dopamine in sexual motivation and performance.
Additionally, intra-mPOA administration of dopamine receptor antagonists has been
shown to lead to impairments in both sexual motivation and performance (Pfaus and
Phillips, 1991). During sexual behavior dopamine is also released into the NAc with
presentation of a receptive female, and remains elevated during the entire display of
copulation (Pfaus et al., 1990a, Pfaus and Phillips, 1991, Damsma et al., 1992, Wenkstern
et al., 1993), suggesting dopamine may be important for mediation of sexual reward.
However, there have been many studies demonstrating that dopamine neurotransmission
does not appear to be critical for mating-induced conditioned place preference (Agmo
and Berenfeld, 1990, Garcia Horsman and Paredes, 2004, Paredes and Agmo, 2004,
Ismail et al., 2009), a well established model for measuring sexual reward (Tzschentke,
2007). Instead, it has been proposed that dopamine in the NAc may play a role in the
prediction of reward upon presentation of a reward-associated cue (Schultz, 2006) or be
important for mediation of incentive motivation for sexual behavior (Robinson and
Berridge, 1993).

6

Endogenous Opioids
Opioids have been shown to be inhibitory to sexual performance as infusion of
morphine, heroin and methadone all lead to impairments in sexual behavior (Pfaus and
Gorzalka, 1987). Similarly, infusion of opioid peptides such as β-endorphin impairs
sexual performance (Hughes et al., 1987). Infusion of µ-opioid receptor antagonists such
as naloxone and natrexone facilitate sexual performance in sexually naïve (Pfaus and
Wilkins, 1995) and sexually experienced male rats (Myers and Baum, 1979). However,
there are also studies that have shown that opioids may have facilitative effects on sexual
behavior. Increasing enkephalin levels ICV using enkephalinase inhibitors that block
degradation of endogenous enkephalin, facilitated sexual behavior and decreased latency
to ejaculate in male rats (Agmo et al., 1994), while intra-VTA morphine or dynorphin led
to improvements in copulatory performance and increased dopamine release in the NAc
(Mitchell and Stewart, 1990). Furthermore, opioid receptors are activated by sexual
behavior as mating induces internalization of µ-opioid receptors in the mPOA (Coolen et
al., 2004b) and VTA (Balfour et al., 2004). Endogenous opioids also appear to be critical
for mediation of sexual motivation, as infusion of naloxone in the VTA prevented the
increase in level changes in the bilevel chamber in anticipation of a sexual receptive
female (van Furth and van Ree, 1996). Endogenous opioids have also been shown to be
activated by sexual reward, as µ-opioid receptors in the VTA are activated by exposure to
conditioned contextual cues associated with prior sexual reward (Balfour et al., 2004).
Furthermore, opioids play a critical role in mediation of sexual reward as both systemic
and intra-mPOA infusion of naloxone blocks development and expression sexual reward
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induced conditioned place preference (Agmo and Berenfeld, 1990, Mehrara and Baum,
1990, Agmo and Gomez, 1993, Paredes and Martinez, 2001, Ismail et al., 2009).

Serotonin
Serotonin (5HT) is generally regarded as being inhibitory to sexual behavior (Hull
et al., 2004) as a common side effect of selective serotonin reuptake inhibitor (SSRI)
antidepressants, which increase extracellular 5HT release, is impaired sexual behavior in
both humans (Rosen et al., 1999) and rats (Mos et al., 1999). There are fourteen known
G-protein-coupled receptors for serotonin that are divided into seven classes; however
only a few thus far have been shown to be related to sexual behavior. The inhibitory
actions of 5HT appear to be mediated by the 5HT1B and the 5HT2 receptors. Systemic or
intracranial administration of a 5HT1B (Fernandez-Guasti et al., 1989a, Fernandez-Guasti
et al., 1992) or 5HT2 (Foreman et al., 1989, Watson and Gorzalka, 1991) agonists impair
copulatory performance, while 5HT2 antagonists facilitate sexual behavior (Gonzalez et
al., 1994). Furthermore, the mPOA and NAc appear to be brain regions important for
5HT’s inhibitory effect on sexual behavior, as 5HT injected into these brain regions
impairs copulatory performance (Verma et al., 1989, Fernandez-Guasti et al., 1992).
Serotonin has also been shown to have facilitatory effects on sexual behavior and these
effects have been shown to be mediated by the 5HT1A receptor, as systemic (Ahlenius and
Larsson, 1990, Haensel et al., 1991, Fernandez-Guasti et al., 1992, Coolen et al., 1997a),
intra-mPOA (Fernandez-Guasti et al., 1992), intra-NAc (Matuszewich et al., 1999), and
intra-MeA (de Castilhos et al., 2006) administration of the 5HT1A agonist, 8-OH-DPAT
facilitates sexual performance. There have been fewer studies on the role of 5HT in
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sexual reward, however it has been shown that systemic administration of 3,4methylenedioxy-methamphetamine (MDMA,“ecstasy”) that leads to a 40-55% depletion
of 5HT in brain regions such as the striatum, hypothalamus, cortex, hippocampus and
NAc blocks formation of conditioned place preference for sexual behavior (Straiko et al.,
2007), suggesting that serotonin may also play an important role in mediation of sexual
reward.

Oxytocin
Oxytocin is a hypothalamic neuropeptide produced in the paraventricular nucleus
of the hypothalamus (PVN) and supraoptic nucleus (SON) (Bargmann and Scharrer,
1951). Oxytocin is generally regarded as facilitatory to sexual performance as intra-PVN
infusion of oxytocin stimulates penile erections (Kita et al., 2006), and systemic, ICV, or
intra-mPOA administration of oxytocin facilitates sexual performance in male rats
(Argiolas and Melis, 2005, Gil et al., 2011). Conversely, oxytocin antagonists have been
shown to impair sexual performance (Argiolas and Melis, 2005). Furthermore, sexual
interaction has been shown to increase cFos in oxytocin neurons of the PVN that have
projections to the spinal cord and are involved in control of penile erection (Witt and
Insel, 1994). Low levels of oxytocin mRNA in the PVN are associated with sexual
impotence in rats (inability to copulate with a sexually receptive female) (Arletti et al.,
1997), further supporting a role for oxytocin in sexual performance. Oxytocin may also
play a role in sexual motivation and reward as oxytocin has been shown to facilitate
sexually conditioned partner preference in male rats (Pfaus, 2009), and interaction with a
sexually receptive female leads to oxytocin release in male rats (Hillegaart et al., 1998).
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Furthermore, neutral odors associated with prior sexual reward have been shown to
activate oxytocin in the PVN (Ménard et al., 2005).
Therefore, it is evident that many neurotransmitters and neuropeptides play an
important role in sexual performance, motivation and reward. As such, studies in
Chapters 2 and 3 of this thesis will focus on a more recently discovered neuropeptide, the
hypothalamic neuropeptide, orexin. Orexin has been implicated to play a key role in
reward associated with food and drugs, but the role of this neuropeptide in mediation of
sexual performance, motivation or reward is currently unclear.

1.2 Orexin and Natural Reward Behavior: Feeding, Maternal and Male Sexual
Behavior
Orexin-A and orexin-B, also known as hypocretin-1 and hypocretin-2, are
hypothalamic neuropeptides produced exclusively in the perifornical dosomedial
hypothalamus (PFA-DMH) and lateral hypothalamic area (LHA), that arise from the
precursor peptide prepro-orexin (de Lecea et al., 1998, Sakurai et al., 1998). The orexins
bind to two G-protein coupled receptors, orexin receptor 1 (OxR1) and orexin receptor 2
(OxR2), with OxR1 being selective for orexin-A and OxR2 being equally selective for
both orexin-A and orexin-B (Sakurai et al., 1998). Orexin neurons project their axons
broadly throughout the brain and spinal cord to regions important for arousal and sleep,
feeding behavior, and reward and motivation (Peyron et al., 1998). OxR1 and OxR2 are
also widely distributed throughout the brain and spinal cord (Trivedi et al., 1998, Marcus
et al., 2001). The discovery of orexins was accompanied with great interest in orexin’s
role in arousal and sleep (Paredes et al., 1997, Chemelli et al., 1999, Lin et al., 1999,
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Furlong and Carrive, 2007, Sakurai, 2007) and in feeding behavior (de Lecea et al., 1998,
Sakurai et al., 1998, Sakurai, 2006). Orexin neuronal dysfunction leads to narcolepsy in
mice (Chemelli et al., 1999), dogs (Lin et al., 1999) and humans (Siegel, 1999, Nishino et
al., 2000, Thannickal et al., 2000), suggesting that orexin is critically involved in arousal
and maintenance of waking state. Orexin neurons indeed project to arousal associate
brain regions such as the locus coeruleus (Peyron et al., 1998). Furthermore,
intracerebroventricular (ICV) administration of orexin-A and orexin-B causes increased
food intake in rats, and fasting leads to upregulation of prepro-orexin mRNA (Sakurai et
al., 1998). With a role established for orexin in feeding it was next hypothesized that
these peptides are involved in mediation of reward and motivation. Indeed, there is now
ample evidence that orexin plays a critical role in reward related to drugs of abuse and
addiction behaviors.

1.3 Orexin, Feeding and Energy Homeostasis
Orexin neurons are localized in brain regions important for regulation of feeding
behavior and energy homeostasis, the PFA-DMH and LHA (Elmquist et al., 1999).
Furthermore ICV infusions of orexin-A and orexin-B stimulate food intake in rats and
mice (Sakurai et al., 1998, Edwards et al., 1999). Thus orexin likely plays a role in
feeding and energy balance. Indeed, human narcoleptics that have orexin neuron
deficiency (Peyron et al., 2000, Thannickal et al., 2000) and decreased orexin-A levels in
CSF (Nishino et al., 2000, Schuld et al., 2002, Scammell, 2003) show decreased food
intake (Lammers et al., 1996) with an increased body mass index (Nishino et al., 2000,
Schuld et al., 2000, Nishino et al., 2001), indicating metabolic abnormalities. Mice with
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genetic ablation of orexin and that display narcoleptic symptoms have significantly
decreased food intake, and eventually develop late-onset obesity (Hara et al., 2001),
suggesting that orexin is an important mediator of energy homeostasis and metabolism.
Additionally, increasing extracellular glucose and leptin levels leads to hyperpolarization
of orexin neurons, while decreasing extracellular glucose and leptin levels leads to
depolarization of orexin neurons, indicating that orexin neurons are glucose and leptin
sensitive (Yamanaka et al., 2003). Orexin neurons are also sensitive to triglycerides, as
intraperitoneal (IP) injection of lipids increases orexin mRNA levels in the hypothalamus
(Chang et al., 2004) and are sensitive to dietary amino acids, as oral gavage of
nutritionally relevant levels of amino acids leads to increased cFos expression in orexin
neurons (Karnani et al., 2011). Furthermore, orexin has been suggested to act as a sensor
for nutritional state as prepro-orexin mRNA is upregulated by fasting (Sakurai et al.,
1998) and hypoglycemia (Griffond et al., 1999). The findings that orexin neurons
respond to glucose, leptin, triglycerides and dietary amino acids further implicate a role
for orexin in energy homeostasis. Orexin neurons are innervated by both the appetite
suppressing peptide, proopiomelanocortin and the appetite stimulatory peptide
neuropeptide-Y (Elias et al., 1998). Furthermore, ICV infusion of agouti related peptide,
which is co-expressed in the same neurons as neuropeptide-Y and stimulates appetite,
leads to increased cFos expression in orexin neurons (Zheng et al., 2002). Thus there is
clear evidence that orexin interacts with the hypothalamic peptides that regulate food
intake and energy homeostasis.

1.4 Orexin and Food Motivation and Reward
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In addition to mediating energy homeostasis, orexin is an important mediator of
motivation and reward associated with feeding. ICV orexin-A and orexin-B infusion
stimulates feeding (Sakurai et al., 1998) and IP infusion of an OxR1 specific antagonist,
SB-334867 reduces food intake in both male and female rats (Haynes et al., 2000).
Moreover, IP pre-treatment with SB-334867 attenuates orexin-A induced feeding
behavior, indicating the actions of orexin-A on feeding are via OrXR1 (Rodgers et al.,
2001). Mice with a genetic ablation of orexin have decreased intake of food (Hara et al.,
2001) and orexin knockout mice show decreased intake of sucrose (Matsuo et al., 2011).
These effects of orexin or orexin receptor antagonism appear to be caused by alterations
in motivation to eat or reward associated with feeding. Orexin-A stimulates feeding when
infused into the nucleus accumbens shell (Thorpe and Kotz, 2005), an area important for
goal-directed behaviors and hedonia related to feeding (Berridge, 1996, Zhang et al.,
1998, Pecina and Berridge, 2000, Pecina et al., 2006). In self administration studies
which assess motivation for food, animals learn to lever press to receive food reward.
ICV administration of SB-334867 attenuates lever pressing on a fixed ratio schedule for
food (Borgland et al., 2009), sucrose pellets (Thorpe et al., 2005) and high fat chocolate
pellets (Nair et al., 2008). SB-334867 also attenuates the number of sucrose reinforcers
obtained in a fixed ratio self administration paradigm in both ad libitum fed and food
restricted rats (Cason et al., 2010). Studies using a progressive ratio self administration
procedure in which the animal must press a lever progressively more times to obtain the
same reinforcer are also used to examine the role of orexin in food motivation.
Motivation in the progressive ratio procedure is determined by the maximum number of
times an animal will lever press to receive the reinforcer, called the breakpoint
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(Richardson and Roberts, 1996). The effects of orexin in the progressive ratio schedule
appears to be dependent on the satiety state of the animal as intra-LHA administration of
orexin-A increased breakpoint responding for sucrose pellets (Thorpe et al., 2005, Choi et
al., 2010), and this breakpoint was increased further following 24 hours of food
deprivation (Thorpe et al., 2005). Further supporting this, IP administration of SB334867 decreased breakpoint for sucrose pellets in sated but not food-restricted rats
(Espana et al., 2010). IP injection of SB-334867 also reduces consumption of high fat,
palatable food in both a fixed ratio schedule (Nair et al., 2008, Choi et al., 2010) and a
progressive ratio schedule (Borgland et al., 2009). The latter study also showed that the
same dose of SB-334867 did not affect intake of normal chow, suggesting orexin-A is
important for mediation of motivation for positive, highly salient reinforcers (Borgland et
al., 2009). In mice, pharmacological blockade of OxR1 using SB-334867 or viral vector
mediated knockdown of prepro-orexin decreases responding for food in a progressive
ratio schedule (Sharf et al., 2010). In contrast, orexin knockout mice do not show any
differences in responses for food on a progressive ratio schedule, suggesting
developmental compensation in orexin knockout mice (Sharf et al., 2010). Another
method of measuring food motivation is an effort based feeding paradigm in which rats
are given a choice between exerting a small amount of effort to obtain regular food
pellets, or jump over a barrier to receive high fat chocolate pellets in a T-maze. Rats will
willingly jump the barrier to obtain the palatable food pellets (Salamone et al., 1994).
Systemic or intra-VTA administration of SB-334867 significantly decreases number of
entries into the high fat-containing arms (Borgland et al., 2009), demonstrating that OxR1
blockade decreases motivation for palatable food. Orexin is also important for cue-
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induced reinstatement of sucrose seeking, as IP SB-334867 significantly attenuates lever
pressing in reinstatement trials in food restricted, but not in ad libitum fed rats (Cason et
al., 2010). Furthermore, SB -334867 pre-treatment also significantly attenuates
yohimbine-induced reinstatement of sucrose seeking, further implicating a role for
orexin-A and OxR1 in food seeking and motivation for palatable food (Richards et al.,
2008).
Orexin is an important mediator of food motivation and is also important for the
rewarding aspects of feeding behavior. Orexin neurons in the LHA show significant cFos
induction following exposure to a conditioned place preference (CPP) apparatus they had
previously learned to associate with food reward (Harris et al., 2005) and the degree of
cFos induction is correlated with the degree of preference animals display for the food
reward paired chamber, thus suggesting that orexin is activated by food reward associated
conditioned cues (Harris et al., 2005). Orexin is also involved in reward based feeding
behavior, a paradigm in which sated animals will over-consume a high fat diet. This is
referred to as non-homeostatic feeding and in humans is thought to be a major contributor
to the obesity epidemic (Berthoud, 2004). IP administration of SB-334867 in sated rats
decreased intake of high fat diet (Choi et al., 2010) and IP administration of SB-334867
attenuates ghrelin enhanced conditioned place preference for high fat diet in ad libitum
fed rats that were not sated (Perello et al., 2010). Finally, orexin-A expressing neurons
are significantly activated in animals expecting a daily meal of regular chow or high fat
chocolate (Choi et al., 2010), suggesting a role for orexin in food anticipation.
In summary, orexin clearly plays a role in mediating reward and motivation
related to food intake. Outstanding questions remain regarding the areas in the brain
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where orexin may be acting to mediate these effects, and the roles of orexin-B and OxR2
as studies described above primarily examine the role of orexin-A and OxR1 in food
motivation and reward.

1.5 Orexin and other naturally rewarding behaviors
Even though a role for orexin in feeding behavior, food motivation and reward is
well documented, a role for orexin in other naturally rewarding behaviors has not been
extensively studied. Studies that examined orexin’s role in the natural rewarding
behaviors maternal behavior and male sexual behavior will be discussed below.

1.5.1 Orexin and maternal behavior
Orexin receptors are found in brain regions shown to be important for mediation
of maternal behavior and aggression (Trivedi et al., 1998) including the paraventricular
nucleus of the hypothalamus (Numan and Corodimas, 1985, Insel and Harbaugh, 1989,
Giovenardi et al., 1997, 1998), nucleus accumbens (Hansen, 1994, Keer and Stern, 1999),
medial preoptic area (Numan, 1974, Numan et al., 1977) and bed nucleus of the stria
terminalis (Terkel et al., 1979). Additionally, it has been shown that lactating female rats
have significantly higher levels of prepro-orexin and OxR1 mRNA in the lateral
hypothalamus compared to pregnant females (Wang et al., 2003), suggesting orexin may
be involved in maternal behavior. D’Anna and Gammie tested this hypothesis and show
that an intermediate doses of orexin-A (0.06 – 1 µg) ICV increases licking and grooming
behavior of the mothers towards the pups, and increases numbers of nursing bouts. In
addition, this intermediate dose of orexin-A induces cFos activation in brain areas
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involved in maternal behavior including the ventral tegmental area, bed nucleus of the
stria terminalis, central and medial amygdala (D'Anna and Gammie, 2006). In contrast, a
higher dose of ICV orexin-A (3µg) impairs maternal behavior by delaying latency to
nurse, decreasing total time nursing and increasing time away from the nest (D'Anna and
Gammie, 2006). Furthermore, this higher dose of orexin-A also decreases maternal
aggression in the mothers towards an intruder male. However, IP injection of SB-334867
(10 or 30 mg/kg), does not significantly affect any aspect of maternal behavior or
aggression, although there were trends towards impaired maternal care (D'Anna and
Gammie, 2006). These findings suggest that intermediate levels of orexin-A may be
important for maintaining proper maternal behavior such as licking and grooming,
however, when levels of orexin are too high maternal care is impaired. Future studies are
needed to further elucidate the role of orexin in maternal behavior and aggression, in
particular to determine where in the brain orexin may be acting to mediate maternal
behavior and aggression.

1.5.2 Orexin and sexual performance & motivation
Several studies have demonstrated a role for orexin in sexual performance, reward
and motivation. It has been long known that electrical stimulation of the lateral
hypothalamus facilitates sexual behavior in male rats (Vaughan and Fisher, 1962,
Caggiula and Hoebel, 1966). Since the lateral hypothalamus contains orexin neurons it
was thus hypothesized that orexin may be important for sexual behavior in male rats.
Sexual behavior culminating in ejaculation in male rats leads to cFos induction in orexin
neurons of the PFA-DMH and LHA (Muschamp et al., 2007). These results suggest that
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orexin may play an important role in the initiation of, or motivation for mating as well as
sexual performance.
Several studies have used pharmacological manipulations to test whether orexin is
critically involved in mediation of sexual motivation and performance. Orexin-A
administration into the medial preoptic area (mPOA), a brain region that is important for
sexual performance (Hansen et al., 1982, Coolen et al., 2004a) facilitates sexual
motivation and performance in male rats. Orexin-A in the mPOA increases sexual
motivation, by decreasing latencies to mount, intromit, and pursue a receptive female
(Gulia et al., 2003). Intra-mPOA orexin-A also increases sexual performance, by
decreasing latency to ejaculate and increasing frequency of mounts and intromissions
(Gulia et al., 2003). These studies suggest that orexin-A may act in the mPOA to
facilitate sexual motivation and performance. In contrast to these findings ICV
administration of orexin-A attenuates sexual motivation, but only in highly sexually
motivated male rats (Bai et al., 2009b). This discrepancy in findings may suggest that
orexin-A has opposing effects on sexual behavior by acting in multiple brain regions,
with facilitatory effects in mPOA, but inhibitory effects in other areas. Studies testing
effects of antagonists however, have also yielded puzzling results. In one study ICV
administration of SB-334867 had no effect on sexual motivation or arousal (Bai et al.,
2009b), and in another study systemic injection of SB-334867 caused only a slight
impairment in sexual performance seen as longer latencies to intromission and decreases
in ejaculation frequency (Muschamp et al., 2007). Thus, with numerous conflicting
studies, the role of orexin in mediation of sexual behavior and performance is unclear.
Moreover, a role for orexin in sexual reward has yet to be tested.
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1.6 Rationale and Objectives: Part 1
In chapters 2 and 3, I set out to test the hypothesis that orexin is a critical mediator
of sexual performance, motivation, and reward.

1.6.1 Objectives
1. Demonstrate that exposure to different parameters of sexual motivation and
performance cause activation of orexin neurons seen as increased expression of
the immediate early gene cFos in orexin neurons. Establish that orexin is a critical
mediator of sexual motivation and performance utilizing cell-specific lesions of
orexin neurons in the hypothalamus of male rats.

2. Show that orexin is activated by conditioned cues related to sexual reward using
cFos expression as marker of neural activity. Establish that orexin is critically
involved in sexual reward by demonstrating that cell-specific lesions of orexin
neurons block conditioned place preference for sexual reward.
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1.7 Introduction: Part 2

1.7.1 Drug Induced Neuroplasticity in the Mesolimbic Sytem
The mesolimbic system, consisting of the interconnected brain regions of the
ventral tegmental area (VTA), nucleus accumbens (NAc) and medial prefrontal cortex
(mPFC) is critical for mediation of natural reward behaviors (Hyman et al., 2006). Drugs
of abuse have been shown to converge upon the mesolimbic system and specifically,
repeated exposure to drugs of abuse causes neural alterations at the levels of gene
expression, synaptic strength and neuron morphology within the mesolimbic system
(Hyman et al., 2006; Kalivas et al., 2009). These alterations subsequently lead to the
development of drug addiction and cause increased susceptibility for relapse (Kalivas et
al., 2009). In rodents, repeated exposure to drugs of abuse leads to sensitization of the
locomotor response to opiates and psychostimulants (Segal and Mandell, 1974, Post and
Rose, 1976, Kalivas and Stewart, 1991), enhanced conditioned drug reward (Lett, 1989,
Shippenberg et al., 1996) and increased lever pressing for conditioned cues associated
with prior drug reward (Crombag et al., 2008). Repeated exposure to drugs of abuse
causes long lasting alterations in numbers of dendritic spines and spine density within the
NAc (Robinson and Kolb, 1997, 1999, Robinson et al., 2002, Li et al., 2003, Li et al.,
2004, Robinson and Kolb, 2004) and VTA (Sarti et al., 2007). Moreover, repeated
exposure to drugs of abuse causes alterations in synaptic strength in VTA dopamine
neurons (Kauer, 2003, Liu et al., 2005) and neurons in the NAc (Thomas et al., 2000,
Thomas and Malenka, 2003). Thus, is clear that repeated exposure to drugs of abuse
leads to neuroplasticity in the mesolimbic system. Until recently, it was unclear as to
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whether natural rewarding behaviors, such as sexual behavior lead to similar
neuroplasticity.

1.8 Sexual Reward and Neuroplasticity
Studies from our lab have recently shown that repeated exposure to sexual
behavior also causes neuroplasticity in the mesolimbic system, similar to that seen
following repeated exposure to drugs of abuse. Repeated sexual experience has been
shown to cause sensitized responses to sexual behavior, seen as facilitation of sexual
performance with experience (Pitchers et al., 2012), as well as cross-sensitization to the
psychostimulant amphetamine (Frohmader et al., 2010, Pitchers et al., 2010). It has also
been demonstrated that these changes persist following a period of abstinence from
mating (Pitchers et al., 2012), as facilitation of sexual behavior and sensitization to
amphetamine are both maintained one week and one month following last sexual
experience (Pitchers et al., 2012). Repeated sexual experience also causes
electrophysiological changes observed as long-term depression in the NAc that persists
after a one week period of abstinence from mating (Pitchers et al., 2012). Furthermore,
some of the neuroplastic changes seen following repeated sexual experience appear to be
dependent on this period of abstinence from mating, consistent with findings that some
neuroplastic alterations seen following repeated exposure to drugs of abuse are dependent
on a period of abstinence from drug taking (Nestler, 2001, Wolf et al., 2004, Kauer and
Malenka, 2007). Repeated sexual experience in male rats, followed by a seven-ten day
period of abstinence from mating causes enhanced drug reward seen as formation of a
conditioned place preference for subthreshold doses of amphetamine (Pitchers et al.,
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2010). This effect is only seen following a period of mating abstinence, and is not
observed one day following last sexual experience (Pitchers et al., 2010). Moreover,
morphological changes in the NAc including increased dendritic branching and increased
numbers of dendritic spines are observed seven days following last mating, but not at
earlier timepoints (Pitchers et al., 2010). It is therefore evident that natural reward causes
neuroplasticity in the mesolimbic system, similar to that caused by repeated exposure to
drugs of abuse. Neuroplasticity induced by sexual behavior appears to regulate the
reinforcing components of sexual behavior and may regulate reward behavior in general.
Yet, abstinence from sexual reward appears to induce a state of increased reward-seeking
and potential vulnerability to the addictive properties of drugs of abuse, which may
mimic the effects of abstinence from drugs of abuse on the “incubation of craving” (Lu et
al., 2004, Lu et al., 2005). Thus, this neuroplasticity following abstinence from sexual
behavior that causes increased reward seeking and vulnerability for drugs of abuse, may
also cause increased susceptibility for other disorders related to reward, including mood
disorders such as depression.

1.9 Drug Addiction and Depression
Drug addiction is often comorbid with other neuropsychiatric disorders, including
mood disorders such as depression (Kessler et al., 2003, Volkow, 2004, DuPont, 1995). It
is estimated that the comorbidity of drug abuse and mood disorders is 19.4%, and drug
abuse increases risk for depression by a factor of 5 (Regier et al., 1990). Withdrawal and
subsequent abstinence from drugs of abuse in human addicts leads to feelings of anxiety
and depressed mood (Koob, 2009). Similarly, studies in rats and mice have shown that
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withdrawal and abstinence from drugs of abuse cause anxiety and depression-like
phenotypes (Perrine et al., 2008).

1.10 Depression
Depression is a mood disorder in which feelings of sadness, loss, anger, or
frustration interfere with everyday life for a prolonged period of time (Krishnan and
Nestler, 2008). It is estimated that 16.2% of adults in the United States will experience a
major depressive episode at some point in their lifetime (Kessler et al., 2003). Depression
is often triggered by stressful life events such as childhood abuse or neglect, chronic
stress, chronic abuse or loss of rewarding social interactions such as death of partner,
friend or relative, or loss of job (Newport et al., 2002, Henn and Vollmayr, 2005,
Krishnan and Nestler, 2008, Nestler and Hyman, 2010, Krishnan and Nestler, 2011).
However, some individuals are more susceptible to develop depression due to genetic and
environmental vulnerability (Krishnan and Nestler, 2008).

1.10.1 Animal Models of Depression
As depression is such a prevalent problem in the human population, many animal
models have been developed to attempt to elucidate the underlying neural mechanisms of
depression. Depression is a multivariate illness with a number of symptoms, including
depressed mood and irritability, cognitive symptoms such as feelings of guilt and
suicidality, anhedonia or inability to experience pleasure, homeostatic symptoms such as
weight loss or gain, insomnia or hypersomnia, appetite and energy abnormalities and
alterations in psychomotor behavior (Nestler and Hyman, 2010). As such, animal models
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of depression can only objectively mimic some but not all symptoms of human
depression. As depression in humans is often triggered by stressful life events, current
animal models rely on exposing animals to stressful stimuli to induce depression-like
behavior. Several chronic stress rodent models of depression have been developed in
attempt to mimic the effects of chronic life stress on development of depression in
humans. Chronic mild stress or chronic unpredictable stress models of depression rely on
exposing animals to daily stressors (i.e. foot shock, hot or cold temperature, swim stress,
restraint) for periods of weeks to months or more (Henn and Vollmayr, 2005, Willner,
2005). Following chronic stress, animals develop anhedonia that can be blocked by
administration of antidepressants (Willner, 2005), thus providing pharmacological
validation of this model. The social defeat model of depression attempts to model
depression following chronic abuse in humans. Rodents are subjected to daily encounters
with an aggressor and social subordination. After a period of weeks to months, these
animals develop depression-like symptoms including anhedonia and social withdrawal
that can be blocked by chronic administration of antidepressants (Krishnan et al., 2007).
The social defeat model also mimics some of the homeostatic symptoms of depression
such as weight gain and insulin resistance (Chuang et al., 2010). The maternal separation
model of depression mimics childhood abuse and neglect, and relies on separating pups
from their mothers for brief period of time during the first few weeks of life. These
animals develop life-long behavioral and neuroendocrine abnormalitites, some of which
can be blocked by antidepressants (Meaney, 2001). All of these animal models reliably
induce depression-like behavior in rodents, and provide valuable insight into
development of depression in humans following stressful life events. However, as
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mentioned above, depression in humans can also be triggered by loss of socially
rewarding stimuli, such as loss of partner, relative or job (Newport et al., 2002, Henn and
Vollmayr, 2005, Krishnan and Nestler, 2008, Nestler and Hyman, 2010, Krishnan and
Nestler, 2011). Currently there are no animal models to study effects of loss of social
reward in humans. Recently, it has been demonstrated that socially monogamous prairie
voles that establish pair bonds develop depression-like behavior when they are separated
from their partner (Bosch et al., 2009), however, few mammals establish pair bonds
(Kleiman, 1977). Thus a reliable animal model for studying effects loss of social reward
on development of depression is needed.

1.11 Neural Circuitry of Depression
An initial trigger for development of depression is activation of the stress system
(Holsboer, 2000). The stress system is controlled by the hypothalamic-pituitary-adrenal
(HPA) axis. In response to a stressor, corticotropin releasing factor (CRF) is released
from the paraventricular nucleus of the hypothalamus (PVN) and acts on the pituitary to
cause release of adrenocorticotropic horme (ACTH) (Koob and Heinrichs, 1999). ACTH
then acts on the adrenal glands to cause release of cortisol (humans) or corticosterone
(rodents) (Koob and Heinrichs, 1999). CRF is the main neurotransmitter in the HPA axis
and is also synthesized in the PVN as well as in extrahypothalamic brain regions
including the central amygdala (CeA) and bed nucleus of the stria terminalis (BnST)
(Swanson et al., 1983). Hyperactivity of the HPA axis is a prominent endophenotype of
human depression (Holsboer, 2000). Depressed humans show increased plasma and
salivary cortisol, as well as increased size and activity of the adrenal glands (Nemeroff
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and Vale, 2005). Depressed humans also show increased CRF mRNA in the
cerebrospinal fluid and hypothalamus (Kling et al., 1991). Rodent models of depression
including social defeat, maternal separation and chronic stress all lead to hyperactivity of
the HPA axis seen as corticosterone hypersecretion (Ayensu et al., 1995, Francis et al.,
1999, Francis et al., 2002, Kieran et al., 2010). Increased levels of CRF in the brain are
also seen in following chronic stress (Stout et al., 2000), social defeat (Keeney et al.,
2006, Marini et al., 2006) and maternal separation (Francis et al., 1999). Thus, it is clear
that stress models of depression mimic some of the neural alterations that are present in
human depression. Moreover, administration of CRF antagonists has been shown to
block development of depression-like behavior in the chronic stress model of depression
(Ducottet et al., 2003).

1.11.1 Drug Addiction, Withdrawal and HPA Axis Alterations
The stress system is connected to the limbic system (Herman et al., 2005). As
such, exposure to stressful stimuli has been shown to lead to activation of the mesolimbic
system, and this activation has been shown to lead to relapse in drug taking in humans
and animal models (Sinha, 2008, 2009). Stress induced activation of the mesolimbic
system has also been shown to cause sensitization of the locomotor response to
psychostimulants (Kalivas and Stewart, 1991, Yap et al., 2005, Mathews et al., 2008),
synaptic adaptations of VTA dopamine neurons (Daftary et al., 2009, Hahn et al., 2009)
as well as morphological changes in the mPFC (Shansky and Morrison, 2009). Moreover,
within the HPA axis CRF signaling appears to play a role in the rewarding aspects of
stress-induced relapse associated with drug withdrawal (Hyman et al., 2006) and CRF
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antagonists have been shown to reduce effects of stress during drug withdrawal and
periods of abstinence (George et al., 2007a, George et al., 2007b, Koob, 2009). Exposure
to drugs of abuse increases HPA axis activity (Sarnyai, 1998, Sarnyai et al., 2001,
Goeders, 2002, Goeders and Clampitt, 2002) seen as increased corticosterone and ACTH
release, as well as activation of CRF neurons in rodents (Sarnyai et al., 2001).
Furthermore, during drug withdrawal, rodents demonstrate enhanced ACTH and
corticosterone release, and increased levels of CRF (Koob and Kreek, 2007, Koob,
2008).Withdrawal and subsequent abstinence from drugs of abuse in human addicts leads
to feelings of depression and anxiety (Koob, 2009), and rodents display anxiety and
depression-like behavior following withdrawal from drugs of abuse (Cryan et al., 2003,
Perrine et al., 2008). Studies in rodents have also shown that administration of CRF
antagonists prevents development of drug withdrawal induced anxiety and depressionlike behavior (Sarnyai et al., 1995, Rodriguez de Fonseca et al., 1997, Basso et al., 1999,
Sarnyai et al., 2001). Thus, there is evidence that the HPA axis is activated by drugs of
abuse and as well as in drug withdrawal. Moreover, CRF signaling appears to be a critical
mediator of drug withdrawal induced anxiety and depression.

1.11.2 Alterations in Stress Responses Following Sexual Behavior
Studies have shown that natural reward behaviors such as sexual activity cause
activation of the HPA axis. Specifically, following mating to ejaculation both sexually
naïve and experienced male rats demonstrate increased plasma corticosterone release
(Bonilla-Jaime et al., 2006, Waldherr et al., 2010, Buwalda et al., 2012) and plasma
ACTH release (Waldherr et al., 2010). Sexual behavior also causes increased cFos
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immunoreactivity in the PVN (Buwalda et al., 2012). Thus, results of these studies
indicate that the HPA axis is acutely activated by sexual behavior. When examining
longer term effects of sexual behavior in male rats, it has been shown that copulation to
ejaculation reduces anxiety-like behavior (Fernandez-Guasti et al., 1989b, Saldivar et al.,
1991) and this anxiolytic effect persists for up to four hours following mating (Waldherr
and Neumann, 2007). In addition, male rats housed with a sexually receptive female and
allowed to mate following contextual fear conditioning, demonstrate decreased fear
responses when exposed to fear associated cues (Bai et al., 2009a). Moreover, brief
exposure to estrous female odors leads to increased risk taking behaviors towards a
predator in male mice (Kavaliers et al., 2001, Kavaliers et al., 2008). In humans sexual
behavior has also been shown to lead to decreased stress responses which may persist for
hours (Brody, 2006). Thus, results of these studies suggest that sexual behavior leads to
decreased stress and anxiety related behaviors in humans and rodents following sexual
activity. In rats, sexual behavior has also been shown to lead to dampened stress
responses one day following mating seen as decreased corticosterone release in response
to acute restraint stress (Ulrich-Lai et al., 2010). Brief exposure to estrous female odors
also blocks the increase in corticosterone seen following exposure to a predator
(Kavaliers et al., 2001). Furthermore, CRF and cFos mRNA are decreased in the PVN
following exposure to forced swim stress in sexually experienced males both 45 minutes
and 4 hours following mating (Waldherr et al., 2010). Thus it is clear that mating causes
alterations in HPA axis activity as well as alterations in responses to stressors, however it
is currently unknown whether there are alterations in stress responses and HPA axis
reactivity following a prolonged abstinence period from sexual behavior. Abstinence
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from sexual behavior leads to increased vulnerability for drugs of abuse and enhances
drug craving, as well as neuroplasticity in the mesolimbic system similar to that seen
following repeated exposure to drugs of abuse (Pitchers et al., 2010). A depression and
substance abuse are often comorbid, (Kessler et al., 2003, Volkow, 2004, DuPont, 1995)
it is hypothesized that abstinence from sexual reward will also lead to depression-like
behavior, and underlying neuropathology including increased stress responses.

1.12 Rationale and Objectives: Part 2
Repeated exposure to sexual behavior causes neuroplastic changes in the
mesolimbic system, some of which are dependent on a period of abstinence from mating,
that may lead to increased vulnerability for drug addiction (Pitchers et al., 2010, Pitchers
et al., 2012),. However, it is currently unknown if abstinence from sexual reward leads to
increased vulnerability for other disorders related to reward processing, such as
depression-like behavior, or alters other systems that are activated by sexual behavior,
such as the HPA axis (Buwalda et al., 2012).

1.12.1 Hypothesis
I hypothesize that an extended abstinence period from sexual reward will lead to
depression-like behavior, including passive stress coping and anhedonia, as well as
underlying neural pathology, including hyperactivity of the HPA axis and alterations in
CRF mRNA expression.
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1.12.2 Objectives
1. Test the hypothesis that a prolonged period of abstinence from sexual
behavior leads to depression-like behavior in male rats using standard tests for
depression in rodents, including passive stress coping and anhedonia.

2. Test the hypothesis that abstinence from sexual reward leads to HPA axis
hyperactivity, including increased corticosterone and ACTH release following
exposure to an acute stressor, and increased CRF mRNA expression in the
paraventricular nucleus of the hypothalamus.

3. Determine that CRF is a critical mediator of sexual reward abstinence induced
depression-like behavior using pharmacological manipulations of CRF
receptors in the nucleus accumbens and medial prefrontal cortex.
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CHAPTER 2
Orexin mediates initiation of sexual behavior in sexually naive
male rats, but is not critical for sexual performance.

Sections 2.1-2.5 were published in Hormones and Behavior 58 (3): 397-404, 2010

2.1 INTRODUCTION
Orexin, also known as hypocretin, is a hypothalamic neuropeptide critical for
feeding behavior (de Lecea et al., 1998, Sakurai et al., 1998, Sakurai, 2006, Benoit et al.,
2008) arousal and sleep (Chemelli et al., 1999, Lin et al., 1999, Furlong and Carrive,
2007, Sakurai, 2007b, Carter et al., 2009, Furlong et al., 2009). Orexin neurons are
localized to the lateral hypothalamic area (LHA) and perifornical dorsomedial
hypothalamus (PFA-DMH) and produce two neuropeptides, orexin-A and B (de Lecea et
al., 1998, Sakurai et al., 1998). Orexin neurons have been shown to project to brain
structures involved in mediation of arousal including the locus coeruleus,
tuberomammillary nucleus and peduculopontine tegmental nucleus (Peyron et al., 1998,
Hagan et al., 1999, Horvath et al., 1999, Baldo et al., 2003). Orexin has also been
implicated in reward and motivation, specifically related to food and drugs of abuse
(Aston-Jones et al., 2009a, Aston-Jones et al., 2009b) and orexin neurons have been
shown to project to reward-related brain structures in the mesolimbic system including
the ventral tegmental area (VTA) and nucleus accumbens (NAc) (Peyron et al., 1998,
Fadel and Deutch, 2002, Martin et al., 2002, Baldo et al., 2003). Orexin neurons are
activated by conditioned contextual cues associated with food and drug reward (Harris et
al., 2005, de Lecea L, 2006, Choi et al., 2010) and have been shown to play a role in
reward-based feeding behavior (Choi et al., 2010). Moreover, intracerebroventricular
(ICV) or intraperitoneal administration of an orexin receptor 1 (ORX1) antagonist results
in reduced motivation for palatable food (Thorpe et al., 2005, Nair et al., 2008), whereas
ICV orexin-A administration can reinstate this motivation (Boutrel et al., 2005).
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The role of orexin in other rewarding behaviors is currently unclear, although
several studies have implicated a role for orexin in control of sexual behavior in male
rats. It has previously been shown that orexin neurons are activated by copulation in male
rats (Muschamp et al., 2007). In addition, administration of orexin-A into the medial
preoptic area (mPOA) resulted in enhanced sexual performance evidenced by reduced
latencies to mount and intromit, and increased frequencies of mounts and intromission
(Gulia et al., 2003). In contrast, ICV administration of orexin-A attenuated sexual
motivation by reducing female preference, although only in highly sexually motivated
males (Bai et al., 2009). Studies using ORX1 antagonists have also demonstrated
contradictory data, as systemic administration of ORX1 antagonist slightly impaired
sexual performance by increasing latency to intromit without affecting other parameters
of sexual behavior (Muschamp et al., 2007), while ICV administration of ORX1
antagonist had no effect on sexual motivation (Bai et al., 2009). Together these studies
suggest that administration of exogenous orexin-A affects sexual performance and
motivation; however, endogenous orexin may not play an important role in mediating
sexual behavior (Bai et al., 2009). Therefore, the goal of the present study was to
determine if endogenous orexin is essential for male rat sexual motivation and
performance.
First, it was determined when during sexual behavior orexin neurons are
activated, testing the hypothesis that orexin neurons are activated upon introduction of
the rewarding stimulus. Moreover, as it has been shown that sexual experience influences
sexual performance (Dewsbury, 1969) and the rewarding properties of sexual behavior
(Tenk et al., 2009), it was determined whether sexual experience influences orexin
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neuron activation during mating. Finally, it was tested whether orexin plays a critical role
in sexual motivation and performance using cell body specific lesions of orexin neurons.

2.2 MATERIALS AND METHODS

2.2.1 Animals
Adult male Sprague–Dawley rats (200–250 g) were obtained from Harlan
(Indianapolis, IN) or Charles River Laboratories (Sherbrooke, Quebec, Canada) and
housed individually or in pairs depending on the individual experiment (see below) in
Plexiglas cages. The colony room was maintained on a 12/12 reversed light–dark cycle
(lights off at 10 am) and food and water were available ad libitum except during
behavioral testing. Female Sprague–Dawley rats were obtained from Harlan
(Indianapolis, IN) or Charles River Laboratories (Sherbrooke, Quebec, Canada) were
bilaterally ovariectomized and implanted subcutaneously with 5% 17-β-estradiol
benzoate silastic capsules. Sexual receptivity was induced by subcutaneous injections of
progesterone (500 μg in 0.1 mL of sesame oil) approximately 4 h prior to mating
sessions. All procedures were approved by the Animal Care Committees at the University
of Cincinnati and the University of Western Ontario and conformed to the guidelines
outlined by the National Institute of Health and the Canadian Council on Animal Care.
All behavioral testing was conducted during the first half of the dark phase under dim red
illumination, except when noted otherwise.

2.2.2 Experimental design
2.2.2A cFos expression studies
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Male rats (n = 48) were housed individually and half of the animals gained sexual
experience in the home cage during 5 twice weekly mating sessions. Mating tests were
performed in the home cage to eliminate arousal and cFos expression induced by
exposure to a different mating arena and exposure to conditioned cues associated with
prior mating (Balfour et al., 2004). A receptive female was introduced into the home cage
and males were allowed to mate until one ejaculation or for 60 min. During each test
sexual behavior was observed. The total number of mounts and intromissions, as well as
the latencies to first mount and intromission (the time from presentation of the receptive
female to the first mount or intromission), and ejaculation (the time from the first
intromission to ejaculation), was recorded (Agmo, 1997). The remaining half of the
animals remained sexually naive. These animals were housed in the same room as the
sexually experienced males, were handled and exposed to odors and sounds associated
with mating, however did not mate. Naive and experienced animals were each further
subdivided into 6 experimental groups (n = 4 per group). The 6 naive and experienced
groups included: control males with no exposure to sexual behavior (home cage); males
exposed to a non-receptive female in the home cage for 15 min (anestrous female). Males
could investigate and interact, however did not mate due to lack of female receptivity;
males exposed to the smells of a receptive female placed in a wire mesh box on top of the
home cage for 15 min (estrous female); males that displayed mounts, but not
intromissions or ejaculation with vaginally masked females (mount); males that displayed
mounts and intromissions only (intromission); and males that mated to one ejaculation
(ejaculation). One hour after the end of the test, males were sacrificed to analyze cFos
expression. Sexually experienced groups were matched on parameters of sexual behavior
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and there were no significant differences between groups prior to the final test. Moreover,
there were no significant differences between naive and experienced groups in numbers
of mounts plus intromissions during the final test.

2.2.2A Perfusions: cFos expression
All males were deeply anaesthetised with sodium pentobarbitol (270 mg/mL) and
were transcardially perfused with 4% paraformaldehyde (500 mL; PFA). Following
perfusion brains were removed immediately and post-fixed for 1 h in the same fixative
then transferred to 20% sucrose solution for cryoprotection. Brains were sectioned on a
freezing microtome (Microm, Walldorf, Germany) in coronal sections of 35 µm and
collected in 4 parallel series in cryoprotectant solution (30% sucrose in 0.1 M PB
containing 30% ethylene glycol and 0.01% sodium azide) and stored at −20 °C until
further processing.

2.2.2B Immunohistochemistry
All incubations were performed at room temperature with gentle agitation. Free
floating sections were washed extensively with 0.1 M saline buffered sodium phosphate
(PBS). Sections were blocked with 1% H2O2 (30% stock solution) in PBS for 10 min,
then extensively rinsed again with PBS. Sections were incubated with an incubation
solution (PBS containing 0.1% bovine serum albumin and 0.4% Triton X-100) for 1 h.
Primary antibody incubations were performed in the incubation solution overnight at
room temperature. Following staining sections were rinsed in PBS, mounted onto plus
charged glass slides and coverslipped with dibutyl phthalate xylene (DPX).
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2.2.2C cFos/orexin
One series of sections was immunoprocessed for cFos and orexin. Sections were
incubated overnight with a rabbit-raised antibody recognizing cFos (rabbit anti-cFos, sc52; 1:10 000, Santa Cruz Biotechnology, Santa Cruz, CA) followed by 1 hour incubations
with biotinylated goat anti-rabbit (1:500, Vector Laboratories, Burlingame, CA) and an
avidin horseradish peroxidase complex (1:1000, ABC kit, Vector Laboratories,
Burlingame, CA). Sections were incubated for 10 min in 0.02% diaminobenzidine (DAB)
(Sigma, St. Louis, MO) in 0.1 M phosphate buffer (PB) containing 0.012% hydrogen
peroxide and 0.08% nickel sulfate, resulting in a blue-black reaction product. Sections
were then incubated overnight with a rabbit-raised antibody recognizing orexin-A (rabbit
anti-orexin-A, H-003-30; 1:20 000, Phoenix Pharmaceuticals, Burlingame, CA) followed
by a 1 hour incubation with biotinylated goat anti-rabbit and ABC, as described above.
Finally, the sections were incubated for 10 min with 0.02% DAB in 0.1 M PB containing
0.012% hydrogen peroxide, resulting in a reddish brown reaction product.
All antibodies have been characterized previously (Chen et al., 1999, Satoh et al.,
2004, Solomon et al., 2007) Immunohistochemical controls included omission of primary
antibodies, western blot analysis demonstrating single bands at appropriate weight (cFos),
and loss of immunohistochemical orexin signal with orexin-B-saporin lesions (orexin).

2.2.2D Data analysis
cFos/orexin: Neurons labelled for orexin or orexin and cFos were counted
bilaterally in three representative sections per animal known to contain maximal numbers
of the orexin neuronal population (Sakurai et al., 1998) spanning −2.3 mm to −3.6 mm
from bregma (Paxinos and Watson, 1998) (Figure 2.1), using a drawing tube attached to a
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Leica microscope (Leica Microsystems; Wetzlar Germany), by an observer blinded to
experimental groups. The PFA-DMH and LHA were delineated based on the location of
the fornix (Figure 2.1a). Percentages of orexin neurons expressing cFos were calculated
and averaged per hemisphere for each animal, and group means were calculated.
Statistical significance between groups was determined using a two-way ANOVA with
sexual experience and sexual behavior during the final test as factors followed by Fisher's
LSD tests with a 95% confidence level.

2.2.3 Orexin lesion studies
2.2.3A Surgery
Males were housed individually and given one pre-test mating session with a
receptive female prior to lesion and sham surgery. Sexual behavior was recorded as
described above and groups were matched based on parameters of mating behavior. Male
rats were anaesthetised with isoflurane (Abbot Laboratories, St. Laurent, Quebec,
Canada) using a Surgivet Isotec4 gas apparatus (Smiths Medical Vet Division, Markham,
Ontario, Canada) and placed in a stereotaxic apparatus (Kopf Instruments, Tujunga, CA)
with a gas mask covering the nose and mouth to maintain anaesthesia. An incision was
made to expose the skull and lambda and bregma were found and determined to be level.
A hole was drilled in the skull using a dremel drill (Dremel, Racine, WI) and glass
micropipettes (40 µm diameter, World Precision Instruments Inc, Sarasota, FL) filled
with a targeted toxin orexin-B-saporin (IT-20, Advanced Targeting Systems, San Diego,
CA; 200 ng/µL in PBS); or unconjugated toxin BLANK-saporin (IT-21, Advanced
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Figure 2.1. Location of orexin neurons in the hypothalamus. (A) Anatomical location of
orexin neurons in the hypothalamus (Paxinos and Watson, 1998). Scale bar: 200 µm. (B)
Single labelled orexin neurons in the PFA-DMH in an unmated control animal. (C)
Orexin neurons in the PFA-DMH expressing cFos following mating. Scale bar: 50 µm.
White arrow indicates a single labelled orexin neuron; arrowhead indicates a cFos
positive neuron; black arrow indicates an orexin neuron expressing cFos. Abbreviations:
PFA-DMH, perifornical dorsomedial hypothalamus; LHA, lateral hypothalamic area; f,
fornix.
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Targeting Systems, San Diego, CA; 200 ng/µL in PBS; sham controls) were lowered into
the hypothalamus. This targeted toxin has been shown to bind with a high affinity to cells
expressing orexin receptor 2 (ORX2) and with a significantly lower affinity for cells
expressing ORX1 (Gerashchenko et al., 2001), and has been shown to specifically ablate
orexin neurons in the hypothalamus (Frederick-Duus et al., 2007). Bilateral infusions of
1 µL (2 per hemisphere) were injected at the following coordinates: AP = −2.8 and −3.2;
ML = 0.7 and 0.8; DV = −9.0 (Paxinos and Watson, 1998). After each infusion the needle
was left in place for 3 min to allow diffusion. Needles were slowly removed and wounds
were closed with wound clips. Two weeks following lesion surgery, all males were tested
for sexual experience during four mating trials and were then subjected to the runway
and/or elevated plus maze test (see below). Surgeries were performed in three different
cohorts, separated by several weeks, to reach sufficient numbers of animals per group.

2.2.3B Sexual behavior
All males were tested for sexual behavior during 4 mating sessions conducted
every second day in the home cage. During each session, males mated with a receptive
female to one ejaculation or for 60 min, whichever came first. Mating behavior was
recorded as described above and copulation efficiency was also calculated [numbers of
intromissions / (numbers of mounts + numbers of intromissions)]. Statistical differences
in parameters of sexual performance were compared between lesion and sham groups for
each trial using a one-way ANOVA with lesion surgery as a factor and Fisher's LSD test
with a 95% confidence level, or when appropriate, non-parametric tests were run using a
Kruskal–Wallis one-way ANOVA with lesion surgery as a factor and Dunn's test with a
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95% confidence level. In addition, data for each group were compared to the pre-surgery
data using paired t-tests.

2.2.3C Sexual motivation: runway test
Following testing of sexual behavior, a subgroup of the now sexually experienced
males were tested for sexual motivation using a straight runway apparatus (MED
Associates Inc., St. Albans, VT) (120 cm long;(Lopez et al., 1999)). Males habituated to
the runway apparatus over two subsequent 10 minute trials conducted on the same day.
Next, two test trials were conducted. During the first trial, a stimulus animal (estrous
female, anestrous female or male) was placed in a goal box with perforated dividers at the
end of the runway. A fan was used to blow the scents of the stimulus animals towards the
male. Experimental males were placed in the start box, the door was opened to allow
access to the runway, and time to reach the goal box was recorded. Once reaching the
goal box, males were given 30 s to interact with the stimulus animal behind the screen.
An identical second trial followed 1 h later. Statistical significance between times to
reach the goal box between trial 1 and trial 2 was analyzed using paired t-tests with a
95% confidence level. Statistical significance between groups was determined using a
one-way ANOVA with lesion surgery as a factor followed by Fisher's LSD tests with a
95% confidence level.

2.2.3D Anxiety-like behavior: elevated plus maze
A subgroup of the now sexually experienced males was tested for anxiety-like
behavior to determine if effects of orexin lesions on sexual performance or motivation
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were due to changes in anxiety or arousal. Males were exposed to the elevated plus maze
apparatus (EPM; MED Associates Inc., St. Albans, VT) in a brightly lit room during the
end of the light phase. The EPM consisted of 4 arms each 50 cm in length extending from
a central junction and was elevated 75 cm. Two arms of the maze were open to the
outside environment and the other two were enclosed with dark siding 40 cm high.
Animals were placed on the EPM and monitored for 5 min. Time spent in open and
closed arms, and total numbers of entries into each arm were recorded using photobeam
arrays. Statistical significance between groups was determined using a one-way ANOVA
with lesion as a factor followed by Fisher's LSD tests with a 95% confidence level.

2.2.3E Perfusions and mating-induced cFos
Following all behavioral testing, all males were deeply anaesthetised with sodium
pentobarbitol (270 mg/mL) and were transcardially perfused with 500 mL of 4% PFA for
lesion verification as described previously. In addition, to test the effects of orexin lesions
on mating-induced cFos expression, groups of sham and lesion males mated until one
ejaculation. One hour following ejaculation, males were transcardially perfused with 4%
PFA as described above. Half of the males in this group were not introduced to a female
and were perfused from the home cage to serve as unmated controls.

2.2.3F Immunohistochemistry
Brains were sectioned using a freezing microtome in 4 parallel series of 35 μm
coronal sections and stored as described above. For lesion verification, one series of
sections containing the hypothalamus from all lesion experiments was single labelled for
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orexin using the same rabbit anti-orexin-A and DAB protocol as described above. One
series of sections from the animals that mated was stained for cFos and orexin as
described above.

2.2.3G Lesion verification
In each animal, numbers of orexin neurons immunoreactive for orexin were
counted bilaterally in the PFA-DMH and LHA in 3 sections expressing maximal numbers
of orexin cells in non-surgery controls, −2.3 mm to −3.6 mm from bregma as described
above. Cells per hemisphere were averaged for each animal, and group means were
calculated. Non-surgery control animals (from cFos experiments) were used to determine
intact/baseline numbers of orexin neurons and data are expressed as percentages
compared to the non-surgery control males (Figure 2.2). Males that had fewer than 20%
orexin cells compared to non-surgery control animals were included in the lesion group.
Animals with greater than 20%, but fewer than 80% of orexin neurons remaining were
included in a partial lesion group. Sham controls did not have significant changes in
numbers of orexin cells. Statistical significance between sham, partial and complete
lesion animals was calculated using a one-way ANOVA and Fisher's LSD test with a
95% confidence level.

2.2.3H Lesion specificity
To verify that lesions were restricted to orexin neurons, one series of sections
containing the hypothalamus from a subset of sham and lesion animals (n = 20) was

58

PFA-DMH

A

LHA

B

3V
f

3V

f

f

C

f

D
3V

3V

PFA-DMH

1 00

*

40
20
0

*
Co ntrol

Sh am

Partial

LHA

1 00

80
60

f

F 1 20
% Orexin cells/control

E 1 20
% Orexin cells/control

f

f

f

80
60
40

*

20

0

L esion

*

Co ntrol

Sh am

Partial

L esion

Figure 2.2. Lesion verification. Representative images showing orexin (A) and MCH (B)
cells in a sham lesion animal injected with BLANK-saporin. Representative images showing loss
of orexin cells (C), but intact MCH cells (D) in a lesion animal injected with orexin-B-saporin.
Scale bar: 400 µm; (E) quantification of orexin neurons in the PFA-DMH (E) and LHA (F) of
sham, partial and lesion males, expressed as percentages of non-surgery controls.*Indicates
significant difference from all other groups (p < 0.001). Sham: n = 35; partial lesion: n = 45;
lesion: n = 19. Abbreviations: PFA-DMH: perifornical dorsomedial hypothalamus; LHA: lateral
hypothalamic area; f: fornix.
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immunoprocessed for melanocyte concentrating hormone (MCH), a hypothalamic
peptide that has overlapping location (but no colocalization) with orexin neurons
(Broberger et al., 1998), using a rabbit-raised antibody recognizing MCH (rabbit antiMCH, H-070-47; 1:150 000, Phoenix Pharmaceuticals, Burlingame, CA) and DAB as
described previously. MCH neurons express ORX1 (Backberg et al., 2002) but not
ORX2, and are not significantly reduced following orexin-B-saporin treatment
(Frederick-Duus et al., 2007). MCH immunoreactive cells were counted bilaterally in two
sections per animal (sham: n = 7; lesion n = 5), using alternate sections to those analyzed
for orexin neurons. Lesions did not significantly reduce numbers of MCH neurons in
either PFA-DMH or LHA (Table 2.1, Figure 2.2B and D; PFA-DMH: p = 0.47; LHA:
p = 0.33). Furthermore, mating-induced cFos expression was counted bilaterally in one
representative section per animal (sham: n = 4; lesion n = 3), using alternate sections to
those analyzed for orexin neurons. Lesions did not affect mating-induced cFos expression
in the PFA-DMH or LHA (Table 2.1; PFA-DMH: p = 0.53; LHA: p = 0.82). Finally,
representative sections used for orexin cell counts (animals: sham: n = 6; lesion: n = 6)
were Nissl counterstained using cresyl violet (5 g cresyl violet acetate (C-5042, Sigma,
St. Louis, MO), 0.5 g of sodium acetate trihydrate (S209, Thermo Fisher Scientific,
Ottawa, Ontario, Canada), and 1 L double distilled water with glacial acetic acid
(AX0073-6, EMD Chemicals, Mississauga, Ontario, Canada) at pH: 3.14). Counts of
Nissl-stained neurons were performed in standard areas of analysis (250 µm × 200 µm) in
the general location of orexin neurons. Numbers of Nissl-stained neurons did not differ
between sham and lesion groups (Table 2.1, PFA-DMH: p = 0.23; LHA: p = 0.33). Since
a deficiency in orexin has been shown to contribute to narcolepsy in mice
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Sham

Lesion

PFA-DMH

LHA

PFA-DMH

LHA

Nissl

93.3 ± 7.2

84.1 ± 7.4

82.8 ± 3.9

75.3 ± 4.6

MCH

101.3 ± 4.1

136.2 ± 8.1

88.2 ± 16.6

119.1 ± 13.5

45.5 ± 6.5

30.1 ± 2.7

40.0 ± 3.8

32.0 ± 5.0

Mating-induced cFos

Table 2. 1. Verification of lesion specificity: analysis of the numbers of neurons stained
for Nissl, MCH or mating-induced cFos demonstrated that there was no significant loss
of neurons in general, MCH cells, or mating-induced neural activation in the PFA-DMH
or LHA following infusions of orexin-B-saporin. Abbreviations: PFA-DMH, perifornical
dorsomedial hypothalamus; LHA, lateral hypothalamic area; MCH, melanocyte
concentrating hormone.
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dogs (Lin et al., 1999) and humans (Siegel, 1999, Nishino et al., 2000, Peyron et al.,
2000, Thannickal et al., 2000) animals were observed to ensure the absence of a
narcoleptic phenotype. Animals were observed for the duration of all behavioral tests
reported in this study and did not display characteristics of narcolepsy.

2.2.3I Mating-induced cFos expression in lesion animals
Numbers of cFos-immunoreactive cells were counted bilaterally in 3 sections per
animals in standard areas of analysis in the ventral tegmental area (VTA; 900 × 900 µm),
mPOA (400 × 600 µm); nucleus accumbens (NAc) core and shell (400 × 600 µm) and the
prelimbic, infralimbic and anterior cingulate subregions of the medial prefrontal cortex
(mPFC) (600 × 800 µm per subregion) by an observer blinded to experimental groups.
Counts were averaged for each animal, and group means were calculated. Statistical
significance was calculated using a two-way ANOVA with sexual experience and lesion
as factors followed by Fisher's LSD test with a 95% confidence level.

2.3 RESULTS
2.3.1 Orexin neuron activation during sexual behavior
A significant increase in cFos expression in orexin neurons was observed
following sexual behavior in both the PFA-DMH (F(5,31) 63.4; p < 0.001; Figure 2.3a) and
LHA (F(5,31) 10.4; p < 0.001; Figure 2.3b), with no effect of sexual experience.
Specifically, in both sexually naive and experienced animals, all experimental groups of
males displaying different parameters of sexual behavior (investigation of anestrous
female, exposure to estrous female odors, display of mounting, intromissions, or
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ejaculation) showed equal induction of cFos compared to home cage controls with a
higher percentage of orexin cells activated in the PFA-DMH (60–80%) versus the LHA
(14–33%), without differences between the experimental groups. These results suggest
that orexin neurons are activated following exposure to the stimulus female without
further activation during sexual performance. Moreover, the activation is not dependent
on incentive salience of the female stimulus as both non-receptive and receptive females
induced activation in sexually experienced males.

2.3.2 Effects of orexin lesions
2.3.2A Sexual behavior
Orexin lesions resulted in facilitation of sexual behavior (mount latency: F(2,47)
3.962; p = 0.034; intromission latency: H = 9.104; p = 0.011). During the first mating
trial, lesion males showed shorter latencies to mount and intromission compared to sham
animals (mount latency: p = 0.03; intromission latency: p = 0.01; Figures 2.4a and b) and
compared to latencies during the pre-surgery mating trial (mount latency: p = 0.02;
intromission latency: p = 0.03; data not shown). Partial lesion males did not differ
significantly from sham males, and neither group differed from the pre-surgery mating
trial. Effects of lesions on mount and intromission latencies were attenuated with sexual
experience, as there were no differences between groups, during any of the subsequent
trials (trial 4 shown in Figures 2.4a and b). Ejaculation latencies (Figure 2.4c), numbers
of mounts (Figure 2.4d) and intromissions (Figure 2.4e) as well as copulation efficiency
(Figure 2.4f) did not significantly differ between groups during any of the trials or within
each group between the first mating trial and the pre-surgery test.
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Figure 2.3. Orexin neurons in PFA-DMH (A) and LHA (B) expressed cFos following all
parameters of mating behavior in naive and experienced animals. Abbreviations: HC,
home cage; AF: anestrous female; EF, estrous female; M, mount; IM, intromission; E,
ejaculation. *Indicates significant difference from all other groups (p < 0.001). n = 4 per
group.
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Figure 2.4. Orexin lesions shortened latencies to mount and intromission in sexually
naive males during trial 1. Orexin lesions did not affect mating during trial 4, after males
gained sexual experience. (A) Mount latency. (B) Intromission latency. (C) Ejaculation
latency. (D) Number of Mounts. (E) Number of intromissions. (F) Copulation efficiency.
*Indicates significant difference from sham. Sham: n = 19; partial lesion: n = 23; lesion:
n = 7.
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2.3.2B Runway test
Orexin lesions did not affect sexual motivation assessed in a straight runway test
in sexually experienced males. Over the course of two test trials, lesion males ran
significantly faster towards an estrous female in the second trial compared to the first trial
(p = 0.03; Figure 2.5). Such increased run time is indicative of sexual motivation (Lopez
et al., 1999). Partial lesion and sham males also ran faster towards an estrous female
during trial 2 (p = 0.03), although this failed to reach significance in sham males
(p = 0.052). None of the groups showed increased speed to run towards an anestrous
female or a male during trial 2. Moreover, no significant differences were observed
between sham, partial and lesion males on speed to run towards any stimulus animal on
neither trial 1 nor trial 2, demonstrating lack of differences in general activity on the
runway.

2.3.2C Anxiety-like behavior
Results thus far suggest that lesions may facilitate initiation of sexual behavior in
naive animals via a potential effect on responses to novelty and/or anxiety-like behaviors
when the males encounter a novel female. In support, lesion males showed decreased
anxiety-like behavior on the EPM, seen as a decreased percentage of time spent in the
closed arms, (p = 0.012; Figure 2.6) and an increased percentage of time on the open
arms (p = 0.023; Figure 2.6) compared to sham males. Partial lesions had no significant
effect. These data further support that lesion decreased anxiety-like behavior.
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Figure 2.5. Orexin lesions did not affect sexual motivation in sexually experienced
males. Shown are times to reach an estrous female in the runway test during both trials 1
and 2. *Indicates significant reduction in time to reach the female in trial 2 compared to
trial 1. Sham: n = 24; partial lesion: n = 26; lesion: n = 12.
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Figure 2.6. Orexin lesions decreased anxiety-like behavior on the elevated plus maze.
Percentage of time spent in the closed arms (left) were decreased and percentage of time
spent in open arms (right) were increased in lesioned males. *Indicates significant
difference from sham. Sham: n = 27; partial lesion: n = 36; lesion: n = 12.
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2.2.3D cFos expression
To assess whether endogenous orexin contributes to mating-induced neuronal
activation in orexin-innervated brain regions, analysis of mating-induced cFos expression
in the VTA, NAc core and shell, mPOA and the mPFC was conducted. In both lesion and
sham males, mating significantly increased cFos in all of the analyzed brain areas
compared to unmated controls (Table 2.2) Lesions did not affect neural activation, as
sham and lesion animals did not differ in baseline or mating-induced cFos expression.

2.4 DISCUSSION
These studies investigated the role of endogenous orexin in sexual performance
and motivation in the male rat. It was found that orexin is not essential for sexual
motivation or performance. Instead, orexin neurons are activated by the female stimulus,
independent of the hormonal status of the female or sexual experience of the male.
Moreover, removal of endogenous orexin by orexin cell-specific lesions decreased
anxiety-like behaviors and facilitated initiation of sexual behavior in sexually naive
males. Thus, the results of this study support a role for orexin in arousal (de Lecea et al.,
2006, Harris and Aston-Jones, 2006, Furlong and Carrive, 2007, Sakurai, 2007a, Boutrel
et al., 2009, Furlong et al., 2009) and anxiety (Suzuki et al., 2005, Davis et al., 2009, Li et
al., 2010), but do not support a critical role for orexin in sexual motivation or
performance.
The results of these studies further clarify the role of endogenous orexin and the
apparent contrasting findings of the previous studies examining the role of orexin in male
sexual behavior using pharmacological tools. Intra-mPOA infusions of exogenous orexin-
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Brain Area

Non Mating

Mating

Sham

Partial

Lesion

Sham

Partial

Lesion

VTA

13.2 ± 9

5.8 ± 3.3

3.2 ± 2.2

83.3 ± 3.3 *

79.4 ± 4.4 *

63.3 ± 20 *

NAc Core

7.9 ± 1.3

7.0 ± 3.0

2.7 ± 1.2

54.8 ± 3.4 *

61.4 ± 5.3 *

53.8 ± 24.2 *

NAc Shell

5.3 ± 3.2

5.0 ± 3.9

2.1 ± 1.2

57.4 ± 2.7 *

60.3 ± 5.2 *

38.6 ± 13.7 *

mPOA

5.9 ± 3.3

7.9 ± 3.3

8.3 ± 5.7

197.8 ± 21.4 *

184.3 ± 11.7 *

224.1 ± 22.4 *

mPFC

28.0 ± 13.2

24.0 ± 11.3

8.6 ± 6.2

296.3 ± 79.9 *

309.8 ± 44.3 *

263.4 ± 98.2 *

Table 2.2. Mating-induced cFos in sham, partial and lesion groups compared to nonmating controls of the same lesion status. *Indicates significant difference from nonmating control (p < 0.001 for all groups). No differences between groups were detected in
either baseline or mating-induced cFos expression. Abbreviations: VTA: ventral
tegmental area; NAc: nucleus accumbens, mPOA: medial preoptic area; mPFC: medial
prefrontal cortex. There were no significant differences between cFos counts in any
subregion of the mPFC, thus the combined expression of the three subregions is shown.
Sham: n = 8; partial lesion: n = 9; lesion: n = 6.
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A led to increased sexual arousal and improved sexual performance, suggesting that
orexin may act in the mPOA to increase motivation and performance of sexual behavior
(Gulia et al., 2003). However, in contrast, ICV infusions of orexin-A attenuated sexual
motivation and arousal (Bai et al., 2009), while an orexin receptor antagonist had no
effect on sexual arousal (Bai et al., 2009), indicating that endogenous orexin may not
play a role in sexual motivation. Finally, ORX1 blockade by systemic injections was
shown to only slightly impair copulatory performance (Muschamp et al., 2007). From
these conflicting studies, a few conclusions can be drawn. First, application of exogenous
orexin-A may affect behavior, but ORX1 blockade is without major effects, suggesting a
minor role for endogenous orexin in regulation of male sexual behavior (Bai et al., 2009).
The current results support this possibility. The current studies using removal of orexin,
by orexin cell-specific lesions indicate that endogenous orexin is not essential for sexual
motivation or performance, in line with observations by Bai et al., (2009). It is important,
however to note that lack of effects of orexin lesions on sexual motivation in the runway
may be due to the fact that animals had gained sexual experience prior to sexual
motivation testing, therefore lack of effect in the runway test may have been due to the
sexual experience of the males. Future experiments may address this caveat by testing the
effects of orexin lesions on sexual motivation in naive males.
It is also possible that the two orexin ligands and the two subtypes of orexin
receptors (ORX1 and ORX2; Sakurai et al., 1998) may regulate sexual behavior in
opposite directions. By utilizing orexin cell lesion techniques, the ligands for both
subtypes of orexin receptors (orexin-A and B) were eliminated in the current study. The
two receptor subtypes are expressed in different brain areas (Trivedi et al., 1998, Marcus
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et al., 2001) and have been shown to differentially regulate memory for cue induced
cocaine-seeking (Smith et al., 2009). Previous studies on sexual behavior have primarily
focused on the role of orexin-A and ORX1 (see discussion above). The orexin receptor
antagonist SB334867 used in the studies thus far specifically targets ORX1 which has a
high affinity for orexin-A and significantly lower affinity for orexin-B (Sakurai et al.,
1998). Likewise, orexin-A has been used as the exogenous orexin in previous studies
(Gulia et al., 2003, Bai et al., 2009). Future studies are needed to investigate the role of
orexin-B and ORX2 in regulation of male sexual behavior.
The current study tested the effects of long term loss of orexin. Muschamp et al.,
(2007) suggested that a long term reduction of orexin following castration may account
for the loss of sexual motivation and performance. This hypothesis was contradicted by
the current findings as orexin cell lesions did not reduce sexual motivation or
performance. It is possible that the long term orexin loss in the current study may have
resulted in compensatory mechanisms, although no changes in mating-induced neural
activation within the circuit mediating sexual behavior were detected. Nonetheless, it is
clear that reduced or lack of orexin does not prevent sexual behavior. Moreover, the
results of the current study do not support a major role for orexin in induction of cFos
expression by sexual behavior. It has been clearly established that orexin contributes to
activation of neurons in the VTA (Korotkova et al., 2003, Borgland et al., 2006, Narita et
al., 2006, Vittoz et al., 2008). However, orexin cell lesions did not block mating-induced
neural activation in the VTA, or in any other reward-related brain regions analyzed,
despite the presence of orexin-immunoreactive fibers in close proximity to the activated
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neurons in sham males. Thus, mating-induced neural activation in these brain regions
does not appear to be dependent on orexin action.
A somewhat unexpected finding of the current study was the effect of orexin
lesions on facilitation of the initiation of sexual behavior in sexual naive, but not
experienced animals. This was shown to be correlated with a reduction in anxiety-like
behaviors. Therefore, the effects of orexin lesions on sexual motivation and performance
may be secondary to its effects on anxiety and arousal. Indeed previous studies have
suggested a role for orexin in anxiety as ICV infusion of orexin-A decreased time on the
open arms of the EPM in mice (Suzuki et al., 2005). Infusion of orexin-A into the
paraventricular nucleus of the thalamus of male rats decreased time spent in the center
area of an open field chamber and decreased novel object exploration, indicating that
orexin may be involved in the generation of anxiety-like behavior (Li et al., 2010). In
addition, dominant male rats that show increased risk taking on the EPM have increased
levels of ORX1 mRNA in the mPFC (Davis et al., 2009). Orexin has also been shown to
alter responses to stress (Ida et al., 1999, Ida et al., 2000), and stimulation of orexin
receptors increases release of corticotrophin releasing factor (Al-Barazanji et al., 2001,
Singareddy et al., 2006), corticosterone (Ida et al., 2000, Kuru et al., 2000) and
adrenocorticotropic hormone (Kuru et al., 2000). Orexin antagonists are currently in
clinical trials for treatment of insomnia, a disorder which is often comorbid with anxiety
disorders (Sullivan and Neria, 2009), and it is hypothesized that orexin antagonists could
potentially be used to treat anxiety disorders (Mathew et al., 2008). Given the growing
body of evidence of a role for orexin in anxiety and arousal it appears that orexin lesions
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may facilitate the initiation of sexual behavior in naive males by reducing anxiety-like
responses associated with the introduction of a novel stimulus, i.e. the female.
Significant activation of orexin neurons was seen following sexual arousal and
sexual behavior in both sexually naive and experienced animals in both the PFA-DMH
and LHA, with 60–80% and 14–33% of orexin cells expressing cFos, respectively. There
is a body of evidence supporting a dichotomy in orexin neuronal function within the
orexin cell population, with the PFA-DMH being critically involved in arousal and the
LHA being critical for reward-related behaviors (Harris et al., 2005, Harris and AstonJones, 2006, Aston-Jones et al., 2009a). Hence, activation of the PFA-DMH orexin cells
by the female stimulus supports the hypothesis that orexin is activated by and is critical
for arousal, including sexual arousal in naive and experienced males, and anxiety
associated with the novel female stimulus in naive males. However, PFA-DMH cells
were activated to similar levels independent of the experience of the males and the
hormonal status of the female, suggesting that the PFA-DMH cells were activated during
general arousal and not specifically by sexual arousal. Moreover, our studies do not fully
support the existence of a completely dichotomous orexin cell population as there was a
significant activation of the LHA following exposure to all parameters of sexual arousal
and performance, regardless of whether the behaviors were associated with reward. Thus,
experienced males exposed to an anestrous female showed equal levels of orexin cell
activation in the LHA compared to experienced males that copulated to ejaculation.
However, only the latter group will form a conditioned place preference for mating (Tenk
et al., 2009); suggesting that copulation to ejaculation is more rewarding than other
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elements of mating. The current study did not specifically test the role of orexin in sexual
reward; hence future studies are needed to address that question.
In summary, the results of these studies demonstrate that orexin is not critical for
sexual performance or motivation. Instead, orexin cell lesions were demonstrated to
reduce anxiety, suggesting that endogenous orexin is involved in increasing anxiety.
Moreover, removal of orexin resulted in facilitation of initiation of sexual behavior in
sexually naive males, suggesting that endogenous orexin may inhibit initiation of mating,
possibly by increasing anxiety in response to the novel stimulus, i.e. the female. These
findings further elucidate the neural circuitry involved in sexual performance and anxiety,
and add to a growing body of literature on the role of orexin in mediation of arousal and
anxiety.
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CHAPTER 3
Lesions of orexin neurons block conditioned place preference
for sexual behavior in male rats.

Sections 3.1-3.5 were published in Hormones and Behavior (59): 1-8, 2011

3.1 INTRODUCTION
The hypothalamic neuropeptide orexin (hypocretin) is found exclusively in the
lateral hypothalamic area (LHA) and the perifornical-dorsomedial hypothalamus (PFADMH) and consists of two active peptides, orexin-A and orexin-B (de Lecea et al., 1998,
Sakurai et al., 1998). Orexin is critical for food intake (de Lecea et al., 1998, Sakurai et
al., 1998, Sakurai, 2006, Benoit et al., 2008), arousal and sleep (Chemelli et al., 1999, Lin
et al., 1999, Sakurai, 2007a, b, Carter et al., 2009). Recent studies have shown that orexin
also plays a critical role in mediation of reward (DiLeone et al., 2003, Aston-Jones et al.,
2009, Aston-Jones et al., 2010) and orexin cells have extensive projections throughout
the brain, including to reward associated brain areas such as the nucleus accumbens
(NAc) and ventral tegmental area (VTA) (Peyron et al., 1998, Fadel and Deutch, 2002,
Martin et al., 2002).
Orexin neurons are activated by conditioned contextual cues associated with food
and drug reward in a conditioned place preference (CPP) paradigm (de Lecea et al.,
2006), a standard paradigm used to determine reward seeking behavior (Tzschentke,
2007). Moreover, excitotoxic lesions of orexin neurons in the LHA or orexin receptor-1
antagonists in the VTA significantly reduce morphine preference in a CPP paradigm
(Harris et al., 2007). In addition, LHA orexin neuronal stimulation, and intra-VTA
orexin-A administration reinstate morphine CPP following extinction (Harris et al.,
2005). Orexin-A administration into the LHA increases self administration of palatable
food (Thorpe et al., 2005) while orexin receptor-1 antagonists block self administration of
food (Nair et al., 2008), ethanol (Lawrence et al., 2006) and nicotine (Hollander et al.,
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2008). Thus, there is ample evidence that orexin plays a role in reward processing related
to food intake and drugs of abuse.
Orexin neurons are activated by sexual behavior in male rats (Muschamp et al.,
2007, Di Sebastiano et al., 2010). In addition, exogenous orexin-A administration into the
medial preoptic area enhances copulatory performance in male rates, evidenced by
shortened latencies to mount and intromission, and increased frequency of mounts and
intromissions (Gulia et al., 2003). However, a critical role for endogenous orexin in
sexual behavior is not supported by findings that orexin cell-specific lesions do not
disrupt sexual motivation or performance (Di Sebastiano et al., 2010), that
intracerebroventricular (ICV) administration of an orexin receptor-1 antagonist does not
disrupt sexual motivation (Bai et al., 2009), and that systemic administration of
antagonist only slightly inhibits sexual performance (Muschamp et al., 2007). However, a
role for endogenous orexin in mediation of sexual reward has yet to be elucidated.
Therefore, the goal of the current study was to test the hypothesis that orexin plays a
critical role in processing of sexual reward. First, it was determined whether orexin
neurons are activated by conditioned cues predicting sexual reward by exposing male rats
to an environment associated with prior sexual behavior. Next, orexin cell-specific
lesions were utilized to determine a specific role for orexin in sexual reward processing
using a CPP paradigm (Agmo and Gomez, 1993, Tenk et al., 2009).
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3.2 MATERIALS AND METHODS
3.2.1 Animals
Adult male Sprague Dawley rats (200-250g) were obtained from Harlan
(Indianapolis, IN) or Charles River Laboratories (Sherbrooke, Quebec, Canada) and were
pair housed for the duration of experiments in Plexiglas cages. The colony room was
maintained on a 12/12 reversed light-dark cycle (lights off at 10 am) with food and water
available at all times except during behavioral testing. Female Sprague-Dawley rats were
obtained from Harlan (Indianapolis, IN) or Charles River Laboratories (Sherbrooke,
Quebec, Canada), were bilaterally ovariectomized and received subcutaneous implants of
5% 17-β-estradiol benzoate in silastic capsules. Sexual receptivity was induced by
subcutaneous progesterone injections (500 μg in 0.1 ml of sesame oil) approximately 4 h
prior to mating sessions. All procedures were approved by the Animal Care Committees
at the University of Cincinnati and the University of Western Ontario and conform to
guidelines outlined by the National Institute of Health and the Canadian Council on
Animal Care.

3.2.2 Experiment 1: cFos Expression Studies
3.2.2A Apparatus
The CPP apparatus (MED Associates, St. Albans, VT) consisted of three
chambers with different visual and tactile cues. The two test chambers (28 x 22 x 21 cm)
had black walls and parallel bar flooring or white walls and metal grid flooring and were
separated by a central compartment (13 x 22 x 21) with grey walls and a smooth, grey
Plexiglas floor. The three chambers were connected by guillotine doors in colors
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matching the chamber with which they were attached and males were confined to one
chamber or allowed to move freely between chambers.

3.2.2B Experimental Design
On the day 1 (pre-test) males (n=5; paired males) were allowed free access to the
entire apparatus for 15 min and the initial preference for each animal was determined. As
a group, animals did not display preference for one chamber, but each animal had a slight
(less than 60 second) preference (Pitchers et al., 2009, Tenk et al., 2009). On days 2 and 3
(conditioning trials), males mated to one ejaculation in the home cage and mating
behavior was observed and recorded (Agmo, 1997). A receptive female was placed in the
home cage and total numbers of mounts and intromissions as well as latencies to first
mount and intromission (time from presentation of a receptive female to first mount or
intromission) as well as latency to ejaculation (time from the first intromission to
ejaculation) were recorded during each trial. Immediately following ejaculation males
were placed into the paired chamber (initially non-preferred chamber for 30 minutes. For
control pairings, males were placed into the unpaired (initially preferred) chamber
without mating for 30 minutes. Half of the animals received sex pairing on day 2 and
control pairing on day 3. The remaining animals received sex pairing on day 3 and
control pairing on day 2. On day 4, a post-test procedurally identical to the pre-test was
conducted and conditioned preference was determined. Another group of males (n=5;
unpaired males) served as a control group and were placed in the chambers without
mating on both conditioning days. A preference score (percentage of time spent in the
sex-paired chamber) and difference score (time spent in the sex-paired chamber minus
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the time spent in the control chamber) were calculated for each animal and compared
using a paired t-test, with a 95% confidence level. Indeed, males formed a significant
CPP for the sex paired chamber seen as an increased preference score (p=0.038) and
difference score (p=0.04) in the post-test compared to the pre-test following one pairing
with ejaculation, confirming previous reports (Straiko et al., 2007, Tenk et al., 2009,
Webb et al., 2009a, Webb et al., 2009b), while control males did not form a preference
for either chamber.

3.2.2C Tissue Processing
One hour following the end of the post-test, males were anesthetised with sodium
pentobarbitol (270mg/mL) and were transcardially perfused with a 0.9% saline solution
followed by 500 mL of 4% paraformaldehyde (PFA) in 0.1M phosphate buffer (PB).
Brains were quickly removed and post-fixed for one hour in the same fixative and
transferred to a 20% sucrose solution for cryoprotection. Brains were sectioned into 35
µm coronal sections on a freezing microtome (Microm, Walldorf, Germany) and
collected in 4 parallel series in cryoprotectant solution (30% sucrose in 0.1 M PB
containing 30% ethylene glycol and 0.01% sodium azide). Brains were stored at -20 C
until further processing.

3.2.2C Immunohistochemistry: cFos/Orexin
Incubations were performed with gentle agitation at room temperature. Free
floating sections were extensively washed in 0.1M saline buffered sodium phosphate
(PBS). Sections were blocked for 10 minutes in 1% H2O2 (30% stock solution) in PBS,
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then again rinsed extensively with PBS. Sections were then incubated for 1 hour in an
incubation solution (PBS containing 0.1% bovine serum albumin and 0.4% Triton X100). Primary antibody incubations were performed overnight at room temperature in the
same incubation solution. Following staining sections were rinsed extensively with PBS,
mounted onto plus charged glass slides and coverslipped with dibutyl phthalate xylene
(DPX).
One series of sections was immunoprocessed for cFos and orexin. Sections
underwent an overnight incubation with a rabbit raised antibody recognizing cFos (rabbit
anti-cFos, SC52; 1:10,000, Santa Cruz Biotechnology, Santa Cruz, CA) which was
followed by incubation with biotinylated goat anti-rabbit (1:500, Vector Laboratories,
Burlingame, CA) for 1 hour and a 1 hour incubation with avidin horseradish peroxidase
complex (1:1000, ABC kit – Vector Laboratories, Burlingame, CA). Finally, sections
underwent incubation for 10 minutes in 0.02% diaminobenzidine (DAB) (Sigma, St.
Louis, MO) in 0.1M PB containing 0.012% hydrogen peroxide and 0.08% nickel sulfate,
which resulted in a blue-black reaction product. Next, sections were incubated overnight
with a rabbit raised antibody recognizing orexin-A (rabbit anti-orexin-A, H-003-30;
1:20,000, Phoenix Pharmaceuticals, Burlingame, CA) followed by 1 hour incubation with
biotinylated goat anti-rabbit and ABC, as described above. Immunoreactivity was
visualized by a 10 minute incubation with 0.02% DAB in 0.1M PB containing 0.012%
hydrogen peroxide, resulting in a reddish brown reaction product.
All antibodies were previously characterized (Chen et al., 1999, Satoh et al., 2004,
Solomon et al., 2007). Controls for immunohistochemistry included: primary antibody
omission, western blot analysis demonstrating bands of appropriate weight (cFos) and
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loss of immunohistochemical signal following lesions of orexin neurons with orexinsaporin (orexin).

3.2.2E Data Analysis
Neurons labelled for orexin or orexin and cFos (Figure 3.1) were bilaterally
counted in the PFA-DMH and LHA in 3 sections per animal known to contain maximal
numbers of orexin neurons, spanning a distance from -2.3 mm to -3.6mm (Paxinos and
Watson, 1998), using a Leica microscope (Leica Microsystems; Wetzlar Germany).
Anatomical location of the PFA-DMH and LHA was determined based on location of the
fornix. Data were expressed as percentages of orexin cells that expressed cFos and
averages were calculated per hemisphere, per section, for each animal, and group means
were calculated. Statistical significance between paired and unpaired groups was
determined for PFA-DMH and LHA using student’s t-test with a 95% confidence level.

3.2.3 Experiment 2: Orexin Cell-Specific Lesion Studies
3.2.3A Lesion Surgery
Males underwent one pre-test mating session in a clean Plexiglas mating cage
(60×45×50 cm3) prior to undergoing lesion or sham surgery. A receptive female was
placed into the cage and males were allowed to mate to one ejaculation or for 60 minutes.
Sexual behavior was recorded as described above and groups were matched on
parameters of mating behavior. Male rats were anesthetized with isoflurane (Abbot
Laboratories, St. Laurent, Quebec, Canada) in a Surgivet Isotec4 gas apparatus (Smiths
Medical Vet Division,
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Figure 3.1. Orexin and cFos immunoreactivity in PFA-DMH (A,C) and LHA (B,D) in
unpaired control (A,B) and paired (C,D) males. White arrow indicates an example single
labelled orexin neuron; arrowhead indicates an example single labelled cFos neuron;
black arrow indicates an example orexin neuron expressing cFos; Scale bar: 50 µm.
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Markham, Ontario, Canada). A gas mask was placed over the nose and mouth to maintain
anaesthesia and males were secured in a stereotaxic apparatus (Kopf Instruments,
Tujunga, CA). An incision was made, the skull was exposed, and lambda and bregma
were found and determined to be level horizontally. A hole was drilled into the skull
using a dremel drill (Dremel, Racine, WI). Glass micropipettes (40µm diameter, World
Precision Instruments Inc, Sarasota, FL) were filled with the targeted toxin orexin Bsaporin (Advanced Targeting Systems, San Diego, CA; 200ng/µL in PBS) or
unconjugated toxin BLANK-saporin (Advanced Targeting Systems, San Diego, CA;
200ng/µL in PBS; sham controls) and were lowered into the hypothalamus. This toxin
has a high affinity for orexin receptor 2 expressing cells, and a significantly lower affinity
for orexin receptor 1 expressing cells (Gerashchenko et al., 2001), and has been shown to
specifically lesion orexin neurons in the hypothalamus (Frederick-Duus et al., 2007, Di
Sebastiano et al., 2010). To ensure the toxin spread would encompass the majority of the
orexin neuronal population, two injections were made per hemisphere at different rostrocaudal coordinates. 1 µL infusions (2 per hemisphere) were infused bilaterally at the
following coordinates: AP = -2.8 and -3.2, ML = 0.7 and 0.8, DV = -9.0. Following each
infusion the needles were left in place for 3 minutes to allow diffusion. Micropipettes
were removed slowly and incisions were closed with wound clips.
Following a two week recovery from surgery, males received four mating
sessions to gain sexual experience and were subsequently subjected to either a
conditioned place preference (CPP) or conditioned place aversion (CPA) paradigm. All
tests were performed during the second half of the dark phase under dim red illumination.
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3.2.3B Conditioned Place Preference (CPP)
The CPP test was conducted as described above, with conditioning trials repeated
twice over the course of 4 consecutive days. A separate group of sham control males
(n=15) was included that did not receive mating paired with either chamber and served as
a negative control group to demonstrate lack of non-specific change in preference. The
post-test was conducted on the sixth day as described previously and preference score
(percentage of time spent in paired chamber) and difference score (time spent in paired
chamber minus the time spent in the control chamber) were calculated. Time in the paired
chamber in the post-test compared to the pre-test was also calculated. Statistical
differences in the pre-test and post-test data were compared using a paired t-test, with a
95% confidence level. Formation of CPP was defined as a significant increase in both
preference score and difference score in the post-test compared to the pre-test.

3.2.3C Conditioned Place Aversion (CPA)
The CPA experiment was conducted in the same apparatus used in the CPP
paradigm using lithium chloride (LiCl) induced visceral illness as the aversive stimulus.
Males underwent a pre-test as described above. Over the course of 4 consecutive
conditioning days immediately following the pre-test, males were injected with a 20
mL/kg dose of 0.15M LiCl and placed into the initially preferred chamber. On alternate
days males were injected with a 20 mL/kg dose of 0.9% saline and placed into the
initially non-preferred chamber. The post-test was conducted on the sixth day as
described above, and preference score and difference score were calculated in the same
manner. Statistical differences in the pre-test and post-test data were compared using a
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paired t-test, with a 95% confidence level. Formation of CPA was defined as a significant
decrease in both preference score and difference score in the post-test compared to the
pre-test.

3.2.3D Tissue Processing
Following completion of all experimental testing, males were anesthetized with
sodium pentobarbital (270mg/mL) and perfused transcardially with 4% PFA as described
above. Brains were removed and stored in cryoprotectant for further processing and
lesion analysis.

3.2.3E Immunohistochemistry
Orexin: One series of sections from the CPP and CPA experiments was
immunoprocessed for orexin using the same rabbit raised antibody recognizing orexin-A
(rabbit anti-orexin-A, H-003-30; 1:20,000, Phoenix Pharmaceuticals, Burlingame, CA)
and DAB for lesion verification.

3.2.3F Lesion Verification
Numbers of orexin neurons in the PFA-DMH and LHA were bilaterally counted
in 3 sections per animal, containing the maximum number of orexin neurons, spanning a
distance from -2.3 mm to -3.6mm relative to bregma (Paxinos and Watson, 1998) using a
Leica microscope (Leica Microsystems; Wetzlar Germany). Cells per hemisphere, per
section were averaged for each animal, and group means were calculated. Numbers of
orexin cells were also counted in a separate group of males that had not undergone
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surgery (n=20) and counts in lesion males were expressed as percentages of these nonsurgery control values. Lesions were classified as follows: males that had fewer than 20%
of the total number of orexin cells compared to non-surgery control animals were
included in the lesion group. Animals with greater than 20%, but fewer than 80% of
orexin cells were included in a separate partial lesion group (Figure 3.2). Sham control
animals did not have significant changes in numbers of orexin cells when compared to
non-surgery controls (Table 1). Statistical significance between sham, partial and lesion
animals was calculated using a one-way ANOVA and Fisher’s LSD test with a 95%
confidence level. Experiments were performed on multiple separate surgical cohorts of
animals due to the low portion of orexin-B saporin treated animals that were verified to
have complete lesions. For CPP two separate experiments were performed to include
intact sham controls (exp.1: n=8 and exp. 2: n=10; combined n=18), males with partial
lesions (exp. 1: n=8 and exp. 2: n=17; combined n=25) and males with complete lesions
(combined n=8). The CPA experiment was performed using a third surgical cohort of
animals. In this experiment 10 males had complete lesions, 19 were partial lesions and 17
were intact sham controls.

3.2.3G Lesion Specificity
In order to determine if lesions specifically targeted orexin neurons, analysis of
melanocyte concentrating hormone (MCH) and Nissl stained neurons in the PFA-DMH
and LHA were conducted, as these markers have been shown previously to be unaltered
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Figure 3.2. Representative images showing orexin neurons in the hypothalamus of a
sham animal injected with BLANK-saporin (A) and loss of orexin neurons in the
hypothalamus of a lesion animal injected with orexin-B-saporin (B). Abbreviations:
PFA-DMH: perifornical-dorsomedial hypothalamus; LHA: lateral hypothalamic area; f:
fornix. Scale bar: 200 µm.
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following administration of orexin-B saporin (Frederick-Duus et al., 2007, Di Sebastiano
et al., 2010). One series of sections from a subset of animals (n=20) was
immunoprocessed for MCH, another hypothalamic peptide with overlapping location, but
no colocalization with orexin neurons (Broberger et al., 1998) using a rabbit-raised
antibody recognizing MCH (rabbit anti-MCH, H-070-47; 1:150,000, Phoenix
Pharmaceuticals, Burlingame, CA). Analysis of MCH immunoreactivity was quantified
in two bilateral sections per animal, using alternate sections to those quantified for orexin
neurons, and no significant damage to the MCH population was observed, indicating
lesions were specific to orexin neurons. To further verify lesion specificity representative
sections from animals used for orexin cell counts (sham: n=6; lesion: n=6) were Nissl
counterstained using cresyl violet. Nissl stained neurons were counted in standard areas
of analysis (250 µm x 200 µm) in the general location of the orexin neuronal population
and there were no significant differences in numbers of Nissl stained neurons in lesion
animals compared to sham.

3.4 RESULTS
3.4.1 Orexin neuron activation by sexual reward
To determine if orexin neurons are activated during seeking of sexual reward,
cFos expression was analyzed in animals that formed a mating-induced CPP and
compared to unpaired control males (Figure 3.3). Exposure to the CPP apparatus resulted
in a significantly greater percentage of orexin neurons that expressed cFos in paired
compared to unpaired males in the PFA-DMH (p=0.0019) and LHA (p=0.026). In both
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Sham
PFA-DMH
LHA

Partial

CPP

97.5 ±
2.6%

97.6 ±
3.7%

PFADMH
49.1 ±
3.2%

CPA

108.8 ±
3.6%

103.8 ±
3.4%

48.9 ±
3.6%

Lesion
LHA

58.0 ±
2.9%

PFADMH
7.1 ±
2.1%

LHA
24.0 ±
2.9%

51.4 ±
3.9%

9.3 ±
2.1%

22.7 ±
4.6%

Table 3.1. Quantitative data for orexin lesion verification. The percentages of orexin
neurons relative to non-surgery control males are listed for the CPP and CPA
experiments. In each experiment, percentages of orexin neurons are significantly lower in
the partial and lesion groups compared to sham controls in the PFA-DMH and LHA
(p<0.001). All data represent mean percentages ± standard error of the mean (SEM). *
indicates significant difference from sham control PFA-DMH; # indicates significant
difference from sham control LHA. Abbreviations: PFA-DMH: perifornical-dorsomedial
hypothalamus; LHA: lateral hypothalamic area; CPP: conditioned place preference; CPA:
conditioned place aversion. Numbers of animals per group: CPP: Sham n=18; Partial
n=25; Lesion n=8. CPA: Sham: n=17; Partial: n=19; Lesion: n=10.
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unpaired and paired males, exposure to the CPP chamber resulted in higher percentages
of cFos-positive orexin cells in the PFA-DMH compared to the LHA orexin population
(unpaired: p=0.003; paired: p<0.0001). Although the increase in percentages of activated
orexin cells in paired compared to unpaired males appeared greater in the PFA-DMH
(28%) than LHA (7.6%), the fold change in orexin activation was similar in both regions
(1.7 fold increase). These results indicate that orexin neurons in PFA-DMH and LHA are
activated by contextual cues associated with sexual reward.

3.4.2 Mating-induced Conditioned Place Preference (CPP)
To determine if orexin is critically involved in sexual reward processing, effects
of orexin lesions on mating-induced CPP were determined. Lesions did not affect any
parameter of sexual behavior during the CPP pairing test (Table 2), confirming our
previous report that orexin lesions do not alter sexual behavior in sexually experienced
male rats (Di Sebastiano et al., 2010) However, lesion males failed to develop a
conditioned preference for a mating-paired chamber, while sham and partial lesion males
did form a mating-induced CPP. In particular, sham and partial lesion males, but not
lesion males, showed a significant increase in preference score (percentage of time spent
in the sex-paired chamber; sham: p=0.003; partial: p=0.04; Figure 3.4a) and a significant
increase in difference score (time spent in the sex-paired chamber minus time spent in the
control chamber; sham p=0.005; partial: p=0.04; Figure 3.4b) during the post-test.
Control unpaired males that did not associate mating with either chamber of the CPP
apparatus did not form a preference for either chamber, confirming that repeated
exposure to the CPP apparatus did not result in preference (Figure 3.4a/b). Sham males
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Figure 3.3. Percentages of orexin neurons expressing cFos in the PFA-DMH and LHA
following exposure to the CPP apparatus in unpaired control males (black bars) and
mating-paired males (white bars). All data are mean ± SEM ; n= 5 animals per group. *
indicates significant difference from unpaired group.
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Mount Latency (s)
Intromission Latency (s)
Ejaculation Latency (s)
# of Mounts
# of Intromissions

Sham
13.0 ± 2.1
18.5 ± 4.1
449.0 ± 53.1
6.1 ± 1.7
11.8 ± 1.0

Partial
13.3 ± 2.1
21.3 ± 5.3
541.5 ± 58.4
5.3 ± 1.0
11.7 ± 0.9

Lesion
12.3 ± 3.0
24.2 ± 7.9
412.1 ± 70.5
4.3 ± 1.3
9.1 ± 1.8

Table 3.2. Sexual behavior during the CPP conditioning trial. All data are mean ± SEM.
No significant differences between groups were detected in any parameter of sexual
behavior. Numbers of animals per group: CPP: Sham n=18; Partial n=25; Lesion n=8.
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spent significantly more time in the paired chamber during the post-test than pre-test,
compared to control unpaired males (95.4 ± 29.7s versus 30.6 ± 13.7s; p=0.017). Lesion
males did not spend more time in the paired chamber during the post-test than pre-test (10.9 ± 56.2s). Although partial lesion males spent 67.7 ± 32.5s in the paired chamber
during the post-test than pre-test, this failed to reach statistical significance.
Finally, as described in the methods, the CPP experiment was conducted in two
separate surgical cohorts and in both experiments sham (n=8 and n=10 resp.) as well as
partial lesioned (n=8 and n=17 resp.) males showed a significant preference (p=0.030.004) and difference score (p=0.04-0.005). Hence, the failure to detect significant
mating induced CPP in lesion animals is not a result of a smaller number of animals in
that group (n=8), but rather a result of the orexin lesions.

3.4.3 Conditioned Place Aversion (CPA)
To determine if orexin lesions blocked CPP by affecting associative learning for a
particular context, males underwent a CPA paradigm. Lesion males, as well as sham and
partial lesion males, formed a significant aversion for the LiCl paired chamber.
Specifically all groups showed a significant decrease in preference score (p<0.001;
Figure 3.5a) and a significant decrease in difference score (p<0.001; Figure 3.5b).
Therefore, orexin lesions do not disrupt associative learning and memory in general.
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Figure 3.4. Orexin lesions prevent mating-induced CPP. (A) Percentages of time spent in
the sex-paired chamber (preference score) during pre- and post-test. (B) Time (s) spent in
the sex-paired chamber minus the time spent in the control chamber (difference score)
during pre- and post-test. All data are mean ± SEM. * indicates significant difference
from pre-test. Numbers of animals per group: Control: n=16; Sham: n=18; Partial: n=25;
Lesion: n=8.
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Figure 3.5. Orexin lesions do not prevent CPA for an aversive stimulus. (A) Percentages
of time spent in the sex-paired chamber (preference score) during pre- and post-test. (B)
Time (s) spent in the sex-paired chamber minus the time spent in the control chamber
(difference score) during pre- and post-test. All data are mean ± SEM * indicates
significant difference from pre-test. Numbers of animals per group: Sham: n=17; Partial:
n=19; Lesion: n=10.
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3.4 DISCUSSION
Results of this study showed that orexin neurons are activated during exposure to
sexual reward-associated contextual signals and are critical for cue-induced seeking of
sexual reward. Thus, the present results expand on a growing body of literature
demonstrating a critical role for orexin in reward processing (Harris and Aston-Jones,
2006, Aston-Jones et al., 2009, Aston-Jones et al., 2010) . These results also add to
findings on the role of orexin in sexual behavior and sexual reward processing. It has
been shown previously that orexin neurons are activated by sexual behavior in male rats
(Muschamp et al., 2007). However, endogenous orexin does not appear to be essential for
sexual performance. In a previous study, it was demonstrated that orexin lesions facilitate
initiation of sexual behavior in sexually naive males (Di Sebastiano et al., 2010). Orexin
lesions also reduced anxiety-like behavior, hence the effect of orexin lesions on initiation
of mating may be due to reduced anxiety associated with the introduction of a novel
female stimulus . The facilitative effects of orexin lesions were attenuated with sexual
experience and orexin lesions did not affect any parameter of sexual performance in
sexually experienced male rats (Di Sebastiano et al., 2010). In addition, orexin lesions did
not alter sexual motivation as determined using a straight runway test (Lopez et al., 1999,
Di Sebastiano et al., 2010). In agreement, Bai and coworkers showed that ICV
administration of orexin receptor antagonists did not disrupt sexual motivation (Bai et al.,
2009). In the current study sexually experienced males with orexin lesions did not show
impaired sexual behavior, therefore endogenous orexin does not appear to be essential for
sexual performance or motivation, but may be critical for processing of sexual reward
and conditioned cue-induced sexual reward seeking behavior.
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The current findings that orexin is essential for sexual reward processing and
specifically for mating-induced CPP are consistent with previous findings that orexin is
critical for the acquisition and expression of food and drug induced CPP (Harris et al.,
2005, Harris et al., 2007). In addition, orexin is essential for conditioned responses, but
not for the reinforcement of cocaine (Aston-Jones et al., 2010). Specifically, the orexin
receptor antagonist SB-334867 attenuated reinstatement of extinguished cocaine (Smith
et al., 2009) and ethanol (Lawrence et al., 2006) seeking induced by conditioned cues, but
not induced by cocaine priming (Smith et al., 2009). Perhaps along the same lines, the
current study shows that orexin lesions prevented conditioned seeking of sexual reward,
but did not affect initiation (seeking) or expression of sexual behavior in the presence of
the receptive female. A potential alternate explanation for these findings is that orexin is
involved in the acquisition or expression of associative memory in general (Jaeger et al.,
2002, Aou et al., 2003, Smith and Pang, 2005, Akbari et al., 2008) and thus effects of
manipulations could be caused by disruption of associative memory in the CPP paradigm,
rather than disruption of conditioned reward seeking. Therefore, the current study set out
to demonstrate that males with orexin lesions maintained the ability to form a conditioned
aversion to lithium chloride induced visceral illness in the same contextual environment
as was used for CPP. Hence, orexin lesions in the current experiment did not disrupt the
ability to form associative contextual memories.
There is ample evidence supporting a dichotomy in orexin neuronal function, with
PFA-DMH neurons critically involved in arousal and waking and LHA neurons involved
in reward (Harris and Aston-Jones, 2006, Aston-Jones et al., 2009, Aston-Jones et al.,
2010). LHA orexin neurons, but not PFA-DMH orexin neurons, are activated by
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conditioned cues associated with cocaine, morphine, or food reward (Harris et al., 2007)
and stimulation of LHA orexin neurons induces or reinstates conditioned preference for
drug reward (Harris et al., 2005, Aston-Jones et al., 2010). The findings in the current
study do not conform with this dichotomy, as neurons in both LHA and PFA-DMH were
activated by cues associated with sexual reward. Other recent evidence also suggests a
role for the PFA-DMH in reward processing, as this population of neurons becomes
activated following exposure to contextual cues associated with cocaine reward and is
involved in cocaine seeking behavior (Hamlin et al., 2008). In addition, intra-NAc
injections of the µ-opioid receptor agonist DAMGO leading to high fat palatable food
intake caused activation of the PFA-DMH and not LHA, further implicating the PFADMH may have some role in reward processing (Zheng et al., 2007). In further support,
PFA-DMH orexin neurons have projections to the VTA (Fadel and Deutch, 2002, Geisler
and Zahm, 2005). Future studies are needed to determine the specific role of each of the
two orexin neuronal subpopulations in sexual reward processing using pharmacological
manipulations rather than cell-specific lesions, as the latter resulted in lesions of both
LHA and PFA-DMH.
The results of this study implicate a role for orexin in conditioned cue-induced
seeking of sexual reward. However, the mechanism by which orexin contributes to this
aspect of sexual function is currently unclear. Orexin activates VTA dopamine neurons
(Korotkova et al., 2003, Borgland et al., 2006, Narita et al., 2006, Borgland et al., 2008)
and thus it is possible that orexin-dopamine interactions may be a critical mediator of
sexual reward induced CPP. However, dopamine neurotransmission does not appear to be
critical for mating-induced CPP (Agmo and Berenfeld, 1990, Garcia Horsman and
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Paredes, 2004, Paredes and Agmo, 2004, Ismail et al., 2009). Instead, endogenous
opioids appear involved in development and expression of mating-induced CPP (Agmo
and Berenfeld, 1990, Mehrara and Baum, 1990, Agmo and Gomez, 1993, Paredes and
Martinez, 2001, Ismail et al., 2009). During sexual behavior, endogenous opioids are
acting on µ-opioid receptors in the medial preoptic area (Coolen et al., 2004), a brain
region critical for mating induced CPP (Agmo and Gomez, 1993). Moreover, in the VTA,
µ-opioid receptors are activated by exposure to conditioned contextual cues associated
with sexual reward (Balfour et al., 2004). Hence, orexin may be interacting with the
endogenous opioid system to mediate conditioned-cue induced seeking of sexual reward.
Indeed, orexin-A induced feeding behavior is blocked by opioid receptor antagonists
naloxone (Clegg et al., 2002) and naltrexone (Sweet et al., 2004). In addition, ICV
administration of the orexin receptor-1 antagonist SB 334867 reduced the effects of the
µ-opioid receptor agonist DAMGO on high fat diet intake (Zheng et al., 2007). Orexin
neurons that respond to the exogenous opioid morphine have been shown to express µopioid receptors (Georgescu et al., 2003) and orexin-1 antagonists block morphine
induced CPP (Harris et al., 2007). Furthermore, injection of orexin-A into the
hypothalamus leads to increased enkephalin release in the VTA, the paraventricular
nucleus of the hypothalamus and the central amygdala (Karatayev et al., 2009) indicating
a role for orexin in mediation of opioid release in the brain. Therefore with ample
evidence for the role of orexin-opioid interactions in mediation of natural and drug
reward, future studies may address a role for these interactions in development of matinginduced CPP.
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In conclusion, the current study demonstrates a role for orexin in conditioned cueinduced seeking of sexual reward and contributes novel information to our knowledge of
the role of orexin in reward processing. These findings provide further elucidation of the
neural circuitry involved in natural reward and sexual reward in particular.
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CHAPTER 4
Loss of Sexual Reward Causes Depression-like Behavior in
Male Rats

4.1 INTRODUCTION
Depression is mood disorder in which feelings of sadness, loss, anger, or
frustration interfere with everyday life for a prolonged period of time (Krishnan and
Nestler, 2008). It is estimated that 16.2% of adults in the United States will experience a
major depressive episode at some point in their lifetime (Kessler et al., 2003). Depression
is often triggered by stressful life events such as childhood abuse or neglect, chronic
stress or chronic abuse. In addition, depression can also be caused by loss of rewarding
social interactions such as death of partner, friend or relative, or loss of job (Newport et
al., 2002, Henn and Vollmayr, 2005, Krishnan and Nestler, 2008, Nestler and Hyman,
2010, Krishnan and Nestler, 2011).
Animal models used to study depression frequently rely on exposing animals to
stressful stimuli. Rodents subjected to early life stress such as maternal separation
(Newport et al., 2002, Millstein and Holmes, 2007), chronic stress via exposure to a daily
unpredictable stressor (Henn and Vollmayr, 2005, Krishnan and Nestler, 2008) or chronic
social defeat by daily encounters with an aggressor (Nestler and Hyman, 2010, Krishnan
and Nestler, 2011) all develop depression-like behaviors, including passive stress coping
behavior, anhedonia, and increased anxiety. In contrast, there is currently no established
animal model to study development of depression following loss of social reward.
Monogamous pair bonded male prairie voles displayed depression-like behavior
following loss of partner (Bosch et al., 2009), but few other mammals establish pair
bonds (Kleiman, 1977). Therefore, the goal of the current study was to determine if loss
of social reward in male rats can cause depression-like behavior. In male rats the most
rewarding social interaction is sexual behavior. Males will perform operant tasks (Everitt
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et al., 1987, Everitt and Stacey, 1987) climb barriers (Sheffield et al., 1951) or cross
electrified grids (Moss, 1924) to gain access to a sexually receptive female, and form a
conditioned place preference for sexual reward (Agmo and Berenfeld, 1990, Tenk et al.,
2009).
Sexual behavior affects stress and anxiety-related behaviors, including decreased
anxiety-like behavior (Fernandez-Guasti et al., 1989, Saldivar et al., 1991, Waldherr and
Neumann, 2007) and decreased fear responses (Bai et al., 2009) shortly following mating.
However, the effects of a prolonged period of abstinence from sexual reward on anxiety
and depression-like behaviors have not been tested. Recently, it has been shown that an
abstinence period from sexual reward increases vulnerability for drugs of abuse in male
rats (Frohmader et al., 2010, Pitchers et al., 2010) while drug craving was not altered
shortly after mating. Therefore, we hypothesize that long term loss of sexual reward will
also cause vulnerability to other disorders related to reward processing, in particular
depression-like behavior. The current studies demonstrate that a prolonged loss of sexual
reward in male rats causes depression-like behavior, including increased passive stress
coping and decreased social interaction, and support the potential development of using
deprivation of this natural reward behavior in male rats as a paradigm to study depression
following loss of social reward.

4.2 MATERIALS AND METHODS
4.2.1 Animals
Adult male Sprague Dawley rats (200-250g) were obtained from Charles River
Laboratories (Sherbrooke, Quebec, Canada or Wilmington, MA, USA) and were housed
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in same-sex pairs for the duration of experimental testing in Plexiglas cages. To identify
animals, tails were labeled with permanent marker. In all experiments, cages mates
underwent the same experimental treatment. The colony room was maintained on a 12/12
reversed light-dark cycle (lights off at 10 am) with food and water available ad libitum
except during behavioral testing. Female Sprague-Dawley rats were obtained from
Charles River Laboratories (Sherbrooke, Quebec, Canada or Wilmington, MA, USA),
were bilaterally ovariectomized and received subcutaneous implants of 5% 17-β-estradiol
benzoate in silastic capsules. Females were administered a subcutaneous progesterone
injection (500 μg in 0.1 ml of sesame oil) to induce sexual receptivity 4 hours prior to
mating sessions. All procedures were approved by the Animal Care Committees at the
University of Western Ontario and University of Michigan and conform to guidelines
outlined by the Canadian Council on Animal Care and the National Institute of Health.

4.2.2 Sexual Behavior
All sexual behavior testing took place during the first half of the dark phase, 3-6
hours after lights off. Adult male Sprague-Dawley rats were randomly divided into two
groups that either mated (experienced group) or were handled and remained sexually
naïve (naïve group) over the course of five consecutive days. On each day, males in the
experienced group were placed in a clean Plexiglas mating cage (60×45×50 cm3) for 10
minutes to acclimate. Subsequently, a sexually receptive female was placed into the cage
and males were allowed to mate to one ejaculation (females were removed after
completion of the post ejaculatory interval) or for 60 minutes, which ever occurred first.
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Durations of the mating sessions averaged 16.7 minutes on the first trial and reduced to
8.7 minutes average on the fifth trial, reflecting the effects of sexual experience on faster
initiation and completion of mating (Pitchers et al., 2012). Mating behavior was observed
and analyzed as described previously (Di Sebastiano et al., 2010, Di Sebastiano et al.,
2011). During each trial latencies to first mount and intromission as well as latency to
ejaculation (time from the first intromission to ejaculation) were recorded. For
experiments that included multiple sexually experienced groups, all groups were matched
on parameters of sexual behavior, including latencies to mount, intromission and
ejaculation during the final mating session as well as numbers of ejaculations during the 5
sessions. Numbers of mounts and intromissions were also recorded. Males in the naïve
group were handled and placed in a clean Plexiglas cage (60×45×50 cm3) for 60 minutes
in the same rooms as sexually experienced males and thus were exposed to the same
levels of disturbance and to distant female odors and sounds of mating.

4.2.3 Forced Swim Test
Sexually experienced or sexually naïve males were tested for depression-like
behavior following a one day, one week or one month period of abstinence from sexual
behavior (n=16 per time point) or handling (n=12 per time point), using the forced swim
test. The forced swim test was conducted in a large cylindrical container, 25.5 cm in
diameter; 45 cm in height, filled with cold tap water (20 ± 1˚C) to a depth of 30 cm.
Testing was conducted during the light phase, 2-6 hours after lights on. 1,7 or 28 days
following last sexual experience or handling males underwent a pre-exposure session to
the forced swim apparatus in which they were placed in the water for 15 minutes. 24
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hours following this pre-test (hence 2, 8 and 29 days following last mating or handling)
males underwent a test session in which they were placed in the water again for 5 minutes
(Porsolt et al., 1977a, Porsolt et al., 1977b, Detke et al., 1995, Porsolt et al., 2001).
Following each swimming session rats were removed from the water, towel dried and
placed under a heat lamp until fur was dry. Forced swimming sessions were recorded
from above with video cameras. Behavior videos were scored by an observer blind to
animal’s treatment using automatic timer software (Stopwatch+; Center for Behavioral
Neuroscience, Atlanta, GA: (http://www.cbnatl.org/research/behavioralcore.shtml (Bosch
et al., 2009). Behavior was scored as follows: Struggling (Climbing): movements when
forelimbs break the surface of the water; Swimming: coordinated movements of the
forelimbs and hindlimbs propelling the animal forward, without breaking the water’s
surface; Floating (Immobility): very slight movements of the limbs sufficient to keep the
trunk at equilibrium. The percentage of time animals spent floating (immobile) during the
second test is considered indicative of a passive stress coping and depression-like
behavior (Porsolt et al., 1977b). Statistical significance in percentage of time animals
displayed immobility was compared between naïve and experienced males using
Student’s t-test with a 95% confidence level.

4.2.4 Tail suspension test
The same groups of sexually experienced or sexually naïve males (1, 7 or 28 days
following last sexual experience (n=16 per time point) or handling (n=12 per time
point)) were then tested for depression-like behavior using the tail suspension test, 24
hours after forced swim test, during the light phase 2-6 hours after lights on. Male rats
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were suspended by their tail from a hook 90 cm off the ground for one minute (Steru et
al., 1985) (Chermat et al., 1986). Test sessions were recorded using a video camera. The
duration of immobility, defined as passive hanging was scored using Stopwatch+
software (Bosch et al., 2009) by an observer blind to the animal’s treatment as a measure
of passive stress coping. Statistical significance in the percentage of time animals were
immobile was compared between naïve and experienced males using Student’s t-test with
a 95% confidence level.

4.2.5 Social Interaction Test
Another group of sexually experienced (n=14) and sexually naïve (n=10) animals
were tested for anhedonia using the social interaction test 28 days following last mating
or handling, during the dark phase, 3-6 hours after lights off. The social interaction
apparatus was a large plastic open field arena (84 x 42 x 30 cm) with a wire mesh box (18
x 11.5 x 8 cm) along the short wall. Males were placed into the apparatus for a 5 minute
habituation period with an empty wire mesh goal box. Following habituation, males were
removed from the apparatus and placed back in the home cage for 1 hour. Next, a social
target animal (unfamiliar adult male Sprague Dawley rat) was placed in the wire mesh
goal box and experimental males were placed back in the arena for 5 minutes to measure
social interaction. Approximately 1 hour later, a sexually receptive female
(ovariectomized, estradiol and progesterone-primed, adult Sprague Dawley rat) was
placed in the wire mesh box and experimental males were again placed in the box for 5
minutes to measure social interaction. The social interaction arena was cleaned with 70%
ethanol between trials. All social interaction sessions were recorded from above using a
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video camera. Social interaction was measured using video tracking software (Stoelting
Any-Maze, Wood Dale, IL) to measure time spent in the interaction zone (28 x 42 cm
area around the wire mesh cage), the avoidance zone (28 x 42 cm) and the neutral zone
(remaining center area of the chamber, 28 x 42 cm). Time spent in each zone was
calculated and statistical differences between naïve and experienced animals were
calculated using a two-way ANOVA and Tukey’s test with a 95% confidence interval.

4.2.6 Sucrose Preference Test
Another group of sexually experienced (n=20) or naïve (n=20) or male rats
underwent a sucrose preference test for anhedonia using methods described by (Willner
et al., 1987) 28 days following last mating or handling. Males were individually housed
on Day 1 of the test and were given two bottles of tap water in the home cage for 48
hours (Days 1 & 2) to allow for habituation. On Days 3 & 4 one of the water bottles were
substituted for a bottle containing a 1% (w/v) sucrose solution, and animals were once
again given 48 hours to habituate to drinking the sucrose solution. On Day 5, animals
were food and water deprived for 6 hours during the second half of the dark phase prior
to testing to maximize sucrose consumption. Bottles containing 1% sucrose or tap water
were weighed and placed into the home cage for 1 hour to measure sucrose preference,
during the first hour of the light phase. Following the 1 hour test bottles were removed,
weighed again and sucrose preference was calculated as follows: (sucrose consumed
(g)/(sucrose consumed (g) + water consumed (g) x 100). Statistical difference in sucrose
consumption between naïve and experienced animals was calculated using Student’s ttest with a 95% confidence level.
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4.2.7 Conditioned Place Preference
Adult male Sprague Dawley rats mated (n=12) or were handled and remained sexually
naïve (n=12). 28 days following last sexual experience or handing males were tested for
CPP for sexual reward, using an unbiased apparatus (MED Associates, St. Albans, VT)
consisting of three distinct chambers. On Day 1 (pre-test) males were given free access to
the entire CPP apparatus for 15 minutes to determine initial preference for either chamber
(Di Sebastiano et al., 2011). On Days 2 and 3 (conditioning trials), males were placed
into a larger mating cage and mated until 1 ejaculation and were then placed into the
initially non-preferred chamber (paired chamber) for 30 minutes, or were taken from the
home cage and placed into the initially preferred chamber (unpaired chamber). Pairings
were conducted in a counter-balanced design. A post-test procedurally identical to the
pre-test was conducted on the fourth day to determine CPP. A preference score (percent
of time spent in the sex-paired chamber) was calculated for each animal. Statistical
significance between pre-test and post-test were compared using a two-way repeated
measures ANOVA and Holm-Sidak test with a 95% confidence level.

4.2.8 Antidepressant Administration
Next, it was tested whether passive stress coping can be blocked by antidepressant
administration, and hence can be considered depression-like behavior. A group of adult
male Sprague-Dawley rats mated (experienced) or were handled and remained sexually
naïve (naïve) over the course of five consecutive conditioning days. Mating behavior was
recorded as described above and males were matched on parameters of mating behavior
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and divided into 4 groups: naïve males treated with saline (n=10), experienced males
treated with saline (n=12), naïve males treated with antidepressant (n=12), experienced
males treated with antidepressant (n=12). 28 days following last sexual experience or
handling males underwent the forced swim test. Sexually naïve or experienced males
underwent a 15 minute pre-exposure session to the forced swim test and were then
administered the antidepressant imipramine (Sigma-Aldrich, St. Louis MO, Cat #I7379;
10 mg/kg in 0.9% saline, intraperitoneal) or saline vehicle (10 mg/kg i.p.) 24, 5 and 1
hours before testing in the 5 minute forced swim test (29 days following last mating or
handling, n=12 per group). Behavior was recorded using video cameras and analyzed as
described above by an observer blind to animal’s treatment. Statistical significance
between naïve and experienced saline or imipramine treated males was determined using
a one-way ANOVA and Fishers LSD test with a 95% confidence level.

4.2.9 Rescue of depression-like behavior by sexual experience
To determine if abstinence from sexual behavior during the 28 day period is
essential for development of depression-like behavior, adult male Sprague-Dawley rats
mated or were handled and remained sexually naïve over the course of 5 consecutive
trials as described above. One group of experienced males (n=11) mated twice weekly
during the 28 day period and were then tested for depression in the forced swim test to
determine if development of depression-like behavior is dependent on an abstinence
period from mating and not caused by other explanations, i.e. length of time from onset
of mating behavior. These males had their final mating session on day 27, underwent the
forced swim pre-test on day 28 and were tested for depression-like behavior in the forced
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swim test 24 hours following the pre-test (day 29). A second group of experienced males
(n=11) underwent a 27 day period of abstinence and mated to ejaculation on day 27,
underwent the forced swim pre-test on day 28 and the forced swim post-test 24 hours
following the pre-test, to determine if development of depression-like behavior can be
rescued by a single re-exposure to sexual behavior. Finally, animals in the experienced
control (n=9) and naïve control (n=8) groups were tested on the forced swim test 28-29
days following last handling or sexual experience, with no mating during the entire 28
day abstinence period. Behavior in the forced swim test was recorded and analyzed as
described above. Statistical significance between groups was determined using a one way
ANOVA and Fishers LSD test with a 95% confidence level.

4.2.10 Anxiety-like behavior: Elevated plus maze
As depression is often comorbid with anxiety in both humans (Kessler et al.,
1994) and animal models (Berton et al., 2006) the same groups of sexually experienced
(n=16 per time point) or sexually naïve (n=12 per time point) males used for the FST and
tail suspension tests in 4.2.3 and 4.2.4 were tested for anxiety-like behaviors 1, 7 or 28
days following last sexual experience or handling. Anxiety-like behavior was tested using
the elevated plus maze apparatus (EPM; MED Associates Inc., St. Albans, VT) during
the end of the light phase in a brightly lit room, prior to the forced swim pre-test. The
EPM was elevated 75 cm off the ground and consisted of 4 arms of equal length (50 cm)
extending from a central junction. Two of the arms were enclosed with dark siding 40 cm
high and the other two arms were open to the external environment. Males were placed
on the central junction and were allowed to freely explore the EPM for five minutes and
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time spent in closed and open arms was monitored using photobeam arrays. Statistical
significance in time spent in open or closed arms between naïve and experienced males
was determined using Student’s t-test with a 95% confidence level.

4.3 RESULTS
4.3.1 Forced Swim Test and Tail Suspension Test
A 28 period of abstinence from sexual behavior caused significantly higher
display of passive stress coping behavior. Sexually experienced males demonstrated a
significantly higher percentage of immobility behavior in the forced swim test and tail
suspension test compared to sexual naïve males 28 days following last sexual experience
(Figure 4.1a; p=0.012 and p=0.036 respectively), but not 1 (Figure 4.1c) or 7 days
(Figure 4.1b) following last sexual experience.

4.3.2 Antidepressant Treatment
Antidepressant administration prevented development of passive stress coping
behavior following a 28 day abstinence period from sexual behavior (Figure 4.2a; F(3,40)
5.551; p<0.003). Sexually experienced males pre-treated with imipramine spent
significantly less time immobile compared to experienced saline treated males (Figure
4.2a; p<0.001). Moreover, sexually experienced males pre-treated with saline showed
increased time immobile during the post-test compared to naïve saline treated controls
(Figure 4.2a; p=0.003), confirming previous results. These results confirm that passive
stress coping behavior seen following 28 days of abstinence from mating is indeed
depression-like behavior, as this behavior can be rescued by antidepressant treatment.
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Figure 4.1.Percentage of time spent immobile in forced swim test and tail suspension test
of sexually naïve (white bars) and experienced (black bars) males at 28 (A), 7 (B), or 1
(C) days following last handling or mating session. Data are presented mean ± SEM.*
Indicates significant difference from naïve males in the same test and same time point.
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4.3.3 Rescue of depression-like behavior by sexual experience
Development of depression-like behavior is dependent on a period of abstinence
from mating, as males that mated twice weekly during the 28 day period did not develop
increased passive stress coping behavior in the forced swim test (Figure 4.2b; F(3,30)
4.643; p=0.01). First, sexually experienced males that underwent a 28 day abstinence
period from mating displayed longer duration of floating compared to sexually naïve
males, confirming our results from the previous experiments (Figure 4.2b; p=0.005). In
contrast, males that mated twice weekly during the 28 days following the initial 5 daily
mating sessions, spent significantly less time immobile in the forced swim test compared
to experienced males that underwent a 28 day period of sex abstinence (Figure 4.2b;
p=0.007) and did not differ significantly in time immobile compared to naïve males.
Males that underwent a 27 day period of abstinence and mated one day prior to first
exposure to the forced swim test still demonstrated higher immobility compared to naïve
males (Figure 4.2b; p=0.032) and experienced males that mating during the 28 day period
(Figure 4.2b; p=0.041) but were not significantly different from sexually experienced
males with prolonged abstinence (p=0.214), indicating that a single experience with
sexual behavior following a 27 day abstinence period from mating did not rescue
development of depression-like behavior. This was not due to a deficit in mating
behavior, as parameters of initiation and performance did not differ after 27 days of
abstinence compared to the same animals’ final mating session of the five consecutive
daily mating sessions (Mount Latency: Day 5, 53.6 ±14.9 s vs. Day 27 46.5± 15.7 s;
p=0.67; Intromission Latency: Day 5, 54.4 ±15 s vs. Day 27, 64.2 ± 18.4 s; p=0.8;
Ejaculation Latency: Day 5, 656.8 ± 137.5s vs. Day 27, 893 ±156.4; p=0.35). These
results confirm facilitation of sexual behavior is maintained following a one month period
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of abstinence from mating (Pitchers et al., 2012), and indicate that lack of a rescue effect
of mating one day prior to testing on the forced swim test on development of depressionlike behavior in sexually experienced animals is not due to impairments in copulatory
performance or sexual motivation.

4.3.4 Anhedonia: Social Interaction
28 days of abstinence from mating caused anhedonia seen as decreased social
interaction (Figure 4.3a; F1,62 9.368; p=0.003). Sexually experienced males spent
significantly less time interacting with a novel male (Figure 4.3a; p=0.038) and receptive
female (Figure 4.3a; p=0.03) compared to sexually naïve males. Naïve and experienced
males did not differ in time spent interacting with an empty goal box during habituation
(p=0.357).

4.3.5 Anhedonia: Sucrose Preference
Abstinence from sexual reward did not cause anhedonia in the sucrose preference
test, as sexually experienced males did not differ significantly in volume of sucrose
consumed compared to sexually naïve males 28 days following last mating or handling
(Figure 4.3b).

4.3.6 Mating-induced Conditioned Place Preference
A 28 day period of abstinence from sexual reward did not affect mating-induced
CPP, as sexually naïve and experienced males both formed a significant preference for a
sexual reward-paired chamber (Figure 4.3c F1,47 8.45; p=0.008). Both sexually naïve and
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experienced males showed a significant increase in preference score (percentage of time
spent in the sex-paired chamber) during the post-test compared to the pre-test: naive:
(Figure 4.3c; 0.037); experienced: (Figure 4.3c; p=0.037). Moreover, initiation or
performance of sexual behavior were not affected by the 28 day abstinence period as
sexually experienced males did not differ in any parameters from their final day of
mating during the 5 consecutive days and were significantly facilitated compared to
sexually naïve males (Mount Latency: Naïve, 559.5 ± 193.8 s vs. Experienced, 104.4 ±
18 s; p=0.02; Intromission Latency: Naïve, 813.5±228.3 vs. Experienced;161.8 ± 36.4
p=0.01; Ejaculation Latency: Naïve, 1934.3 ± 322.4 vs. Experienced, 678.75 ± 46.4;
p<0.001).

4.3.7 Anxiety-like Behavior: Elevated Plus Maze
Neither sexual behavior nor a period of abstinence caused alterations in anxietylike behaviors. There were no significant differences in time spent in the open arms
(Figure 4.4a ) and closed arms (Figure 4.4b) on the EPM between sexually naïve and
experienced males 1, 7 or 28 days following last sexual experience.

4.4 Discussion

The results of these studies demonstrate that an extended abstinence period from
sexual behavior; a powerful social reward behavior, causes a depression-like phenotype
in male rats. Depression-like behavior was evident as enhanced passive stress-coping
behavior in the forced swim and tail suspension tests. Immobility in these tests is
indicative of depression-like behavior and was blocked by treatment with the tricyclic
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antidepressant imipramine (Porsolt et al., 1977a, Porsolt et al., 1977b). Development of
depression-like behavior was dependent on a period of abstinence from mating, as mating
twice weekly during the 28 day period prevented enhanced passive-stress coping
behavior in the forced swim test. Furthermore, engaging in sexual activity one time prior
to testing in the forced swim test was not sufficient to rescue depression-like behavior,
confirming that development of depression-like behavior requires loss of social reward,
and is not caused by other explanations such as length of time following first mating
session. Thus, theses studies suggest that development of depression-like behavior
following loss of sexual reward is dependent on a prolonged period of abstinence from
mating, and may provide a new model to study human depression following loss of social
reward.
In the current studies we observed depression-like behavior, including increased
passive stress coping following a prolonged abstinence period from sexual reward,
comparable to depression-like phenotypes observed in stress models of depression. In the
social defeat model of depression, defeated animals also demonstrate increased
immobility in the forced swim test to a similar magnitude as that observed in the current
study in both rats (Hollis et al., 2010) and mice (Keeney et al., 2006). Maternal separation
in rats has also been shown to lead to increases in passive stress coping behavior, again to
a similar magnitude as that seen in the current studies (Aisa et al., 2007, Lee et al., 2007).
(Hulshof et al., 2011). Finally, in the chronic mild stress model of depression, mice and
rats also demonstrate increased passive stress coping (Bielajew et al., 2003, Mineur et al.,
2006). Thus, loss of sexual reward appears to induce depression-like behavior to a similar
magnitude of that seen in stress models of depression, such as social defeat, maternal
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separation and chronic mild stress. Alterations in passive stress coping behaviors provide
an effective method for screening depression-like behaviors in rodents, due to the
responsivity of the forced swim and tail suspension tests to antidepressant activity
(Porsolt et al., 1977a, Porsolt et al., 1977b, Chermat et al., 1986). However, these stress
models of depression are also associated with alterations in stress axis activity (Ayensu et
al., 1995, Francis et al., 1999, Francis et al., 2002, Kieran et al., 2010), as well
neuropathology similar to that observed in human depression (Francis et al., 1999, Stout
et al., 2000, Keeney et al., 2006, Marini et al., 2006). Thus, loss of sexual reward may
also lead to alterations in stress responsivity and underlying neuropathology of
depression.
Loss of sexual reward also caused anhedonia, another hallmark of depression
(Nestler and Hyman, 2010) seen as decreased social interaction with a novel male and an
estrous female 28 days following last mating. However, social defeat appears to induce a
higher magnitude of social avoidance than the current study, in both rats (Hollis et al.,
2010) and mice (Berton et al., 2006). This difference in magnitude is likely due to the
fact that in the social defeat paradigm, animals are chronically being attacked by another
conspecific, and may thus develop a higher level of avoidance, whereas in the current
study decreased social interaction more likely reflects a loss of motivation for social
interaction. The effects of maternal separation in the social interaction test are unclear, as
maternally separated animals have been shown to have decreased social interaction
(Maciag et al., 2002), while other studies have shown that maternal separation does not
alter social interaction (Hulshof et al., 2011). Finally, it has been shown that animals

133

exposed to the chronic mild stress paradigm do not show alterations in the social
interaction test (D'Aquila et al., 1994).
Loss of sexual reward did not cause reduced sucrose preference. The chronic mild
stress model of depression has been shown to reliably induce anhedonia in the sucrose
preference test following long-term exposure to stressors (Willner et al., 1987,
Pucilowski et al., 1993, Willner, 2005). Likewise, chronic social defeat in rats (5
consecutive weeks of defeat) (Rygula et al., 2005) or mice (10 consecutive days of
defeat) (Krishnan et al., 2007) causes decreased sucrose preference. In contrast, rats
exposed to shorter term social defeat (4 consecutive days) did not demonstrate anhedonia
in the sucrose preference test (Hollis et al., 2010), even though they did develop
increased passive stress coping in the forced swim and tail suspension tests, as well as
decreased social interaction. Moreover, male rats exposed to maternal separations do not
demonstrate decreased sucrose preference (Matthews et al., 1996, Shalev and Kafkafi,
2002). These results suggest that development of anhedonia in the sucrose preference test
requires long term exposure to a stressor and provide a potential explanation for the lack
of decreased sucrose preference in the current study. Moreover, we hypothesize that lack
of anhedonia for sucrose in the current study may be due to the need in this paradigm to
expose the animals to the rewarding sucrose stimulus for 2 days prior to testing,
potentially preventing development of anhedonia.
Another measure of anhedonia is animal’s interest in pleasurable activities such as
sexual behavior (Nestler and Hyman, 2010). We have demonstrated that following a 28
day period of abstinence from mating males do not display decreased sexual motivation
or performance (Pitchers et al., 2012), and have unaltered sexual reward. Thus, these
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results suggest loss of sexual reward induces anhedonia in the form of reduced social
interaction, but there is no loss of reward associated with the consumption of a rewarding
substance or consummatory behavior with a rewarding stimulus. Hence, abstinence from
sexual reward induced decreased “wanting” or incentive motivation for a salient stimulus,
but did not alter the “liking” or reward for the consumption of the salient stimulus
(Robinson and Berridge, 1993). In contrast, males that have been socially defeated
demonstrate decreased attempts to copulate with a receptive female (Rygula et al., 2005).
In the chronic mild stress paradigm, sexually experienced males show impairments in
copulatory performance seen as increased latencies to mount and intromission, and
decreased frequency of mounts and ejaculations (Gronli et al., 2005). Maternally
separated males are also impaired in their copulatory performance during their first
mating trial in adulthood, as latencies to mount and intromission are lengthened, and
ejaculation frequency is decreased (Rhees et al., 2001). Likewise, human depressed
patients often lose interest in sex and demonstrate sexual dysfunction (Mathew and
Weinman, 1982, Dell'Osso et al., 2009, Galecki et al., 2011). However, depressed
humans have also been reported to engage in sexual risk behaviors, including multiple
partners and decreased condom use (Shrier et al., 2001, Khan et al., 2009). In our lab, we
have shown that 28 days of abstinence from mating not only causes depression-like
behavior, but also causes increased vulnerability for drugs of abuse (Pitchers et al., 2010).
As sexual risk behavior is also associated with drug taking (Peugh and Belenko, 2001,
Rawson et al., 2002, Raj et al., 2007, Fisher et al., 2011), and depressed patients have a
high incidence of substance abuse (Volkow, 2004), loss of sexual reward may be a
valuable model to study comorbid depression and substance abuse.
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Abstinence from mating did not result in anxiety-like behavior. Thus, in contrast
to the anxiolytic effects of sexual behavior shortly following mating, there do not appear
to be long term effects of sexual behavior on anxiety. Moreover, this finding is in contrast
to the induction of anxiety in other depression models, in which animals are exposed to
stressors. Stress models of depression such as social defeat, chronic stress or maternal
separation all lead to alterations in anxiety-like behavior as well as in depression-like
behavior (Daniels et al., 2004, Vyas and Chattarji, 2004, Krishnan et al., 2007). As an
abstinence period from sexual behavior is not a stressor such as attack, restraint, cold, or
physical separation from the mother, it does not cause anxiety-like behavior. Moreover,
in the current studies males were housed with a same sex cage mate and some
environmental enrichment during the entire abstinence period, to avoid social isolation
stress, which has also been shown to cause anxiety and depression-like behavior (Karim
and Arslan, 2000, Dandekar et al., 2009, Djordjevic et al., 2012). Thus, loss of sexual
reward appears to be an animal model of depression without anxiety that is not caused by
stress or agonistic attacks. Even though in humans anxiety can be comorbid with
depression, this is not the case for all individuals suffering depression (Prigerson et al.,
1995, Kessler et al., 1996)
Recently it was shown that monogamous, pair bonded male prairie voles that are
separated from their partner for 3-5 days develop depression-like behavior, seen as
increased immobility in the forced swim and tail suspension tests (Bosch et al., 2009).
These males also demonstrated increased anxiety-like behavior, seen as decreased
numbers of entries into the open arms of the EPM (Bosch et al., 2009). However males
that were separated from a same sex sibling partner also demonstrated decreased entries
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into the open arms (Bosch et al., 2009), a suggesting that effects on anxiety may be due to
the fact that these males are socially isolated during partner separation. In order to form a
pair bond males prairie voles were housed for five consecutive days with a female, during
which mating behavior occurred (Bosch et al., 2009). In the current studies males were
only housed with females during a once daily mating session for course of 5 consecutive
days. Mating sessions lasted on average 16.7 minutes on the first trial, and were reduced
to 8.7 minutes by the fifth trial, suggesting that development of depression-like behavior
following loss of sexual reward requires only brief daily exposure to sexual behavior, as
opposed to long-term cohabitation with a female. Moreover, in the current studies,
development of depression-like behavior was observed following a prolonged (28-29
day) abstinence period from sexual behavior, and not at earlier timepoints, (1 or 7 days),
whereas prairie voles separated from their partner developed depression depression-like
behavior following 3-5 days of partner separation (Bosch et al., 2009). It is currently
unknown whether depression-like behavior following partner separation is maintained at
longer intervals of partner separation.
In conclusion, the current study demonstrates that loss of sexual reward causes
depression-like behavior in the absence of chronic stressors or social isolation. The
primary difference of the current findings compared to established rodent models for
depression is that development of depression in the latter are dependent on chronic stress
or long-term exposure to agonistic attacks. Instead, the findings presented here may
resemble depression induced by loss of socially rewarding events and we propose this to
be a useful model to study depression-like behavior following loss of social reward in
rodents. This model meets criteria to validate animal models of depression, as loss of
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social reward causes anhedonia and passive stress coping, giving this model homology to
symptomology seen in human depression or face validity (Krishnan and Nestler, 2010).
Furthermore, this model has pharmacological validity (Krishnan and Nestler, 2010) as
passive stress coping following loss of social reward can be blocked by antidepressants.
This model also displays construct validity (Krishnan and Nestler, 2010), as development
of depression-like behavior is dependent on a period of abstinence from mating, and as
such requires loss of social reward, similar to development of depression-like behavior
following loss of social rewards in humans. Moreover, abstinence from sexual reward has
also been shown to cause increased vulnerability for psychostimulant abuse in male rats
(Pitchers et al., 2010) and increased ethanol consumption in drosophila (Shohat-Ophir et
al., 2012). Given the comorbidity of depression and substance abuse, it will be important
to determine which neural alterations are caused by loss of sexual/social reward to cause
such behavioral pathology.
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CHAPTER 5
Loss of Sexual Reward Causes Enhanced Stress Reactivity in
Male Rats

5.1 INTRODUCTION
In humans, mood disorders such as depression can be triggered by stressful life
events (Kessler, 1997, Brown, 1998, Kendler et al., 1999, Pine et al., 2002). Stress
activates the hypothalamic-pituitary-adrenal (HPA) axis, causing release of corticotropin
releasing factor (CRF) from the paraventricular nucleus of the hypothalamus (PVN),
which stimulates the anterior pituitary to secrete adrenocorticotropic hormone (ACTH),
leading to release of cortisol (humans) or corticosterone (cort; rodents) from the adrenal
glands. These adrenal steroids then regulate the stress response via negative feedback and
activation of glucocorticoid receptors in hypothalamus (Jones et al., 1977, Keller-Wood
and Dallman, 1984, Evanson et al., 2010), pituitary (Cole et al., 2000, Russell et al.,
2010), hippocampus (Sapolsky et al., 1984, Jacobson and Sapolsky, 1991, Furay et al.,
2008), and prefrontal cortex (PFC) (Hill et al., 2011, Radley and Sawchenko, 2011). CRF
is also produced and released from neurons in extra-hypothalamic brain regions, namely
the bed nucleus of the stria terminalis (BnST) and central amygdala (CeA) (Koob and
Heinrichs, 1999, Bale and Vale, 2004). CRF acts on two receptors, CRF receptor 1
(CRFR1) and CRF receptor 2 (CRFR2) (De Souza, 1987, Bale and Vale, 2004) expressed
in areas such as the nucleus accumbens (NAc) and prefrontal cortex (PFC) (Van Pett et
al., 2000), brain areas that are critical for mediation of the emotional aspects of the stress
response (Menzaghi et al., 1993, Morgane et al., 2005, Jankord and Herman, 2008).
CRFR1 and CRFR2 have been shown to play opposite roles in mediation of the stress
response, with CRFR1 inducing stress responses and CRFR2 attenuating stress responses
(Bale and Vale, 2004, Contarino and Papaleo, 2005).
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Human depression is associated with hyperactivity of the HPA axis (Holsboer,
2000). Depressed patients show increased CRF levels in the cerebrospinal fluid
(Nemeroff et al., 1984) as well as increased CRF mRNA in the hypothalamus (Kling et
al., 1991). In addition, depressed suicide patients show atrophy of the PFC and NAc
(Manji et al., 2001) as well as decreased CRF receptor binding sites in the PFC
(Nemeroff et al., 1988). In animal models of depression that are dependent on exposure
to stressful stimuli, such as social defeat, chronic stress or maternal separation these
animals show increased CRF mRNA in the PVN (Francis et al., 1999, Stout et al., 2000,
Keeney et al., 2006, Marini et al., 2006). Furthermore, development of depression-like
behavior in the chronic stress model of depression can be blocked by systemic
administration of CRF receptor antagonists (Ducottet et al., 2003), while intra-NAc
infusion of CRF induces depression-like behavior (Chen et al., 2012). Both CRFR1 and
CRFR2 have been shown to play a role in development of depression, again with some
evidence for opposing roles, with a pro-depressant role for CRFR1 activation and antidepressant effects of CRFR2 activation. (Shaham et al., 1998, Hammack et al., 2003,
Wang et al., 2005, Henry et al., 2006, Wang et al., 2006, Wang et al., 2007).
In the previous chapter (Chapter 4), it was demonstrated that an extended (28 day)
period of abstinence from sexual behavior caused depression-like behavior, including
enhanced passive stress-coping behaviors and decreased social interaction. However, it is
unknown if the CRF system plays a regulatory role in these behavioral alterations.
Therefore, the goal of the current studies was to test the hypothesis that loss of sexual
reward leads to increased HPA axis activity, including increased CRF levels in the PVN
as well as enhanced cort and ACTH release in response to an acute stressor. In addition,
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we tested the hypothesis that the CRF system is critical for the development of
depression-like behavior following loss of sexual reward by chronically infusing CRF
receptor antagonists either into the cerebroventricular system or locally into the NAc or
PFC, mesolimbic brain regions that are important for development of depression
(Krishnan and Nestler, 2008), during the final week of mating abstinence.

5.2 MATERIALS MATERIALS
5.2.1 Animals
Adult male Sprague Dawley rats (200-250g) were obtained from Charles River
Laboratories (Sherbrooke, Quebec, Canada or Wilmington, MA, USA). For the duration
of experimental testing males were housed in same-sex pairs in Plexiglas cages. To
identify animals, tails were labeled with permanent marker. In all experiments, cage
mates underwent the same experimental treatment. The colony room was maintained on a
12/12 reversed light-dark cycle (lights off at 10 am). Food and water were available ad
libitum except during behavioral testing. Female Sprague-Dawley rats were obtained
from Charles River Laboratories (Sherbrooke, Quebec, Canada or Wilmington MA,
USA). Females were ovariectomized bilaterally and were implanted subcutaneously with
5% 17-β-estradiol benzoate in silastic capsules. 4 hours prior to mating sessions females
were administered a subcutaneous progesterone injection (500 μg in 0.1 ml of sesame oil)
to induce sexual receptivity. All procedures were approved by the Animal Care
Committees at the University of Western Ontario and University of Michigan and
conform to guidelines outlined by the Canadian Council on Animal Care and the USA
National Institute of Health.
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6.2.2 Sexual Behavior
Testing for sexual behavior took place 3-6 hours after lights off, during the first
half of the dark phase. Over the course of five consecutive days, adult male SpragueDawley rats were either mated (experienced group) or were handled and remained
sexually naïve (naïve group). Males in the experienced group were placed in a clean
Plexiglas mating cage (60×45×50 cm) on each of the five conditioning days for 10
minutes. Following the 10 minute habituation, a sexually receptive female was placed
into the cage and males were allowed to copulate ejaculation or for 60 minutes. Mating
behavior was recorded and analyzed as previously described (Di Sebastiano et al., 2010,
Di Sebastiano et al., 2011). Latencies to first mount and intromission and latency to
ejaculation were recorded during each trial as well as numbers of mounts and
intromissions. Males in the sexually naïve group were placed into clean Plexiglas cages
(60×45×50 cm3) for 60 minutes, in the same rooms and at the same time as the
experienced males were allowed to mate and were thus exposed to the same handling and
environment, but without mating.

5.2.3 Activation of CRF neurons by sexual behavior
5.2.3A Tissue Collection
To determine if CRF neurons are activated by sexual behavior, cFos expression
was determined after mating in sexually naïve or experienced males. Adult male
Sprague-Dawley rats were divided into experimental groups as follows: Naïve no sex
(NNS): handled for five consecutive days. Experienced no sex (ENS): mated to one
ejaculation on five consecutive days. Both of these groups were perfused 24 hours after
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last handling or mating from the home cage and served as controls. Naïve sex (NS):
handled for four consecutive days, and mated to one ejaculation on fifth day. Experienced
sex (ES): mated to one ejaculation on five consecutive days (n=5 per group). Both of
these groups were perfused one hour following the end of mating. Males were perfused
transcardially with 0.9% saline followed by 500 mL of 4% paraformaldehyde (PFA) in
0.1M phosphate buffer (PB). Brains were quickly removed and post-fixed for one hour in
the same fixative, then transferred to 20% sucrose for cryoprotection. Brains were
sectioned into 35 µm coronal sections on a freezing microtome (Microm, Walldorf,
Germany) and collected in 4 parallel series in a cryoprotectant solution (30% sucrose in
0.1M PB containing 30% ethylene glycol and 0.01% sodium azide) and were stored at
-20ºC until further processing.

5.2.3B Immunohistochemistry
One series of sections for each animal was immunoprocessed for CRF and cFos
as a marker for neural activation using immunohistochemistry. Free floating sections
were washed extensively with 0.1M saline buffered sodium phosphate (PBS) between
incubation steps and all incubations were performed at room temperature using gentle
agitation. Sections were pre-incubated for 10 minutes using 1% H2O2 (30% stock
solution) in PBS and for 1 hour in the incubation solution (PBS with 0.1% bovine serum
albumin and 0.4% Triton X-100). Sections were incubated overnight with a rabbit raised
antibody recognizing cFos (rabbit anti-cFos, SC52; 1:10,000 in incubation solution, Santa
Cruz Biotechnology, Santa Cruz, CA), followed by biotinylated goat anti-rabbit (1 hour;
1:500 in incubation solution, Vector Laboratories, Burlingame, CA) and avidin
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horseradish peroxidase complex (ABC; 1 hour; 1:1000 in PBS; Vector Laboratories,
Burlingame, CA). cFos-immunoreactivity was visualized using nickel-enhanced
diaminobenzidine (DAB; Sigma, St. Louis, MO; 0.02% in 0.1M PB containing 0.012%
hydrogen peroxide (Fisher, Pittsburg, PA) and 0.08% nickel sulfate (Sigma, St. Louis,
MO) resulting in a blue-black reaction product. Sections were next incubated overnight
with a rabbit raised antibody recognizing CRF (rabbit anti-CRF, T-4036 1:2,000,
Peninsula Labs, San Carlos CA) followed biotinylated goat anti-rabbit and ABC, as
described above. CRF immunoreactivity was visualized with DAB (10 minutes; 0.02% in
0.1M PB containing 0.012% hydrogen peroxide). Both antibodies have been
characterized previously (Bovetto et al., 1996, Di Sebastiano et al., 2010, Di Sebastiano
et al., 2011). Following completion of staining sections were rinsed extensively with PB,
mounted onto plus charged glass slides and coverslipped with dibutyl phthalate xylene
(DPX).

5.2.3C Analysis
Neurons labeled for CRF or CRF and cFos were counted bilaterally in all sections
containing CRF positive neurons in the, PVN, CeA and BnST using a Leica microscope
(DMR5; Leica, Walldof, Germany). Counts were averaged per hemisphere for each
animal, group means were calculated and statistical significance between naïve and
experienced groups was determined using a two-way ANOVA with a 95% confidence
level.
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5.2.4 Changes in CRF mRNA following mating abstinence
5.2.4A Tissue Collection
Adult male Sprague Dawley rats gained sexual experience over the course of five
consecutive mating trials (n=10) or were handled and remained sexual naïve (n=10). 1 or
28 days following last sexual experience or handling males were euthanized with sodium
pentobarbital (270mg/kg); brains were rapidly removed and flash frozen on dry ice in
sterile RNAse free conditions. Microdissections of the BnST, CeA and PVN were
performed by isolating tissue with a sterile blunt end needle from frozen coronal sections.

5.2.4B mRNA isolation and real-time polymerase chain reactions
Tissue punches were homogenized and RNA was isolated using TriZol reagent
(Invitrogen, Carlsbad CA) for quantitative real time reverse transcription polymerase
chain reaction (qRT-PCR). RNA was checked for concentration and quality using
spectrophotometer (Nanodrop; Thermo Scientific, Wilmington, DE). Reverse
transcription of RNA was performed using a High Capacity cDNA Reverse Transcription
Kit (Applied Biosystems Inc., Foster City, CA) according to manufacturers’ instructions
and a BioRad Thermal Cycler (Hercules, CA), using equal amounts of RNA for each
sample. Quantitative analysis of gene expression was determined using real-time qRTPCR. Each reaction for was performed with TaqMan chemistry using 2µL of cDNA,
10µL of TaqMan Universal PCR Master Mix 2X (Applied Biosystems Inc., Foster City,
CA), 0.8µL of 25mM MgCl2 (Invitrogen, Carlsbad CA), 6.2µL DEPC and 1µL of
TaqMan gene expression assay solution for the gene of interest. qRT-PCR reactions were
performed for CRF (Rn01462137_m1), and glyceraldehydes-3-phosphate dehydrogenase
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(GAPDH; Rn99999916_s1) in the PVN, CeA and BnST. Reactions were performed
using the Rotorgene (Corbett Life Sciences, Valencia CA) and the following PCR
conditions: hold at 50ºC for 2 min, hold at 95ºC for 10 min, 40 cycles of 95ºC for 15 sec
and 58ºC for 1 min. Cycle threshold (Ct) levels were determined using a optimal
threshold line generated from standard curve 5-log dilutions of cDNA from the brain
region of interest for each probe. Standard curves were considered optimal when a line of
best fit through the Ct values of the dilutions had an efficiency value between 0.8-1 and
an R2 greater than 0.99. Each sample was analyzed in triplicate and Cts for each
experimental sample were determined and averaged over the replicates. CRF levels
within a sample were normalized to their respective GAPDH levels to generate the ΔCt
value. The ΔΔCt value was calculated as 2^(ΔCt (sample) - ΔCt (average of naïve control
group)) x100 and, CRF in each animal was expressed as a change over the average of the
naïve control group within each time point. Statistical significance between naïve and
experienced groups were calculated using Student’s t-test with a 95% confidence level.

5.2.5 Acute Restraint Stress and Blood Collection
Sexually experienced (n=12) or naïve (n=10) males underwent acute restraint to
measure stress responses according to methods described previously (Vahl et al., 2005).
All stress testing was conducted during the light phase, 2-5 hours after lights on. 28 days
following last mating or handling males were transported to a testing room and placed in
a cylindrical polyethylene tail access restrainer (Model #51335, Stoelting, Wood Dale
IL). Immediately, a small laceration was made at the base of the tail and a baseline blood
sample was collected in an eppendorf tube filled with 10µL of 100µM EDTA. Males
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were then restrained for 29 minutes, after which another blood sample was collected (30
minutes, end of restraint). Males were placed back in the holding cage and blood was
again collected 60 and 120 minutes post restraint. All blood samples (200-400µL) were
collected within 1-2 minutes and immediately placed on ice. Blood samples were
centrifuged; plasma was extracted and stored at -20ºC until further processing. Cort and
ACTH were measure using ImmuChem™ 125I radioimmunoassay (RIA) kits (cort, cat
#07120102; ACTH, cat # 07106102; MP Biomedicals, Solon, OH) according to
manufacturer’s instructions. The cort assay required 10µL of plasma and intra- and
interassay coefficients of variation were 7.1% and 7.2%. The ACTH assay required
100µL of plasma and had intra- and interassay coefficients of variation of 4.1% and
3.9%. Statistical differences in cort and ACTH levels between naïve and experienced
males over time was calculated using a two way repeated ANOVA (factors: experience
and time) and Tukey’s test, with a 95% confidence level.

5.2.6 Chronic ICV CRF receptor antagonist administration via osmotic minipumps
5.2.6A Surgery
Adult male Sprague-Dawley rats mated (experienced) or were handled and
remained sexually naïve (naïve) over the course of five consecutive mating trials.
Experienced groups were matched on parameters of sexual behavior. 21 days following
last sexual experience males were implanted with an osmotic minipump (Model 2001,
Alzet, Cupertino CA). Pumps were filled 12 hours prior to implantation, with CRF
receptor 1 antagonist: CP 154-526 (n=8) 1mg/mL, in 0.45% acetic acid vehicle in sterile
saline; Cat. # 2779, Tocris Bioscience, Ellisville MO), CRF receptor 2 antagonist:
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Antisauvagine-30 (n=7) 2mg/ml in saline; Cat # 2071, Tocris Bioscience, Ellisville MO),
or vehicle (acetic acid n=9 or saline n=10). Pumps were connected to the brain infusion
cannula with vinyl catheter tubing (Alzet, Brain Infusion Kit 2, Cupertino CA) and stored
in 37°C incubator with cannulas in sterile saline. Male rats were anesthetized with
isoflurane (MWI, Boise ID) in a Surgivet Isotec4 gas apparatus (Smiths Medical Vet
Division, Markham, Ontario, Canada), secured in a stereotaxic apparatus (Kopf
Instruments, Tujunga, CA) with a gas mask secured over the nose and mouth to maintain
anesthesia. An incision was made to expose the skull, lambda and bregma were found
determined to be level. A hole was drilled into the skull using a Dremel drill (Dremel,
Racine, WI) at coordinates relative to bregma: AP= -0.5mm, ML= 1.5mm, DV= -3.9mm.
The unilateral brain infusion cannula (Alzet, Brain Infusion Kit 2, Cupertino CA) was
implanted and secured with dental cement (Lang Dental Manufacturing Company,
Wheeling IL) and the osmotic minipump was implanted (Alzet, Model 2001, Cupertino
CA) under the flank. Surgical incisions were closed with wound clips and males were
allowed one week to recover from surgery during which osmotic minipumps chronically
infused vehicle, CRFR1 antagonist or CRFR2 antagonist at a rate of 1.0μL/hr for the
remaining 6.5 days (infusions thus ended on day 27).

5.2.6B Forced Swim Test
One day after termination of chronic infusion and 28 days following last mating
session, males were tested for depression-like behavior in the forced swim test. The
forced swim test was conducted during the light phase, 2-6 hours after lights on. The
forced swim apparatus was a large cylindrical container, 25.5 cm in diameter, 45 cm in
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height, and was filled with cold tap water (20 ± 1˚C) to a depth of 30 cm. 28 days after
last mating or handling, rats were pre-exposed to forced swim test and were placed in the
water for 15 minutes. 24 hours following pre-exposure (thus, 29 days following last
mating or handling) males underwent the test session and were placed in the water for 5
minutes (Porsolt et al., 1977a, Porsolt et al., 1977b, Detke et al., 1995, Porsolt et al.,
2001). After swimming sessions were completed, males were removed from the water;
towel dried and placed under a heat lamp until fur was dry. All forced swimming sessions
were recorded from above. Behavior was scored using automatic timing software
(Stopwatch+; Center for Behavioral Neuroscience, Atlanta, GA: (http://www.cbnatl.org/
research/behavioralcore.shtml) (Bosch et al., 2009) by an observer blind to the animal’s
treatment. Behavior was scored as follows: Struggling (Climbing): movements of both
the fore- and hindlimbs that break the surface of the water; Swimming: movements that
propel the animal forward, requires coordinated movement of both the fore- and
handlings. Floating (Immobility): slight movements of the fore- and hindlimbs to keep
body at equilibrium, with very little movement. Percentage of spent floating (immobile)
during the second test is indicative of a passive stress coping and depression-like
behavior (Porsolt et al., 1977b). Experimental groups included: naïve males treated with
vehicle (saline; n=4 or 0.45% acetic acid vehicle; n=5; n=9 total), experienced males
treated with vehicle (saline; n=5 or 0.45% acetic acid vehicle; n=5; n=10 total),
experienced males treated with CRFR1 antagonist (n=9), experienced males treated with
CRFR2 antagonist (n=8). Statistical significance in time spent immobile between groups
was determined using a one-way ANOVA and Fisher’s LSD test with a 95% confidence
level.
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5.2.6C Tissue collection real time qPCR
To determine if chronic administration of a CRFR1 antagonist during the final
week of mating abstinence blocked the increase in CRF mRNA levels in the PVN
observed following a 28 day period of abstinence from mating, males were overdosed
with sodium pentobarbital (270mg/kg); brains were rapidly removed and flash frozen on
dry ice in sterile RNAse free conditions. Microdissections of the PVN were performed,
and qRT-PCR for CRF was conducted as described above.

5.2.7 Acute ICV CRF receptor antagonist administration
As males in the osmotic minipump experiment were tested in the forced swim test
without antagonist infusions at the time of testing, another group of males was used to
test the effects of acute CRFR1 antagonist administration on depression-like behavior.
Adult male Sprague-Dawley rats mated or were handled and remained sexually naïve
over the course of five consecutive mating trials. Experienced groups were matched on
parameters of sexual behavior. All males were implanted with a 21 gauge unilateral guide
cannula in the lateral ventricle (Plastics One, Roanoke VA), using the same stereotaxic
surgical techniques and coordinates as described above. During the 1 week surgical
recovery period, males were handled daily to habituate them to the process of intracranial
injections. Following 1 week recovery from surgery males received a single intracranial
infusion 15 minutes prior to the testing on the second day of the forced swim test session
of vehicle (5 µL; 0.45% acetic acid in sterile saline; n=8) or CRFR1 antagonist, CP 154526 (n=8) 1mg/mL, in 0.45% acetic acid vehicle in sterile saline; Cat. # 2779, Tocris
Bioscience, Ellisville MO). Infusions were conducted using a microinfusion pump
156

(Harvard Apparatus, Holliston, MA) connected to a 26 gauge microinjector (4.1mm with
0.5 mm projection, Plastics One, Roanoke VA) over a 1 minute period after which
microinjectors were left in place for 1 minute to allow diffusion. Behavior was recorded
and scored as described above. Statistical significance in percentage of time spent
immobile between groups was calculated using a one-way ANOVA and Fishers LSD test
with a 95% confidence level.

5.2.8 Local Manipulations CRFR1 in Nucleus Accumbens or Prefrontal Cortex
Local manipulations of CRFR1 were conducted in a manner procedurally
identically to described above, but bilateral brain infusion cannulas (Plastics One,
Roanoke VA) were directed at the NAc (coordinates relative to AP = 1.7 mm, ML= 1.2
mm, DV= -7.3 mm) or mPFC (coordinates relative to bregma AP = 2.7 mm, ML= 0.3
mm, DV= -3.5mm) and CRFR1 antagonist (CP 154-526; 1mg/mL, in 0.45% acetic acid
vehicle in sterile saline) was infused using osmotic minipumps Alzet, Model 1007D
(Cupertino CA) at 0.5μL/hr for 6.5 days following surgery. Experimental groups
consisted of: naïve males treated with vehicle (0.45% acetic acid in sterile saline, n=9; in
the NAc), experienced males treated with vehicle (n=9, in the NAc), naïve males treated
with CRFR1 antagonist in the NAC (n=9) or mPFC (n=10), experienced males treated
with CRFR1 antagonist in the NAc (n=11) or mPFC (n=10). Statistical significance in
time spent immobile between groups was calculated using a Kruskal-Wallis One Way
ANOVA Ranks and Dunn’s test 95% confidence level.
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5.3 Results
5.3.1 Activation of CRF neurons by sexual behavior
Sexual activity did not activate CRF neurons in the PVN, CeA, or BnST.
Specifically, cFos was not expressed in any CRF neurons following mating in either
sexually naïve or experienced males in the PVN, CeA, or BnST (Figure 5.1). cFos
immunoreactive cells were detected in the vicinity of CRF neurons. However, sexual
experience (independent of mating on final test day) reduced total numbers of CRF
neurons in the CeA (Figure 5.2d; p=0.049) but did not affect numbers of CRF neurons in
the in PVN (Figure 5.2e) or BnST (Figure 5.2f).

5.3.2 Activation of CRF mRNA by abstinence from sexual behavior
28 days of abstinence from sexual behavior caused significant up regulation of
CRF mRNA in the PVN of sexually experienced males compared to sexually naïve males
(Figure 5.3a; p=0.012). CRF mRNA in the PVN was not significantly different between
experienced and naïve males 1 day following last mating or handling (Figure 5.3a). In the
CeA, CRF mRNA levels were significantly decreased in sexually experienced animals
both 1 and 28 days following last sexual experience compared to sexually naïve males 1
and 28 days following handling respectively (Figure 5.3a; p=0.034 and p=0.0004,
respectively). In the BnST, CRF mRNA did not differ significantly between sexually
naïve and experienced males either 1 or 28 days following last handling or mating
(Figure 5.3c).
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A) PVN

B) CeA

C) BnST

D) BnST

Figure 5.1. Representative images of neurons in the (A) PVN, (B) CeA, (C) BnST
expressing CRF (brown, cytosolic) and cFos (black, nuclear) at 10x magnification. (D)
Representative image of CRF expressing neuron (white arrow) and cFos expressing
neuron (black arrow) that are not colocalized in the BnST (40x magnification).
Abbreviations: PVN, paraventricular nucleus of the hypothalamus; CeA, central
amydgals; BnST, bed nucleus of the stria terminalis.
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Figure 5.2. Mean numbers of CRF neurons in naïve and experienced males that mated 1
hour before (NS: naïve sex, ES: experienced sex) or 24 hours prior to tissue collection
(ENS: experienced no sex, NNS: naïve no sex) in the PVN (A), CeA (B) and BnST (C).
Mean numbers of cells based on all animals in naïve or experienced groups, independent
of mating behavior immediately prior to tissue collection, in the PVN (D), CeA (E) and
BnST (F). Data are presented mean ± SEM. * Indicates significant difference from naïve.
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Figure 5.3. CRF mRNA expression in the PVN (A) CeA (B) and BnST (C) of sexually
naïve and experienced males 1 and 28 days following last handling or mating. Data are
presented mean ± SEM.* Indicates significant difference from naïve males.
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5.3.3 Acute Stress Responses
28 days of abstinence from sexual behavior did not alter baseline cort and ACTH
release, as sexually naïve and experienced males did not differ in plasma cort or ACTH
levels at the 0 minute timepoint. However, 28 days of abstinence from sexual behavior
caused increased plasma cort (Figure 5.4a; F1,75 12.283, p<0.001) and ACTH (Figure
5.4b; F1,56 20.031, p<0.001) release in response to acute restraint stress. Both sexually
naïve and experienced males displayed enhanced cort and ACTH release in response to
acute restraint stress at 30 minutes post restraint, and enhanced cort release at 60 minutes
post restraint, compared to baseline levels (p<0.001 for cort and ACTH, both timepoints).
However, sexually experienced males displayed significantly greater cort and ACTH
release in response to acute restraint stress 28 days following last mating compared to
sexually naïve males. Specifically, sexually experienced males showed a higher
magnitude of peak cort at 30 (Figure 5.4a; p=0.042) and 60 minutes (Figure 5.4a;
p<0.001) and ACTH at 30 (Figure 5.4b; p<0.001) and 60 minutes (Figure 5.4b; p=0.034)
compared to sexually naïve males. Sexually experienced males also demonstrated
prolonged cort and ACTH release as cort remained elevated from the 30 to the 60 minute
timepoint in experienced males, but decreased significantly at 60 minute timepoint
compared to the 30 minute timepoint in sexually naïve males (Figure 5.4b; p<0.001) .
ACTH release was also prolonged in experienced males, as ACTH levels returned to
baseline levels at the 60 minute timepoint in sexually naive males, but remained elevated
compared to baseline in sexually experienced males (Figure 5.4b; p<0.043).
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Figure 5.4. Plasma corticosterone (Cort) (A) and ACTH (B) levels in response to acute
restraint stress in sexually naïve and experienced males 28 days following last handling
or mating. Data are presented mean ± SEM. * indicates significant difference from naïve
males at the same timepoint. # indicates significant difference from 0 minute timepoint. +
indicates significant difference between the 30 and 60 minute timepoints.
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5.3.4 Effects of chronic ICV treatment with CRF receptor antagonists
Chronic treatment with a CRFR1 antagonist during days 21-27 of mating
abstinence prevented development of depression-like behavior seen following a 28 day
period of abstinence from mating (Figure 5.5a; F3,38 4.016; p=0.015). Specifically, males
treated with CRFR1 antagonist-treated spent significantly less time immobile compared
to experienced vehicle treated males (Figure 5.5a; p=0.002), and were not significantly
different from naïve vehicle treated males. Males treated with a CRFR2 antagonist did
not show less time immobile compared to experienced vehicle-treated males, but also did
not show significantly more time immobile compared to naïve-vehicle-treated males
(Figure 5.5a), suggesting that CRFR2 antagonist administration had a partial effect on
this phenotype. A 28 day period of abstinence from mating induced depression-like
behavior as experienced vehicle treated males spent significantly increased time
immobile compared to naïve vehicle treated males (Figure 5.5a; p=0.015), confirming
results of Chapter 4. Furthermore, chronic administration of CRFR1 receptor antagonist
blocked the sex abstinence induced increase in CRF mRNA expression in the PVN. CRF
mRNA in sexually experienced males treated with CRFR1 antagonist (109.8 ± 27.5%;)
did not differ from sexually naïve males (101.1 ± 8.3%), while vehicle-treated sexually
experienced males had a strong trend towards increased CRF mRNA (159.1 ± 30.8%;
p=0.059) compared to naïve males

5.3.5 Effects of acute CRFR1 antagonist administration on depression-like behavior
Administration of CRFR1 antagonist immediately prior to the forced swim test
prevented expression of depression-like behavior in sexually experienced male rats
(Figure 5.5b; F2,37 3.855; p=0.031). Males treated with CRFR1 antagonist showed
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decreased time immobile compared to experienced vehicle-treated males (Figure 5.5b;
p=0.019) and did not differ from naïve vehicle-treated males. Experienced vehicle-treated
males again spent increased time immobile compared to naïve vehicle-treated males
(Figure 5.5b; p=0.037).

5.3.6 Local Manipulations of CRFR1 in the Nucleus Accumbens and Medial
Prefrontal Cortex
To determine where in the brain CRF is acting on CRF1 receptors to cause
depression-like behavior following loss of sexual reward, CRFR1 antagonists were
infused into the NAc or mPFC for days 21-27 of the 28 day abstinence period. Indeed,
CRFR1 antagonism in either NAc or mPFC prevented development of depression-like
behavior (Figure 5.5c; H = 9.157; p=0.027). Specifically, Experienced vehicle treated
males spent increased time immobile compared to naïve vehicle treated males (Figure
5.5c; p<0.05) confirming the previous findings. Antagonism of CRFR1in either the NAc
or mPFC prevented development of passive stress coping, as CRFR1 antagonist-treated
males did not differ significantly in time spent immobile compared to naïve vehicle- or
antagonist-treated males (Figure 5.5c). However, experienced NAc antagonist-treated or
PFC antagonist-treated males also did not differ significantly in time spent immobile
from experienced vehicle-treated males (Figure 5.5c), indicating a partial effect of the
local CRFR1 antagonism. Therefore, these results suggest that CRFR1 may be acting
simultaneously in multiple brain regions to cause development of depression-like
behavior.
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Fig. 5.5. (A) Percentage of time spent immobile in vehicle-treated sexually naïve males
(Naïve Vehicle), sexually experienced males (Exp Vehicle); sexually experienced
CRFR1 antagonist treated males (Exp CRFR1 Antag) and sexually experienced CRFR2
antagonist treated males males (Exp CRFR2 Antag) that received vehicle or antagonist
infusions during the final 7 days of abstinence (B) Percentage of time spent immobile in
vehicle-treated sexually naïve males (Naïve Vehicle), sexually experienced males (Exp
Vehicle); sexually experienced CRFR1 antagonist treated males (Exp CRFR1 Antag) that
were acutely treated with vehicle or CRFR1 antagonist 15 minutes prior to testing on the
forced swim test. (C) Percentage of time spent immobile in sexually naïve (Naïve) or
experienced (Exp) males treated with either vehicle or CRFR1 antagonist in the NAc or
mPFC. Data are presented as mean ±SEM * indicates significant difference from naïve
vehicle, # indicates significant difference from experienced vehicle.
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5.4 DISCUSSION
Previously, we showed that sexual experience followed by a prolonged (28 days),
but not short (1-7 days) period of abstinence from sexual reward caused increased
depression-like behaviors, consisting of increased passive stress coping and decreased
social interaction. In the current study, we demonstrated that these depression-like
behaviors are associated with enhanced HPA activity, namely increased stress-induced
ACTH and cort release and increased CRF mRNA in the PVN. Thus, these results
provide further insights into the mechanisms by which loss of sexual reward causes
development of depression and validation of loss of sexual reward in male rats as a model
for depression-like behavior, as this model demonstrates homology to pathology seen in
human depression, or pathological validity (Krishnan and Nestler, 2010). In humans,
major depression is associated with hyperactivity of the HPA axis, increased CRF mRNA
and protein levels in the PVN and CRF secretion into the cerebrospinal fluid (Kling et al.,
1991), as well as increased plasma and salivary cortisol (Nemeroff and Vale, 2005).
A potential mechanism for the observed increases in PVN CRF and enhanced
stress-induced release of cort and ACTH may be decreased glucocorticoid negative
feedback (Reul and de Kloet, 1985, Nemeroff, 1993, Koob and Heinrichs, 1999). It is
hypothesized that the hyperactivity of the HPA axis seen in depressed humans may be
due to alterations in glucocorticoid negative feedback, as depressed patients fail to mount
an appropriate negative feedback response in the dexamethasone (synthetic
glucocorticoid) suppression test (Rush et al., 1996, Holsboer, 2000). Studies in depressed
humans have demonstrated decreased glucocorticoid receptor (GR) mRNA expression in
the hippocampus and prefrontal cortex (Webster et al., 2002). Rodents also demonstrate
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reductions in GR binding in the hippocampus and hypothalamus following social defeat
(Buwalda et al., 2001), in the hippocampus and PFC following maternal separation
(Meaney et al., 1996) and in the hippocampus, hypothalamus, and PFC following chronic
stress (Makino et al., 1995, Raone et al., 2007). Furthermore, early life stressors such as
decreased maternal care which causes alterations in stress responses also leads to longlasting epigenetic modifications of GR in the hippocampus (Weaver et al., 2004, Weaver,
2007). Specifically, rat pups that receive low maternal care have increased stress
responses, associated with low levels and hypermethylation of exon17 of the GR
promoter in the hippocampus (Weaver et al., 2004, Weaver, 2007), and decreased
binding of the GR promoter to the transcription factor NGF1-A (Weaver et al., 2004,
Weaver, 2007), suggesting an epigenetic mechanism by which social experience may
cause long term adaptations to stress responses. Future studies will therefore determine if
loss of sexual reward may cause increased stress responses via decreased GR expression
and hypermethylation of GR exon I7 in the hippocampus.
The second major finding of the current study was that the development of
depression-like behavior was dependent on activation of CRFR1 in brain areas including
the NAc and PFC, as CRFR1 antagonism during the final days of sex reward abstinence
prevented the increase in passive stress coping behaviors. ICV infusion of a CRFR2
antagonist had a partial effect on development of depression-like behavior. Activation of
both CRFR1 and CRFR2 has been implicated in depression-like behaviors (Shaham et
al., 1998, Hammack et al., 2003, Wang et al., 2005, Henry et al., 2006, Wang et al., 2006,
Wang et al., 2007). Other reports have shown that activation of CRFR1 can be prodepressant and induces stress responses, while CRFR2 activation can have antidepressant

169

effects and cause attenuation of the stress response (Bale and Vale, 2004, Contarino and
Papaleo, 2005). The current findings do not support opposite roles for CRFR1 and
CRFR2 in the effects of sexual reward abstinence on development of depression, but
rather a more dominant role for CRFR1. The greater role for CRFR1 may be based on the
critical involvement of the NAc and PFC that both express high levels of CRFR1, but
only low levels of CRFR2 (Van Pett et al., 2000). A potential mechanism by which CRF
may mediate the development of depression-like behavior is via the dynorphin/kappa
opioid system as CRFR1 receptor activation in either NAc or PFC, has been shown to
activate the dynorphin/kappa opioid receptor system to induce depression-like behavior
(Land et al., 2008, Tejeda et al., 2010). The dynorphin/kappa opioid receptor system has
been shown to exert pro-depressant effects when activated and antidepressant effects
when blocked (Mague et al., 2003, McLaughlin et al., 2003, Beardsley et al., 2005,
Carlezon et al., 2006).
The ligand that causes CRFR1 activation is potentially CRF. CRF has a 10x
higher affinity for CRFR1 than CRFR2 (Bale and Vale, 2004), with CRFR2 having a
higher affinity for urocortin II and III (Bale and Vale, 2004), suggesting that CRF via
activation of CRFR1 during the 28 day period of abstinence causes development of
depression-like behavior. In addition, urocortin I has equal affinity for both CRFR1 and
CRFR2 (Lovenberg et al., 1995, Perrin et al., 1995), and therefore cannot be ruled out as
an additional contributor to the development of depression-like behavior following loss
of sexual reward. The sources of CRF projections to the NAc or the mPFC are not clear.
Both regions receive inputs from PVN (Silverman et al., 1981, van der Kooy et al., 1984)
and the NAc also received inputs from the BnST and CeA, as part of the extended

170

amygdala (Koob, 1999). The current study was not able to identify which CRF neurons in
PVN or extra hypothalamic sites were activated during sexual behavior, as cFos
expression was not observed in CRF neurons following mating in either naïve or
experienced males, suggesting that CRF neurons are not activated by sexual behavior.
Previous studies have shown cFos activation in the PVN (Buwalda et al., 2012), BnST
(Coolen et al., 1996) and amygdala (Coolen et al., 1996, Veening and Coolen, 1998)
following sexual behavior. PVN CRF neurons have also been show to express cFos
following other stimuli, including water deprivation (Benedetti et al., 2008) or
lipopolysaccharide administration (Rorato et al., 2008). However, it should be noted that
a lack of cFos activation does not indicate that sexual behavior does not cause activation
of CRF neurons. The current study did identify an up-regulation of CRF mRNA in PVN,
coinciding with the timepoint development of depression-like behavior is observed,
suggesting that the PVN may be the source of CRF acting in NAc and mPFC to induce
this negative affective state.
An unexpected finding of the current study was a reduction in CRF mRNA and
protein in the CeA, both immediately following sexual behavior and after prolonged
period of sex reward abstinence. These results indicate that sexual behavior does indeed
influence CeA CRF neurons, by causing down regulation of CRF gene and protein
expression in these cells. It is not entirely clear how this decreased CRF in the CeA may
mediate depression-like behavior. The amygdala is an important brain area for regulation
of emotions, particularly related to fear, stress and aversive stimuli (Eibl-Eibesfeldt and
Sutterlin, 1990). In human depression, amygdala volume is reduced (Sheline et al., 1998).
In contrast, in the maternal separation model of depression, CRF mRNA in the CeA is
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increased (Menzaghi et al., 1993) and glucocorticoids have been shown to be stimulatory
to CeA CRF mRNA levels (Schulkin et al., 1994, Shepard et al., 2000). Hence, the
current findings that CRF is decreased in CeA during abstinence from sexual behavior
suggest that there is no chronic elevation of glucocorticoids during the abstinence period.
This is supported by a lack of difference in baseline cort and ACTH levels in sexually
experienced and naïve males following the prolonged period of mating abstinence. But,
whether CeA CRF plays a role in the development of depression following loss of sexual
reward remains unclear.
A major finding of the current study, together with our previous findings, is that
increased levels of CRF in the PVN and the development of depression-like behavior
require a prolonged period of abstinence from sexual reward and are not induced
immediately after sexual behavior. Development of depression-like behavior is
completely prevented by twice weekly mating during the 28 days following daily sexual
experience, demonstrating that abstinence from mating is critical. It is currently unknown
what mechanisms underlie the effects of abstinence on subsequent alterations in behavior
and neuropathology. One hypothesis for the pro-depressant effects of chronic stress is
that stress reduces neurogenesis and numbers of spines in the hippocampus (Pham et al.,
2003, McEwen, 2005, 2010, Veena et al., 2011, Schoenfeld and Gould, 2012). In
apparent contrast, sexual behavior, either once or daily during a 14 day period, promotes
neurogenesis and spinogenesis in adult male rats (Leuner et al., 2010), despite the fact
that mating causes increased cort and ACTH release (Buwalda et al., 2001, Bonilla-Jaime
et al., 2006, Leuner et al., 2010). Likewise, running or exposure to an enriched
environment, which cause activation of the HPA axis also increase hippocampal
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neurogenesis (Schoenfeld and Gould, 2012). However, it is important to note that shortly
following mating, and thus at the timepoint that increased neurogenesis has been
demonstrated, sexual behavior causes a dampening of the stress responses and reductions
in anxiety-like behavior (Fernandez-Guasti et al., 1989, Saldivar et al., 1991, Waldherr
and Neumann, 2007, Waldherr et al., 2010). Therefore, it is critical to examine the effects
of prolonged periods of abstinence from sexual reward on neurogenesis and spinogenesis
in the hippocampus, as well as in the NAc and mPFC. Recent studies form our laboratory
have shown that a short period of abstinence from sexual behavior (7 days) caused
increased numbers of spines in the NAc (Pitchers et al, 2010), but this returned to
baseline after the prolonged 28 day period of abstinence (Pitchers, 2012), suggesting that
spinogenesis is a dynamic and time-dependent process.
Another hypothesis for the effects of chronic stress on depression is that of stress
sensitization: the view that previous exposures to stressors may cause an enhanced stress
response upon re-exposure to a stressor and favor development of depression (Anisman
and Merali, 2003, Anisman et al., 2003a). Anisman and colleagues showed that systemic
infusions of the inflammatory cytokine, tumor necrosis factor-alpha (TNF-alpha) caused
activation of the HPA axis (Anisman et al., 2003b). Moreover, re-exposure to TNF-alpha
elicited a sensitized stress response (Anisman et al., 2003b). Of particular interest was
their finding that re-exposure to TNF-alpha triggered the most sensitized and robust stress
effect after a re-expousre interval of 28, but not 7 days (Anisman et al., 2003b). Thus,
inflammatory cytokines may also play a role in the development of depression following
abstinence from sexual reward. It has been well documented that humans with depression
have elevated inflammatory cytokines (Maes, 1994, Maes and Smith, 1998, Schiepers et
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al., 2005, Kim et al., 2008, Dinan et al., 2009, Pace and Miller, 2009, Dowlati et al.,
2010). Moreover, it has been suggested that exercise is an effective treatment in
depressed patients (Biddle, 1989, Beesley and Mutrie, 1997, Barbour et al., 2007, Greer
and Trivedi, 2009, Carek et al., 2011, Rozanski, 2012) as it has anti-inflammatory actions
(Das, 2004, Petersen and Pedersen, 2005, Gleeson et al., 2011, Rethorst et al., 2012).
Recently it has been shown that TNF-alpha levels in serum of depressed patients may be
a predictor for the antidepressant effects of exercise, with high TNF-alpha levels linked to
better outcomes for exercise, but poor outcomes for antidepressant treatment (Rethorst et
al., 2012). Thus, we hypothesize that sexual behavior and subsequent abstinence from
sexual behavior may influence inflammatory and immune responses in the brain. Even
though effects of sexual behavior on the brain immune system have not yet been
reported, environmental enrichment has been shown to decrease inflammatory markers
and cause a blunted pro-inflammatory response (Williamson et al., 2012). Moreover,
exposure to females, without mating, has been shown to increase mast cells in the brains
of male rats (Asarian et al., 2002). These mast cells have been implicated in the
regulation of anxiety-related behaviors, suggesting that increased mast cells following
exposure to female stimuli may mediate dampened anxiety responses (Nautiyal et al.,
2008).
In conclusion, results of these studies demonstrate that loss of sexual reward,
which causes depression-like behavior, also leads to underlying neuropathology of
depression including HPA axis activity and increased CRF in the PVN. Moreover, these
studies provide insight into the mechanism by which CRF may modulate depression-like
behavior following loss of sexual reward, via CRFR1 in the NAc and PFC. We suggest
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that these studies of the effects of loss of sexual reward demonstrate homology to
pathology seen in human depression following loss of social reward and may thus
provide further insights into this particular form of depression.
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CHAPTER 6: GENERAL DISCUSSION

6.1. Orexin and Sexual Reward
Results from Chapter 2 demonstrated that the hypothalamic neuropeptide orexin
plays a role in arousal and anxiety related to sexual behavior in sexually naive male rats,
but is not critical for male sexual performance or motivation (Di Sebastiano et al., 2010,
Di Sebastiano and Coolen, 2012). Results from Chapter 3 demonstrated that orexin is a
critical mediator of sexual reward (Di Sebastiano et al., 2011, Di Sebastiano and Coolen,
2012). Together, these studies formed a critical step in identifying the role of orexin in
natural reward behavior (Di Sebastiano and Coolen, 2012) and specifically in sexual
reward.

6.1.1 Future Directions - Orexin
In our previous studies, we demonstrated the role of orexin using cell specific
lesions of orexin neurons in the PFA-DMH and LHA (Di Sebastiano et al., 2010).
However, as the lesioning technique permanently eliminated orexin neurons, it is
currently unknown if orexin is involved in the acquisition of stimulus-reward learning or
the expression of this learned association. We tested the role of orexin in sexual reward
using the CPP paradigm, which includes both a phase of acquisition of the associative
memory of reward-cue associations and a phase of expression of the seeking of the
reward-associated cue (Tzschentke et al, 2007). Future studies may utilize
pharmacological manipulations of orexin neurons in the PFA-DMH and LHA either
during the CPP conditioning trials; to determine if orexin is involved in acquisition of
sexual reward induced CPP, or during the post-test to determine if orexin is involved in
the expression of mating induced CPP. Studies may also utilize newly developed
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technologies such as optogenetics, which rely on activation or inhibition of specific
neurons via expression of light activated proteins, channelrhodopsin or halorhodopsin,
respectively (Fenno et al., 2011). This technique has a higher temporal resolution than
pharmacological techniques (Fenno et al., 2011), and as such, would allow for more
precise activation or inactivation of orexin neurons during the acquisition or expression
phases of mating induced CPP.
In addition, it is unclear where in the brain orexin is acting to mediate sexual
reward. Orexin is synthesized exclusively in the PFA-DMH and LHA (de Lecea et al.,
1998, Sakurai et al., 1998), but has broad projections, and orexin receptors are widely
distributed throughout the brain and spinal cord (Trivedi et al., 1998, Marcus et al.,
2001). Orexin neurons project to both the NAc and VTA (Peyron et al., 1998, Fadel and
Deutch, 2002, Baldo et al., 2003) and contact dopamine positive cells in the VTA (Fadel
and Deutch, 2002). Furthermore, both orexin receptor 1 and orexin receptor 2 are located
in the NAc and VTA, including on DA cells in the VTA (Korotkova et al., 2003, Narita
et al., 2006). In the NAc orexin-A infusion stimulates feeding behavior (Thorpe and
Kotz, 2005), suggesting a role for orexin in food reward, as the NAc plays an important
role in hedonia related to feeding (Berridge, 1996, Pecina and Berridge, 2000). Orexin
action in the VTA has also been shown to be important for food motivation and reward,
as infusion of an orexin receptor 1 antagonist decreases seeking of high-fat, palatable
food (Borgland et al., 2009). Much more is known about the role of orexin in the VTA in
drug reward. Administration of an orexin receptor-1 antagonist into the VTA blocks
morphine induced CPP (Harris et al., 2007) and intra-VTA administration of orexin-A
has been shown to reinstate morphine CPP following extinction (Harris et al., 2005).
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Thus, future experiments may use pharmacological or optogenetic manipulations of
orexin receptors 1 or 2 in the VTA and NAc to determine if orexin action in these brain
regions is critical for mediation of sexual performance, motivation or reward. As
dopamine has been shown to play a role in reward-cue association learning (Robinson
and Berridge, 1993, Berridge, 1996) and reward prediction (Schultz, 1997, 1999, 2006,
2010); transgenic studies may utilize mice that have a conditional knockout (Friedel et
al., 2011) of orexin receptors that are located on dopamine neurons to determine if orexin
acts via dopamine to mediate sexual reward.

6.2 Development of an animal model for depression following loss of sexual reward
Studies from Chapter 4 demonstrated that a 28 day period of abstinence from
sexual behavior causes depression-like behavior including passive stress coping and
anhedonia in male rats. Studies from Chapter 5 demonstrated that this prolonged loss of
sexual reward induced depression-like behavior is also associated with underlying
neuropathology of depression seen as increased corticotropin releasing factor (CRF)
mRNA in the paraventricular nucleus of the hypothalamus (PVN) and increased
corticosterone (cort) and ACTH responses to an acute stressor. Finally, it was shown that
development of depression-like behavior following loss of sexual reward is mediated by
CRF receptor 1 in mesolimbic brain regions, the NAc and PFC.

6.2.1 Future Directions: Interactions with vulnerability to addiction
In addition to causing depression-like behavior, abstinence from sexual reward
also causes increased vulnerability for psychostimulant abuse in male rats (Pitchers et al.,
2010). Given that depression and substance abuse have a high comorbidity (Volkow,
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2004); it will be interesting to determine which neural alterations caused by abstinence
from sexual reward lead to this behavioral pathology. As CRF is activated by drugs of
abuse (Sarnyai et al., 2001) as well as by withdrawal and abstinence from drug taking
(Koob and Kreek, 2007, Koob, 2008), CRF may also be an important mediator of the
enhanced drug reward (Pitchers et al., 2012) and locomotor sensitization to amphetamine
(Pitchers et al., 2010) seen following a period of abstinence from mating. Thus, future
studies may examine the effects of CRF antagonists in limbic brain regions that express
CRF receptors and are also involved in depression and addiction, such as the PFC and
NAc (Van Pett et al., 2000, Krishnan and Nestler, 2008) during the final week of mating
abstinence on development of conditioned place preference for a subthreshold dose of
amphetamine and sensitization of the locomotor response to psychostimulants (Pitchers et
al., 2010).

6.2.2 Glutamate
In the discussion of Chapter 5, I discussed the potential effects of prolonged
sexual reward abstinence on neurogenesis, spinogenesis, and cytokines in the
development of depression. However, many more transmitters and neural factors have
been implicated in depression. Many studies have shown that glutamate, the main
excitatory neurotransmitter in the central nervous system is altered in depressed patients,
as they show increased plasma glutamate levels compared to healthy controls (Kim et al.,
1982, Altamura et al., 1993, Mitani et al., 2006). Glutamate receptor trafficking is also
decreased in the striatum (Kristiansen and Meador-Woodruff, 2005) and thalamus
(Clinton and Meador-Woodruff, 2004) of depressed patients and enhanced membrane
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expression of ionotropic 2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl) propanoic acid
(AMPA) receptors is observed in the hippocampus following treatment with

antidepressants (Martinez-Turrillas et al., 2007), suggesting a role for glutamate receptor
trafficking in mediation of depression. Glutamate receptor trafficking and function is also
altered by exposure to drugs of abuse (Thomas et al., 2008, Wolf and Ferrario, 2010).
Studies from our lab have shown that a one month period of abstinence from mating also
induces alterations in glutamate receptors, including increased surface expression of the
AMPA glutamate receptor subunits, GluA1 and GluA2 in the NAc (Pitchers et al., 2012),
and decreased AMPA/NMDA ratio in the NAc (Pitchers et al., 2012). These sex
abstinence-induced changes in glutamate receptor expression and trafficking are partially
similar to changes induced by abstinence from drugs of abuse. Abstinence from repeated
cocaine exposure causes increased cell surface AMPA and NMDA receptor subunit
expression in the NAc and different receptor subunits have been shown to be
differentially affected by drug withdrawal (Conrad et al., 2008, Wolf and Ferrario, 2010).
These changes are thought to contribute to alterations in the locomotor response to
psychostimulants and increased drug seeking (Vanderschuren and Kalivas, 2000, Conrad
et al., 2008, Wolf and Ferrario, 2010, Ferrario et al., 2011). Thus, as glutamate and
glutamate receptors appear to play a critical role in depression and drug withdrawal, and
have also been shown to be altered by a periods of abstinence from sexual behavior,
future studies may test the functional role of these alterations in development and
expression of depression-like behavior following loss of sexual reward as well as
alterations in stress responses.
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6.2.3 BDNF
Brain derived neurotrophic factor (BDNF), is the most prevalent growth factor in
the central nervous system (Autry and Monteggia, 2012). Depressed humans shown
reduced plasma BDNF (Duman and Monteggia, 2006) as well as decreased BDNF levels
in the hippocampus (Karege et al., 2005, Castren et al., 2007). Chronic stress in rodents
has been shown to decrease BDNF signaling and this is reversed by chronic treatment
with antidepressants (Nestler et al., 2002, Duman and Monteggia, 2006). Furthermore, in
the social defeat model of depression, VTA specific deletions of BDNF blocked
development of depression-like behavior (Berton et al., 2006). Moreover, BDNF is also
critically involved in drug addiction as well as withdrawal. A single infusion of cocaine
increases BDNF levels in the NAc (Russo et al., 2009), and infusion of BDNF into the
NAc leads to increased drug taking and seeking, and enhances drug craving after
withdrawal (Graham et al., 2007). Moreover, infusion of BDNF into the VTA during
withdrawal enhances drug seeking behavior (Corominas et al., 2007). Much less is
known about the role of BDNF in sexual behavior; however it has been shown that
mating behavior leads to upregulation of BDNF mRNA in the PFC (Kakeyama et al.,
2003). Thus, as BDNF is involved in depression, and appears to facilitate drug seeking
following drug withdrawal, BDNF may also be altered following abstinence from sexual
reward, and mediate vulnerability for depression via the mesolimbic system. Future
studies therefore may utilize pharmacological manipulations of BDNF during mating or
the period of abstinence to test the functional role of BDNF on development of
depression-like behavior and alterations in stress responses observed following loss of
sexual reward.
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6.3 Orexin interactions with CRF and the stress system
In addition to playing a critical role in mediation of reward, the hypothalamic
neuropeptide orexin has also been shown to be involved in mediation of anxiety and
depression-like behavior. Orexin-A infusion into the paraventricular nucleus of the
thalamus of male rats causes decreased anxiety-like behavior on the elevated plus maze
(Li et al., 2010). Orexin has also been shown to play a role in depression-like behavior,
with activation of OxR1 having a pro-depressant effect and activation of OxR2 having an
antidepressant effect (Scott et al., 2011), suggesting orexin differentially regulates
depression-like behavior depending on which receptor is activated. Orexin has also been
shown to interact with the stress system, as stimulation of orexin receptors increases CRF
mRNA levels (Al-Barazanji et al., 2001, Singareddy et al., 2006), as well as ACTH (Ida
et al., 1999, Ida et al., 2000a, Kuru et al., 2000) and corticosterone release (Ida et al.,
2000b, Kuru et al., 2000). Orexin mRNA is also increased in response to acute restraint
stress (Ida et al., 2000a). Furthermore, orexin neurons in the hypothalamus also express
CRF receptors, and CRF application to brain slices has been shown to increase orexin
signaling (Winsky-Sommerer et al., 2004). Thus, it is clear that there are interactions
between orexin and the CRF system, which may play a role in mediation of stress
responses.
The studies in this thesis demonstrated a critical role for orexin in mediation of
sexual reward (Di Sebastiano et al., 2011), and for CRF in mediation of development of
depression-like behavior following loss of sexual reward. Therefore, orexin and CRF
may be acting together to mediate development of depression-like behavior following
loss of sexual reward as well as alterations in stress responses.
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6.4 Overall Conclusions
Results of the studies in this thesis further elucidate the neural circuitry of sexual
reward. Furthermore, results of these studies provide insight into the mechanism by
which loss of natural rewards can influence disorders related to reward processing such
as substance abuse and depression.
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2010-211::2:
AUP Number: 2010-211
AUP Title: Neural regulation of rewarding behavior and substance abuse
Approval Date: 03/22/2010
The YEARLY RENEWAL to Animal Use Protocol (AUP) 2010-211 has been approved.
1. This AUP number must be indicated when ordering animals for this project.
2. Animals for other projects may not be ordered under this AUP number.
3. Purchases of animals other than through this system must be cleared through the
ACVS office.
Health certificates will be required.
REQUIREMENTS/COMMENTS
Please ensure that individual(s) performing procedures on live animals, as described in
this protocol, are familiar with the contents of this document.
The holder of this Animal Use Protocol is responsible to ensure that all associated safety
components (biosafety, radiation safety, general laboratory safety) comply with
institutional safety standards and have received all necessary approvals. Please consult
directly with your institutional safety officers.
Submitted by: Kinchlea, Will D
on behalf of the Animal Use Subcommittee
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PI: Coolen, Lique
Protocol Number: #10531
Approval Period: 03/02/2011 - 03/02/2014
Funding Agency: Canadian Institutes of Health Research
Title: Effects of Sexual Experience on Drug Responsiveness
DRDA Number:
Date: 03/03/2011
Dear Principal Investigator,
The University of Michigan Committee on Use and Care of Animals (UCUCA) has
reviewed your application to use vertebrate animals (Application #10531). This project
has been approved. The proposed animal use procedures are in compliance with
University guidelines, State and Federal regulations, and the standards of the "Guide for
the Care and Use of Laboratory Animals."
When communicating with the UCUCA Office please refer to the Approval Number
#10531. The approval number must accompany all requisitions for animals and
pharmaceuticals.
The approval date is 03/02/2011. The approval period is for three years from this date.
However, the United States Department of Agriculture (USDA) requires an annual
review of applications to use animals. Therefore, each year of this application prior to the
anniversary of its approval date, you will be notified via email to submit a short annual
review. Your continued animal use approval is contingent upon the completion and return
of this annual review. You will also be notified 120 days prior to the expiration of the
approval period so that your renewal application can be prepared, submitted and
reviewed in a timely manner in the eSirius program and an interruption in the approval
status of this project avoided.
UCUCA approval must be obtained prior to changes from what is originally stated in the
protocol. An amendment must be submitted to the UCUCA for review and approved
prior to the implementation of the proposed change.
The University's Animal Welfare Assurance Number on file with the NIH Office of
Laboratory Animal Welfare (OLAW) is A3114-01, and most recent date of accreditation
by the Association for the Assessment and Accreditation of Laboratory Animal Care
International (AAALAC, Intl.) is November 06, 2009.
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If you receive news media inquiries concerning any aspect of animal use or care in this
project, please contact James Erickson, News and Information Services. If you have
security concerns regarding the animals or animal facilities, contact Bill Bess, Director of
Public Safety.
Sincerely,
Richard Keep, Ph.D.
Professor, Neurosurgery
Chairperson, University Committee on Use and Care of Animals
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